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ABSTRACT 
Marino, Dante; M.S.; Department of Plant Pathology; College of Agriculture, Food 
Systems, and Natural Resources; North Dakota State University; May 2011. Screening of 
Germplasm Accessions From the Brassica species for Resistance Against PG3 and PG4 
Isolates of Blackleg. Major Professor: Dr. Luis de! Rio. 
Blackleg is a disease of canola and rapeseed cultivars that is caused by the fungus 
Leptosphaeria maculans (Desm.) Ces. & de Not., and it is by far the most destructive 
pathogen of canola in North America. In recent years, blackleg strains belonging to 
pathogenicity groups (PG) 3 and 4 have been discovered in North Dakota. Recent 
outbreaks of the disease have added a sense of urgency to characterize the risk these new 
strains represent for the canola industry and to identify sources of resistance against them. 
Thus, the objectives of this study were to screen germplasm collections of Brassica rapa, 
B. napus. and B. juncea for their reaction to PG3 and PG4 and to evaluate the reaction of a 
sample of currently used canola commercial cultivars grown in North Dakota to PG3 and 
PG4 as means to estimate the risk these new strains represent. All canola germplasm and 
commercial cultivars were evaluated in replicated trials in greenhouse conditions using 
cotyledon bioassays. In 2009 and 2010, the effect of these strains, using five inoculation 
sequences, on the reaction of canola seedlings was also evaluated. Field trials were not 
conducted because of the limited geographical distribution of the new strains. No adequate 
sources of resistance were identified among the 277 B. rapa and 130 B. napus accessions 
evaluated; however, 22 of the 406 accessions of Brassicajuncea evaluated were considered 
to have moderate levels of resistance. B. juncea seedlings that survived these inoculations 
were self-pollinated and their progeny (F 1) were also screened. As before, surviving 
seedlings were self-pollinated. These F 2 seeds are the elite materials that could be used in 
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future breeding programs. The complementary study evaluating the role of sequence 
inoculations in reaction of canola seedlings to blackleg indicated that an increased 
susceptibility to PG3 occurred when seedlings were first inoculated with PG4; however, 
reaction to PG4 was not enhanced by a prior inoculation with PG3. All 75 commercial 
cultivars evaluated were susceptible to PG3 and PG4, indicating that the risk these new 
strains represent to the canola industry of the region is serious. Further, when a subsample 
of 16 cultivars were challenged with PG2, they were either resistant or moderately 
resistant, suggesting the ratings the industry are using relate to reaction of those cul ti vars to 
PG2 but not to the new strains; thus, growers should use caution when using these ratings 
while deciding on which cultivars to plant. 
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CHAPTER 1. INTRODUCTION 
Blackleg, caused by the fungus Leptosphaeria maculans (Desm.) Ces. & de Not. 
Phoma lingam (Tode ex. Schw.) is its anamorph. Blackleg is the most destructive pathogen 
of canola in North America (Fitt et al., 2006) and has an economic impact on canola 
production worldwide. According to the Northern Canola Growers Association, North 
Dakota leads the production of canola in the United States. The total amount of canola 
production in North Dakota was recorded at 1 million metric tons in 2010. The total value 
of canola production in North Dakota has also reached a record of $437 million (NCGA, 
2010). 
As canola is an important crop to North Dakota, blackleg disease is becoming main 
concern that needs to be investigated. There is a lack of knowledge about the impact of 
new strains of L. maculans on commercially available canola cultivars. Also, there is 
limited knowledge on what sources of resistance can be used to combat the disease. This 
study provides to contribute to the research of blackleg disease by identifying sources of 
resistance against the new strains and by characterizing the reaction of commercial 
cultivars to these strains. 
One of the traits that make this pathogen difficult to control is its ability to change 
virulence profile. A set of three differential cultivars, Westar, Glacier, and Quinta has been 
used in North America to characterize pathogenicity groups (PG) (Mengistu et al., 1991). 
A larger set has been developed to identify strains to race level (Balesdent et al., 2005), but 
the set is not available to the scientific community at large. 
Isolates that show virulence profiles typical of PG 2 have been the most prevalent in 
the upper Northern Plains since the discovery of blackleg in North Dakota canola fields in 
1991 (Lamey and Hershman, 1993). Since then, resistance to PG2 isolates has been 
incorporated into most commercial cul ti vars. The recent discovery of isolates belonging to 
PG3, PGT, and PG4 in western Canada and North Dakota (Bradley et al., 2005; Chen and 
Fernando, 2006); however, is an indication that the blackleg population may be shifting. 
And while the prevalence of PGs 3 and 4 in North Dakota at the time of discovery was 
limited to a few counties, it is just a matter of time for the new strains to spread to all 
canola growing regions of North Dakota. Further, a potential shift in virulence of blackleg 
is cause for alarm since their impact on commercial canola genotypes is largely unknown. 
Germplasm collections are very useful genetic resources for all kinds of traits 
including disease resistance. Recently Zabala (2008) reported Brassica rapa plant 
introductions with acceptable levels of resistance against Sclerotinia sclerotiorum. Khot 
(2006) identified sources of resistance to the same pathogen in a Brassica napus collection. 
Resistance to blackleg can be expressed at the seedling stage and in adult plants 
(Delourme et al., 2006). The former is considered vertical or monogenic resistance and can 
be easily detected in greenhouse inoculations; expression of horizontal resistance in adult 
plants is more easily detected under field conditions. Thus, all screenings and evaluations 
need to be conducted in controlled environments like greenhouse rooms. This research was 
motivated by the need for information on sources of resistance to PG3 and PG4 strains of 
blackleg and the lack of information on the reaction of commercial cultivars to them. The 
main objectives of this study were to identify sources of resistance within the collections of 
Brassica rapa, B. napus and B. juncea accessions maintained by the USDA- National 
Genetics Resources Program (NGRP) and to characterize the reaction of commercially 
available canola genotypes to PG3 and PG4 strains of blackleg. The secondary objective is 
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to develop pre-breeding materials by self-pollinating the accessions selected through 
different rounds of inoculations. 
3 
CHAPTER 2. 
LITERATURE REVIEW 
2.1. Economic Importance of Crop and Pathogen 
2.1.1. Economic Importance of the Crop 
Major canola producing countries in Europe are Germany, France, Poland, Sweden, 
The United Kingdom, and Ukraine. In Asia, China and India are the main canola 
producers. In Oceania, Australia is the major producer while on the American continent the 
USA and Canada are the top producers. Spring varieties are commonly grown in Australia, 
India, China, the Northern Plains and Pacific Northwest of the USA, Northern Europe and 
most of Canada. Winter types are commonly grown in southwest Europe, China, Eastern 
Canada, the Pacific Northwest, and southeastern parts of the United States (Berry and 
Spink, 2006; Kimber and McGregor, 1995). 
In 2009, North Dakota accounted for approximately 90% of the canola area 
harvested in the United States (Kandel, 2009). An estimated 305,000 ha were planted in 
that year, down from a high of 535,000 ha in 2001. In the last ten years, the average yield 
in North Dakota has ranged from 1.23 to 1.84 tons per hectare; the 2009 harvest was valued 
at approximately $213 million. In 2009, production of winter canola expanded in 
Oklahoma and for the first time into western states such as Oregon and Idaho. In that year, 
those three states produced 38,500 metric tons, a sizable increase from the 10,500 metric 
tons harvested in 2008 (USDA, 20 I 0). 
The main force driving the increase of canola production in these states is related to 
the mandate for biodiesel use in Washington and Oregon, which started in 2006 and 
encourages local biodiesel production (Painter and Roe, 2007). In North Dakota, farmers 
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were encouraged to increase canola production because of the establishment of new 
crushing facilities in the region and more competitive market prices of the commodity. In 
Canada, the crop is grown in 8. 76 million ha, and its contribution to the economy is 
estimated at approximately $13.8 billion in Canadian currency (CCC, 2010). 
2.1.2. Economic Importance of Blackleg Disease 
Blackleg epidemics caused significant economic damages in different regions and 
years and remains a major concern in most canola producing areas in the world (Gladders 
et al., 2006). 
In the United Kingdom, blackleg epidemics in 2002 and 2003, caused yield losses 
estimated at €56 million each season (Fitt et al., 2006). In Australia, the disease was 
responsible for losses of€ 11.3 million in 1998 and 1999 (Khangura and Barbetti, 2001 ). In 
France, blackleg accounts for 5 to 20% yield reductions with an estimated value ranging 
between €36.8 and €147 million (Allard et al., 2002). In Poland, the effects of blackleg 
have not been quantified, and the disease is caused by L. biglobosa, a closely related 
species. L. biglobosa can cause severe cankers on the mid and upper part of the stem under 
the stress of hot summer temperatures, which are normally observed before harvest (Huang 
et al., 2005; Jedryczka et al., 1999; West et al., 2001; Karolewski et al., 2002). 
While there is no official quantification of the yield losses caused by blackleg in 
canola in North Dakota, anecdotal information by growers estimate its impact at up to 45% 
of obtainable yield in some fields in recent years (L. del Rio, personal communication). 
Field surveys conducted between 1991 and 2002 indicated the statewide incidence of 
blackleg in North Dakota fields at 6.7%, with a peak of 27.7% in 1992 and 5.9% of the 
fields with more than 45% incidence in 2002 (Lamey et al., 2003). 
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2.2. Canola/Rapeseed 
2.2.1. Taxonomic Classification 
The Brassicaceae family consists of 375 genera and 3,200 species of plants. The 
Brassica genus consists of approximately 100 species. Among them, Brasica napus L., 
spp. oleifera, is known as oilseed rape or rapeseed, which is thought to have originated 
from a cross that had a maternal donor derived from two diploids and related species such 
as Brassica oleracea and B. rapa. 
2.2.2. Development of Cano/a as a Commercial Crop 
Canola is a genetic variation of rapeseed developed in the early 1970s by Canadian 
plant breeders who used traditional plant breeding methods to produce rapeseed plants with 
low eicosenoic and erucic acid contents. In 1973, the oil and food processing industry, 
advised by the Canadian Health and Welfare Department, converted varieties of rapeseed 
with higher erucic acid content (more than 40%) into cultivars with .:::;5% erucic acid and 
low glucosinate content (3% mg per gram or less in food products). In 1974, Dr. Baldur 
Stefansson, a plant breeder from the University of Manitoba, developed the first Brassica 
napus variety, named "Tower," which was identified as canola and had less than 2% of 
erucic acid and a total of 30 µmoles/g of glucosinalate levels (Codex, 2001 ). 
2. 2. 3. Uses of Cano/a/Rapeseed 
The manipulations of genes that control oil quality make the attainment of different 
products possible. As an example, commodity canola oil contains traces of erucic acid, 5% 
to 8% saturated fats, 60% to 65% monounsaturated fats, and 30% to 35% polyunsaturated 
fats. In addition, cultivars that yield oils with 45% or more erucic acid have seed meals 
high or low in glucosinolates are classified as industrial rapeseed. Their end use is as 
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lubricants and hydraulic fluids. Also, the term "specialty canola" refers to cultivars with 
oils that contain less than 4% linolenic acid (18:3) and/ or greater than 70% oleic acid 
(18: I) for use in high temperatures or continuous frying. These characteristics confer 
greater temperature stability and improved shelf life to the specialty oil (Potts et al., 1999; 
Mc Yetty and Scarth, 2002). 
2.2.4. Types o/Canola Cultivars 
Winter varieties of canola are those that require a vernalization period, while spring 
varieties do not. In Australia, most of the canola crops are spring varieties and are grown 
between latitudes 30° S and 38° S. The normal planting time is April or May, and the 
growing season is 5-7 months with crops ripening in late spring or early summer. The 
normal yield is 1 to 2 metric tons per ha. Under an excellent production environment, a 
yield of 5 t/ha can be reached. Early frosts after flowering are responsible for important 
yield losses due to the abortion of seeds. 
Spring type cultivars B. napus are produced in Canada, northern Europe, and China. 
Also, in the Northern Plains and in the southeastern United States, where the winters are 
mild, spring type B. napus can be grown as a fall-planted crop. In Canada, the growing 
season lasts for less than 4 months, and spring varieties are the most predominantly 
planted. 
Spring type B. rapa cultivars are planted in fertile areas in Canada and in northern 
Europe, China and India. In India, B. juncea is dominant, whereas in Europe and Canada, 
B. juncea is planted in minor areas just for condiment use (Sovero, 1993). In the USA, 
spring cultivars of Brassica napus dominate the markets, and major production areas are 
the Northern Plains and the Pacific Northwest (Raymer et al., 1990). 
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2. 2. 5. Agronomic Requirements 
For both the spring and winter varieties, the average sowing rate varies between 4 
and 6 kg ha-1 when using varieties and 4 kg ha-1 when using hybrid seeds. The goal is to 
achieve a population of 50-70 plants m-2 with both varieties. Under normal soil conditions, 
for both winter and spring varieties, the canola seed is located no deeper than 2 cm. The 
crop is swathed 10 to 20 days before harvest to hasten the drying rate and avoid any 
shattering due to wind or hail. The crop exhibits its natural tolerance to grass selective 
herbicides such as trifluralin and clopyralid. Over a hundred herbicide tolerant hybrids 
have been released during the last decade, accounting for 95% of the total canola acreage 
(CCC, 2011). 
Among the different traits introgressed, the most importants are related to the 
tolerance to triazine, imidazolinone, and glyphosate herbicides. These varieties have been 
widely adopted by farmers and have allowed the canola industry to grow steadily. The use 
of this technology makes it possible to reduce costs, to simplify the management of the 
crop, and to control broad leaves and grass weeds with a single pass of an herbicide in post-
emergency. Glyphosate- and glufosinate-resistant varieties are predominant, accounting for 
55% and 28% of the seed market, respectively. Clearfield or Imidazolinone-tolerant 
varieties account for 12% of canola production (Harker et al., 2000). Imidozolinone 
herbicides contain acetolactate synthase inhibitors (ALS) that control broadleaf and grass 
weeds. Liberty Link canola (LL), also called glufosinate-tolerant canola, can be offered 
over glyphosate or imidazolinone, therefore lessening the risk of resistance development. 
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2. 2. 6. Pest Problems 
Canola plants, like most cultivated crops, are attacked by a number of insect pests. 
Some of the most important insect pests in North Dakota are the redlegged earth mite 
(Halotydeus destructor Tucker), blue oat mite (Penthaleus major Duges), cutworms 
(Agrotis infusa Boisduval), cabbage aphids (Brevicoryne brassicae L.) and mustard aphid 
(Lipaphis erysimi Kaltenbach), Diamond back moths (Plutella xylostella L.), Heliothis 
caterpillars (Helicoverpa punctigera Wallengren), known as Native budworm and H. 
armigera (Hilbner) and Rutherglen bug (Nysius vinitor Bergroth). The most susceptible 
stages of the crop are from planting to seedling and from flowering to seed set (Knodel, 
2010). 
The most difficult weeds to control are broad leaf weeds, especially those belonging 
to the Brassicaceae family; because there are no other herbicide options that control these 
weeds by using conventional varieties in post-emergency applications. For that reason, the 
use of herbicide-tolerant cultivars is increasing every season. 
Among the most important diseases that limit the development of canola are 
Sclerotinia stem rot (Sclerotinia spp.) and Blackleg (Leptosphaeria maculans). Other 
diseases include phytophthora root rot, caused by the fungus Phytophthora megasperma 
var. megasperma, downy mildew, caused by Peronospora parasitica, and altemaria leaf 
spot, caused by the fungus Alternaria brassicae, which can cause serious yield loss in wet 
seasons (Howlett et al., 1999). Blackleg is one of the most destructive diseases affecting 
canola. The fungus can be carried on infected seeds, survive on canola stubble, kill 
seedlings, or reduce seed yield in older plants. To avoid these diseases, rotation is one of 
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the best management practices, and forecast models play a key role in improving the 
efficiency of fungicide applications (Salam et al., 2003). 
2.3. Blackleg Disease 
2. 3.1. Causal Organisms 
Blackleg (Phorna stern canker), caused by Leptosphaeria maculans (Desrn.) Ces. et 
de Not. anarnorph Phoma lingam (Tade: Fr.), is the disease that causes the most serious 
economic impact on canola production worldwide. L. maculans can survive on canola 
residues. Under undesirable crop rotation conditions, there is an increase in the inoculum 
pressure for subsequent canola crops. The seedling stage is the most vulnerable, but 
symptoms can also appear during the entire growing season. In Europe and the USA, L. 
maculans co-exists with L. biglobosa. (West et al., 2002), which is associated with damage 
in upper stern lesions. 
2.3.2. Symptoms 
When ascospores or pycnidiospores of L. maculans infect cotyledons or rosette 
leaves, the pathogen spreads from leaf lesions down through the petiole to the stem (Figure 
1). The fungus enters through stomata or wounds (Huang et al., 2003). Circular pale grey 
lesions with numerous pycnidia in the center of cotyledons and dead leaf tissue indicate the 
first symptoms of seed-borne infections (Gugel and Petrie, 1992). On dead leaves, stern 
and roots, L. maculans produces globose and ostiolate black pseudothecia (300-500 um 
diameter). Asci contain 8 asco, are clavate and bitunicate and measure 80-125 x 15-22 µm 
(Punithalingarn and Holliday, 1972). 
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Ascospores have 5 septae, are cylindrical and yellow to brown; ascospores measure 
35-70 x 5-8 µm. Pycnidia are globose and have 200-400 µm diameter of. Pycnidiospores 
are shortly cylindrical and hyaline and measure 3-5 x 1.5-2 µm. 
The fungus moves biotrophically in the lamella and petiole of the leaf, without 
manifestation of symptoms, from cotyledons and leaf lesions to infect the stem and 
hypocotyls (Hammond and Lewis, 1987). As a consequence, severe seedling blight can be 
provoked. This type of infection causes the stem to constrict above the ground and below 
the first leaves (Barbetti and Khangura, 1999). 
Phoma stem cankers are developed when the pathogen colonizes and kills the stem 
cortex, wood and xylem cells of the host (West et al., 2001). Compared with leaf lesions, 
stem cankers have a purple or black border and are similar in shape. Those lesions, which 
encircle the basal stem, result in lodging and death of the plant. 
The lesions originate on the leaves and are associated with leaf scars, which transfer 
to the stem base where they are usually a dark brown or purple color and produce a crown 
or root collar. Dry rots, or cankers, are formed during the pod development and seed 
ripening stage. Terms such as canker, blackleg, crown, collar rot and basal canker are used 
to describe symptoms of a stem base disease (Hammond and Lewis, 1987). 
Stem cankers (upper or phoma stem lesions) originate from phoma leaf spot lesions 
that move to the upper parts of the stem and occur at flowering stages (Hammond, 1985). 
Crown cankers and phoma stem lesions encircle the stem, which causes the pods to ripen 
prematurely causing the plant to lodge (Davies, 1986). 
In roots, the symptoms of the fungus are caused by the growth of the pathogen 
within the xylem tissues during the flowering stage. Subsequently, cankers appear on the 
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stem base and completely girdle the stem during pod filling. These cankers destroy 
vascular tissues and limit plant growth, which results in yield reduction. The incidence and 
severity of epidemics depend on several factors, which include the rate of inoculum 
survival, maturation of fruiting bodies, timing of ascospore release, infection conditions, 
host growth stage at time of infection, and host resistance (Fit et al., 2003). 
Figure 1: A and B - Early development of blackleg symptoms on seedlings, C and D -
Blackleg stem symptoms on adult plant. 
2.3.3. Disease Epidemiology 
2.3.3.1. Disease Cycle 
L. maculans is a monocyclic pathogen. Epidemics of this disease are initiated by 
airborne ascospores (sexual spores), which are the primary inoculum and can originate 
from infected stubble for at least three years after the harvest of an infected crop (Guo and 
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Fernando, 2005). Pycnidiospores asexual spores were important during the epidemic that 
occurred during the 1970s in Australia (Barbetti, 1976; Hua et al., 2004 ). In Canada, 
pycnidiospores are also crucial in the development of the disease (Guo and Fernando, 
2005). 
Pycnidiospores inoculum is needed in large doses to develop disease symptoms, 
and they are not important as ascospores in the development of widespread epidemics 
(Wood and Barbetti, 1977; Salam et al., 2003). Seedling emergence often coincides with 
early ascospore showers (Salam et al., 2003) and are highly susceptible to infection up to 
the six-leaf stage (Khangura and Barbetti, 2001). After infection, pycnidiospores (asexual 
spores) act as secondary inoculum and are spread by rain to adjacent plants (Fernando et 
al., 2003). Canker development is still possible after the six-leaf stage, but the yield losses 
are of minor importance (Hammond, 1985). The link between cotyledon leaf lesions and 
the severity of crown cankers is related to temperatures in the range of 11 /18°C for growth 
stages up the 5th leaf, whereas infections occur at nearly all growth stages at the 
temperature range of 18/24°C (Hua et al., 2005). 
2.3.3.2. Survival and Pathogenic Activity 
The fungus survives as a saprophyte on infected stubble and its pathogenic activity 
has two periods of symptomless growth. The first occurs in leaves after the penetration of 
stomata by the hyphae produced from airborne ascospores before the appearance of leaf 
lesions (Toscano-Underwood et al., 2003). During this period of intercellular growth, the 
fungus is biotrophic. The second symptomless period occurs between the appearance of 
leaf lesions and the appearance of cankers on the stems (Huang et al., 2006). Once strains 
of compatible mating types meet, pseudothecia are formed and mature on the woody 
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remains of infected plants. After this necrotrophic phase, the pathogen produces pycnidia in 
the dead tissues (Hammond, 1985). Rain splash is involved in the dispersal of 
pycnidiospores to other plants. Temperature and humidity (rainfall and dew) mainly 
influence the process of pseudothecial maturation, which ranges from 51 days after harvest 
in France to 9 months after harvest in Saskatchewan, Canada (Khangura et al., 2007). The 
optimal environmental conditions for the formation of pseudothecia and the release of 
spores are 14°C and 100% RH (West et al., 2001). 
Researchers can predict the pseudothecia maturity and release of ascospores by 
tracking the weather conditions 16 to 19 rain days after harvest, when average temperatures 
are 14°C. Other factors such as rainfall, heavy dew, and high humidity affect the release of 
ascospores (Salam et al., 2003). 
2. 3. 3. 3. Disease Dispersal 
Driven by wind, ascospores can be dispersed up to 5 km from the infested stubble 
(Guo and Fernando, 2005; West and Fitt, 2005). From 9 pm to 4 am, when temperatures 
are 13 to l 8°C and RH is higher than 80%, dispersal of ascospores and pycnidiospores 
occurs. After rainfall :.::2mm, peak ascospores dispersal occur for numerous hours and 
continues for the next 3 days, while the peak pycnidiospores dispersal occur during rainfall 
(Guo and Fernando, 2005). The periods of ascospores and pycnidiospores dispersal 
coincide with susceptible growth stages of canola. The process of ascospores' release can 
last three to four months or even longer, with a production peak one or two months after its 
onset (Khangura et al., 2001 ). Ascospore dispersal in Saskatchewan starts on canola 
stubble in June while some ascospores remain until late July. Variations between locations 
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and seasons influence the temporal pattern of ascospore discharge and make it difficult to 
manage blackleg at regional and individual farms (Khangura et al., 2002). 
2.3.3.4. Inoculation Period 
The time from inoculation to penetration decreases with increasing temperature. 
Observed 24 hours after inoculation at temperatures of 5°C, the penetration process 
through stomata occurs and decreases to 16 hours, when the temperature increases to 10°C. 
The time needed for penetration decreases to 12 h after inoculation at temperatures of 15 
and 20°C (Huang et al., 2003). 
The optimum temperature for infection is about l 8°C; at this temperature the 
shortest wetness period is needed for infection to occur (Biddulph et al., 1999). The 
efficiency of infection is greatest at 18-20°C, with most lesions produced when the wetness 
duration is at least 48 hours. This happens as a result of a temperature increase from 5 to 
20°C, decreasing the time for germination and penetration (Toscano-Underwood et al., 
2001). 
Also, the incubation period, time from inoculation to the appearance of the first 
lesions, decreases from 15 to 5 days when temperatures increase from 8 to 20°C (Toscano-
Underwood et al., 2001). But, leaf wetness duration influences the length of the incubation 
period only at sub-optimal temperatures. 
The process of canker development occurs at optimal temperatures of 20 to 24 °C 
and the development of the disease decreases when the temperature ranges from 4 to 8°C. 
Also, temperatures of 28 to 30°C stop the development of the disease (Li et al., 2006). At 
18 and 24°C (which represent temperatures of night and day), the severity of crown 
cankers increase, compared with temperatures of 11 and l 8°C. 
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Phoma leaf spots occur under leaf wetness duration ranging from 8 to 72 hours, 
when temperatures range from 8 to 24 °C (Biddulph et al., 1999). Leaf wetness duration of 
48 h at 20°C generated the higher number of leaf spot lesions; as leaf wetness duration 
decreases with increasing or decreasing temperatures, the amount of lesions decrease. 
2. 3.4. Leptosphaeria maculans as Blackleg Causal Agent 
2.3.4.1. Taxonomy 
According to its taxonomical classification, Leptosphaeria maculans (Desm.) Ces. 
& de Not. (anamorph Phoma lingam Tode ex Fr.) belongs to the Kingdom: Fungi; Phylum: 
Ascomycota; Class: Dothideomycetes (Loculoascomycetes); and order: Pleosporales. 
2. 3. 4. 2. Morphological, Physiological and Genetic of L. maculans 
The taxonomic group of L. maculans comprises several closely related species that 
are morphologically similar (Cozinjnsen et al., 2001 ). Two pathotypes of L. maculans are 
differentiated among various isolates according to the production of the phytotoxin 
sirodesmin PL, and their ability to cause stem cankers on canola. The 'A' group, also 
termed Tox+, produces sirodesmin PL, which acts as a virulence factor in the late stages of 
canola infection and causes stem cankers. The 'B' group, which is genetically similar to 
'A' group, also termed ToxO, comprises several species, is weakly virulent, and does not 
produce sirodesmin PL or cause stem cankers (Rouxel et al., 2004 ). 
Many isolates of leptosphaeria maculans grow as saprophytes or as pathogens on 
crucifers. Based on the morphological characteristics of pseudothecia, two related species, 
L. maculans and L. biglobosa, can be isolated as saprophytes or as pathogens (Shoemaker 
and Brun, 200 I). The existence of up to seven subspecies within these two species was 
revealed using biochemical criteria (Mendes-Pereira et al., 2003). Brassica crops with stem 
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canker lesions are related to the existence of L. maculans. On the other hand, phoma stem 
lesions are caused by L. biglobosa. Existing in Europe, Canada and the USA, the two 
species are dispersed worldwide and show few differences (Mendes-Pereira et al., 2003). 
Located in most of the productive regions around the world L. maculans is a new and 
expanding species which threatens to overcome the less harmful L. biglobosa (West and 
Fitt, 2005). 
This species complex provides different methods for researching speciation issues 
because of the existence of "the close taxonomic, biological and geographical relationships 
between L. maculans and L. biglobosa" (Rouxel and Balesdent, 2005) 
2. 3. 4. 2. 1. Mating Types 
The importance of sexual reproduction of L. maculans is related to the production 
of ascospores as a source of genetic variation. Mating type (MAT) genes are helpful in 
determining the relationship of closely related species (Poggeler, 1999). L. maculans has a 
single mating type (MAT) locus with two alternate forms, also called idiomorphs (Venn, 
1979). For two isolates to mate, idiomorphs must be different. According to Cozijnsen and 
Howlett (2003), "idiomorphs in L. maculans encode single proteins with DNA-binding 
domains, such as an alpha box for MAT 1-2 strains". Sexual reproduction is the source of 
ascospores production and enables genetic recombination. More population genetic studies 
are needed that characterize genetic diversity and epidemiology (Cozijnsen and Howlett, 
2003). 
2.3.4.2.2. Toxin Production 
Toxins are implicated as virulence factors in numerous fungal diseases and can be 
host-specific or non-host specific (Markham and Hille, 2001; Howelett, 2006). Among the 
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nonspecific phytotoxins isolated, epopythiodiosoperazines (EPTs) are the most important, 
while specific toxins have not been isolated (Gugel and Petrie, 1992). Host-selective toxins 
are secondary metabolites implicated in cell death in plant-fungus interactions and can be 
used for rapid screening and the selection of blackleg resistance plants (De March et al., 
1986). Four different phytotoxins of blackleg were isolated from different isolates of L. 
maculans: sirodesmins H, J 2, K 3 and phomalirazine 6 (Pedras et al., 1990). Two host-
selective toxins, phomalide 4 and phomalairdenone A 55, were isolated from L. maculans. 
Phomalide 4 appears to be essential for host-selectivity and virulence of L. 
maculans when the pathogen causes damage on leaves of Brassica napus, B. rapa and 
other susceptible species. Phomalairdenone A 550, produced by Polish isolates of L. 
maculans, causes chlorotic, necrotic, and reddish lesions on susceptible cultivars of B. 
juncea, but not on B. napus or B. rapa (Pedras, 2001 ). 
2.3.4.2.3. Genetics 
L. maculans can be grown on a specific media. It is haploid, transformable and 
outcross is also possible. Field gel electrophoresis techniques indicate L. maculans has 15 
chromosomes ranging in size from 0.6 and 3.5 Mb. (Morales et al., 1993) The interactions 
between Westar, Quinta and Glacier cultivars and L. maculans at the seedling stage is due 
to the existence of three sets of corresponding avirulence and resistance genes (Ansan-
Melayah et al., 1998). 
Ascospores, the source of primary inoculum, have genetic variability, which is 
generated as a result of sexual reproduction. A single mating type locus and two different 
varying forms are present in the Ascomycetes, which make reproduction possible 
(Cozijnsen et al., 2001 ). 
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2.3.4.2.4. Pathogenicity Groups and Races 
There are currently two classification systems in use. North America (US and 
Canada) uses the PG system, but Europe and Australia have moved into race classification. 
Classification into pathogenicity groups has been made possible through the evaluation of 
the interactions between isolates and three differential cultivars, two of which share a 
common resistance gene (Rm/3) but carry an extra resistance gene. The other differential, 
Westar, does not carry any resistance gene. Table 1 shows the reaction in differential 
cultivars when they are inoculated with different PGs. 
Classification into races rather than pathogenicity groups has resulted in a more 
accurate assessment of the virulence structure of L. maculans populations and facilitated 
the use and transfer of R genes among cultivars from different regions (Rouxel et al., 
2003). To date, nine avirulence genes (AvrLml-AvrLm9) have been identified in 
Leptosphaeria maculans, combinations which could theoretically generate up to 512 
different races of the fungus. However, in Europe, only eight races have been identified 
(Balesdent, 2006). From the number of PGs and races identified, it is clear that the North 
American system is no longer adequate to describe the blackleg populations from the 
region; a single PG probably has multiple races. 
Currently, only a few countries lead the research on race structures, which include 
Germany, France, Canada, and Australia. Nevertheless, this research is limited in terms of 
comparison between race structures in various countries because an international set of 
differentials is still not available for researchers as countries lack a common race 
terminology and a shared plant and isolate differential (Balesdent, 2005). 
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Table 1. Pathogenicity group system used to classify Leptosphaeria maculans strains into 
pathogenicity groups. 
Pathogenicity Differentials 
groups 1 Westar( none )2 Glacier (Rlm2, 3) 
PGl 0 (R)3 0 (R) 
PG2 7-9 (S) 0-2 (R) 
PG3 7-9 (S) 7-9 (S) 
PG4 7-9 (S) 7-9 (S) 
PGT 7-9 (S) 3-6 (I) 
Classification according to Mengistu et al. 
2 Resistance genes in parentheses 
Quinta (Rlml,3) 
0 (R) 
3-6 (I) 
3-6 (I) 
7-9 (S) 
7-9 (S) 
3 According to the Delwiche rating scale (1980), R = Resistant reaction (0-3); I= Intermediate 
reaction (3-6), and S = Susceptible reaction (6-9). Mengistu et al., 1991 
2.3.5. Disease Management 
2.3.5.1. Cultural Practices 
Infected seed is the major cause of the introduction of blackleg into previously 
uninfected regions (Hall et al., 1996). Adjusting the time of seeding to avoid coincidence 
with conditions that favor high levels of inoculums is not always effective, especially in 
areas where ascospores are released throughout the entire growing season (Gugel and 
Petrie, 1992). Crop rotation of at least 3 years between canola crops reduces the severity of 
blackleg because it lowers the vitality of the fungus on the stubble of previous canola 
crops. But the effectiveness of crop rotation may be diminished if there are adjacent fields 
with infected stubble because ascospores can be dispersed up to 2 km (Petrie, 1986). 
Cultivation and burial of crop residues promotes its fast decomposition and shortens the 
survivability of the pathogens on infested materials (Abawi and Grogan, 1979). 
2.3.5.2. Fungicides 
Different factors such as the epidemiology of the disease and economic return of 
the crop influence the chemical management decisions in different regions (West et al., 
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2001). In order to protect the seedling for a long period of time, flutriafol, combined with 
other management practices, is used to coat fertilizer granules. This option offers good 
protection when there is low cultivar resistance, when the crop has high yield potential, and 
when the level of inoculum is moderate to severe (Barbetti and Khangura, 1999). 
In Canada and Europe, iprodione, thiram and carbathin are used as seed treatments 
(West et al., 2001). The use of foliar fungicide is recommended with cultivars with low to 
moderate level of resistance (Brown et al., 1976). According to the 2011 Field Crop 
Fungicide Guide, in North Dakota, the options suggested for seed treatment include the 
following active ingredients: azoxystrobin, fludioxonil, and metalaxyl. Also, the following 
combinations are recommended: difenoconazole + metalaxyl M + fludioxonil + 
thiamethoxam; thiram + carboxin + metalaxyl + clothianidin; as well trifloxistrobin+ 
carboxin + metalaxyl + clothianidin (McMullen and Markell, 2010). 
Foliar fungicide applications, especially with triazoles have produced inconsistent 
degrees of control (Gugel and Petrie, 1992). Furthermore, application of fungicides is 
generally inefficient because targeting the disease accurately is complicated due to the 
asymptomatic phase of the disease, which makes identification difficult. This also adds to 
an increased risk of environmental pollution because fungicides may be applied when they 
are not necessary. The application of prothioconazole as a foliar fungicide does not control 
phoma stem cankers in the average enviromnental conditions of Canada where the primary 
inoculum comes from stubble infested fields that release conidia and ascospores throughout 
the entire growing season (Kharbanda, 1992). In order to control crown canker in western 
Europe, the application of difenconazole as a foliar fungicide or in mixture with 
carbendazim and/or flusilazole normally offers good quality control (Gladders et al., 1998). 
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In western Europe, autumn, which coincides with the seedling stage, is the best time 
to apply foliar fungicide in order to manage crown canker epidemics (Gladders et al., 
1998). It is important to use accurate forecast models to predict the severity of epidemics 
because the fungicides have low eradicant activity and limited protectant activity as a result 
of "chemical decomposition, leaf expansion and the production of new untreated leaves" 
(West et al., 2001). According to the 2011 Field Crop Fungicide Guide, in North Dakota, 
the options for foliar sprays include the following active ingredients: azoxystrobin, applied 
at 2 to 4 leaf stage, or pyraclostrobin, also applied at 2 to 4 leaf stage (McMullen and 
Markell, 2010). 
Researchers in the UK are trying to develop more accurate forecast models because 
the ones based on weather patterns and ascospore development that predict the incidence of 
phoma leaf spotting on crops in the autumn often do not allow growers sufficient time to 
control the disease before the fungus reaches the stem. As a consequence of the inaccuracy 
of the current model, farmers in the UK have often applied fungicides unnecessarily (Fitt et 
al., 1997). The new models under development are based on the link among weather factors, 
ascospore maturation, release and infection. Also, they use immunological techniques to 
detect airborne ascospores and symptomless leaf infection. In France, a model has been 
developed that uses weather factors such as 7 rain-days after sowing, maturation of 
pseudothecia or first detection of >20 ascospores per day and other biological parameters 
to predict the risk of infection (Penaud et al., 1999). 
2.3.5.3. Resistant Cultivars 
Resistant cultivars have been used to manage the disease in Australia, Canada and 
Europe (Bansal et al., 1994 ), but the change of the pathogen and the apparition of new 
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races make relying only on this practice unsustainable. For this reason, breeding for 
disease resistance is a continuous effort (Delourme et al., 2006). 
In the past, the use of resistant varieties and four-year crop rotations has effectively 
controlled the disease, but such a long rotation program has become unpopular among 
growers. Chemical control of the disease is not economically viable in most conditions 
(West et al., 2001). For these reasons, it is crucial to breed for resistance (Fernando et al., 
2007). 
2. 3. 5. 4. Genetic Resistance 
Host resistance has been the most economical and effective method to control 
blackleg (Delourme et al., 2006). There are 14 major genes conferring resistance against L. 
maculans (Balesdent et al., 2002). The introgression of few of these genes in adapted 
cultivars prevents the spread of the pathogen to the stem and the development of cankers. 
Resistance in Brassica napus is controlled monogenically by specific resistance 
genes that interact in gene-for-gene mode or by genes inherited poligenically and expressed 
quantitatively. Nevertheless, the development of new pathotypes as a consequence of the 
pathogen's ability to change is making the management of the disease unsustainable 
through the use of cultivars with race-specific resistance (Delourme et al., 2006). 
Qualitative resistance, also known as vertical or complete resistance, is considered 
single-gene-race specific and protects the plant when the corresponding avirulent allele is 
predominant in the local L. maculans population (Rouxel et al., 2003). This kind of 
resistance operates in cotyledons and leaves during the first symptomless phase, 
immediately after the penetration of leaves by hyphae from the ascospores (Balesdent et 
al., 2001). Although vertical resistance is expressed as a hypersensitive reaction, it has 
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been considered non-durable (Lindhout, 2002; Parlevliet, 2002). Environmental factors 
such as temperature have influenced the expression of the resistance (Huang et al., 2006). 
The use of vertical resistance puts pressure on the pathogen to shift their 
populations and as a consequence, resistance could breakdown. This situation has been 
already observed with blackleg in France and Australia (Brun et al., 2000; Sprague et al., 
2006). 
Quantitative resistance controls the spread of the pathogen down the leaf petiole or 
into the stem tissues during the long period of symptomless growth between the appearance 
of leaf lesions and the appearance of cankers on stems (Pilet et al., 1998; Delourme et al., 
2006). It acts by impeding the growth of the pathogen within the stem tissues, and has been 
associated with more rapid lignifications of resistant cultivars (Hammond & Lewis, 1987). 
This kind of resistance is mediated by many genes and is more durable (Boyd, 2006). 
As a result, selecting cultivars for quantitative resistance currently relies on field 
experiments that assess stem cankers before harvest (Fitt et al., 2006). Although 
quantitative resistance is more stable or durable than vertical resistance, the level of 
protection may not be as effective (Pilet et al., 2001 ). In Australia, L. maculans can 
overcome this kind of resistance under glasshouse conditions (Li et al., 2005). 
Conventional methods for blackleg resistance breeding have the constraints of 
dealing with polygenic pools of genes, the important variability of pathogens (Williams, 
1992), and the complexity of field testing designs (Pilet et al., 1998). While progress has 
been made to understand resistance at a molecular level, studying genetics is increasingly 
important because it gives plant breeders methods to develop long lasting resistant 
cul ti vars. 
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Knowing the genetic background of a cultivar is necessary to predict how it will 
perform when exposed to new pathotypes. Unfortunately, genetic background information 
is usually not revealed by the seed industry, and often cultivars are rated as resistant, but 
there is no information about which pathotypes they are resistant to. 
The most important factors to consider when breeding for durable resistance are the 
types of resistance present in the host and the genetic background of the host and 
pathogens, although the area and climate where the crop is grown should also be 
considered. Durable resistance is difficult to breed for a pathogen like L. maculans, in 
which air-borne ascospore dispersal and sexual recombination of the pathogen occurs 
frequently (McDonald and Linde, 2002). Taking this into account, modeling the effects of 
different deployment strategies in space (pattern of areas sown with cultivars with different 
genes) and time (seasonal pattern of deployment), in relation to different measures of 
resistance durability (van den Bosch and Gilligan, 2003), can be used to guide different 
proposed deployment strategies (Pietravalle et al., 2006). 
The breakdown of resistance, caused by major genes, occurred recently in Australia 
(Li et al., 2003). The durability of major gene resistance may be increased by 
diversification schemes, which classify the current commercial cultivars by the resistance 
genes they carry in order to guide strategies for deployment of these genes (Gladders et al., 
2006). Modeling the effects of different deployment strategies in space (pattern of areas 
sown to cultivars with different genes) and time (seasonal pattern of deployment), in 
relation to different measures of durability of resistance (van den Bosch and Gilligan, 
2003), can be used to guide different proposed deployment strategies (Pietravalle et al., 
2006). 
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The symptomless phase of blackleg disease makes identifying a correct time to 
apply fungicides difficult (Rouxel and Balesdent, 2005). For the above reasons, it is a 
priority to breed cultivars with durable resistance, which is referred to as quantitative 
resistance. In the meantime, the possibility of developing cultivars with vertical resistance 
makes it possible to find accessions with resistance that could be used in subsequent 
breeding programs to breed for more durable resistance. The possibility of developing 
cultivars with qualitative resistance makes the management of the disease feasible until 
cultivars with quantitative resistance are available. The value of vertical resistance in an 
accession is to find resistance genes that can be introgressed into commercial cultivars. 
Plants that have acceptable levels of vertical resistance should also be tested to determine 
how they will perform. And those will be source o resistance in accessions that could be 
used in subsequent breeding programs. In this study, different collections of accessions 
were screened in order to find sources of vertical resistance. 
2.3.5.4.1. Factors Implicated in Field Resistance 
In order to sustainably manage Phoma stem canker, it is important to breed cultivars 
that are resistant at both stages. Seedling and adult plant resistance have different genetic 
backgrounds, and in the adult, the resistance slows down and obstructs the spread of the 
disease in the leaf and seedlings. The process obstructs the spread of the disease down the 
petiole to the hypocotyls or stem (Rimmer and van den Berg, 1992). 
Field resistance to phoma stem canker is the product of numerous factors: one of 
them is genetic resistance to penetration of cotyledons by conidia (Badawy et al., 1991 ). 
Another component is disease escape, which happens when plants drops infected leaves 
before the pathogen has the chance to enter the stem. Additionally, the disease tolerance 
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component lessens the manifestation of symptoms in the plants by working with the 
genetic resistance component. Furthermore, tolerance characteristics could be provided by 
inhibitory chemicals, the toughness and thickness of the stem. Finally, cultural practices 
such as good crop rotation and environmental factors such as temperature decrease the risk 
of infection and do not contribute to disease development (West et al., 2001 ). 
Different sources of resistance are expressed at various stages of development of 
plants (Rimmer and van Der Berg, 1992). Total resistance at seedling and adult stages of B. 
nigra and B. juncea L. has been introgressed into B. napus (Roy, 1984; Struss et al., 1991). 
The majority of the introgressed seedling resistance were found to be monogenic or 
oligogenic at the intraspecific level (Stringam et al., 1992). 
It has been reported that gene linkage controls resistance at both developmental 
stages in B. napus (Zhu and Rimmer, 2003). While other studies suggest a consistent 
correlation between plant resistance stages, the existence of allelic loci was not proved. 
Other research has concluded that separate genetic control governs resistance at both stages 
(Ballinger and Salisbury, 1996). 
2. 3. 5. 4. 2. Screening for Resistance 
When screening for resistance, factors such as spore concentration, temperature, 
and photoperiod influence the manifestation of the symptoms. However, Bansal et al., 2002 
reported that increase of inoculum concentration over the range of 5 x 105 to 4 x 106 
pycnidiospores per ml, respectively, did not affect levels of cotyledon infection. When 
pycnidiospore-inoculum was used, incubation time period did not have a marked effect on 
the number infected plants. Wood and Barbetti' s study (1977) reported that under a natural 
light photoperiod of 8 h at 10, 15, or 20°C, a temperature of 20°C caused more rapid 
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symptom development than lower temperatures. As a result, it can be concluded that low 
temperatures slow down disease incidence, but do not decrease it (Wood and Barbetti, 
1977). 
Seedlings can be screened for qualitative resistance in cotyledon tests (Balesdent et 
al., 2001 ), which was the practice used to screen the different collections of Brassicas. 
Cotyledon biossays are among the most effective methods for screening resistant 
materials against blackleg in greenhouse conditions (Rimmer and van den Berg, 
1992).Temperature during the incubation period is one of the critical factors that influences 
disease severity. The expression of symptoms is delayed as temperatures decrease after 
being inoculated with ascospores of L. maculans. Other factors that influence the duration 
of the incubation period are inoculum concentration, relative humidity, photoperiod 
duration, and the degree of plant tissue injury (Bansal et al., 2002). 
2.4. Nonparametric Data Analysis 
The Delwiche scale (1980) that measures severity of infection is an example of an 
ordinal scale. The differences between the measured values and means cannot be 
interpreted in the same sense as the means observed in a continuous scale. Parametric 
statistics were used in previous studies until to analyze non-parametric information using 
simple experimental design such as one-way layout (Munzel and Bandelow, 1998). With 
the latest development of software, plant pathologists can analyze ordinal data using 
nonparametric methods generated from more complex designs. The statistical approach to 
manage ordinal data should keep the initial order of the ordinal scale values. The use of 
rank transformations methods is adequate for this task. Differences in ranks are the 
parameter that allows easy identification of the differences between ordinal values. 
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The Kruskal-Wallis and Friedman tests are two nonparametric methods based on 
rank transformation. The first test gives the same kind of information as the one-way 
analysis of variance (ANOVA) and the second test is adequate to analyze randomized 
complete block design (RCBD). 
The Brunner nonparametric method allows the analysis of any experimental 
design using normalized distributions instead of the sampler distribution. The normalized 
distribution represents random variables such as continuous and ordinal categories. The 
relative treatment effects can be assessed by the midrank values. There is a connection 
between the mean ranks and the relative effects of the Brunner method used in many 
nonparametric analyses. The ranks are used as a natural and convenient tool for estimating 
the relative treatment effects. The use of estimated relative effects and confidence intervals 
in this kind of analysis can be used to detect differences between treatments (accessions). 
The lower the relative effect of a particular accession the higher will be its resistance value. 
Relative effects are analogous to means used in parametric statistical analysis. 
The median disease ratings per isolate provide one convenient and traditional 
summary of the central value for each treatment. The estimated relative effects will be 
values linked to the median rating where the largest values will correspond with the largest 
median ratings. 
Shah and Madden (2004) also developed a method which used normalized 
distribution to test the null hypothesis. This method was used to analyze data obtained 
from the cotyledon inoculation test, which was used to evaluate the collections of Brassica 
germplasms when challenged with isolates of PG3 and PG4 of blackleg. Median disease 
severity ratings "provide one convenient summary of the central value of each treatment" 
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(Shah and Madden, 2004). Using Brunner's method, the confidence interval parameter was 
deducted based on the standard error (se). The parameters estimated relative effects (RE) 
and confidence intervals were used to detect differences between treatments. A lower value 
of RE indicated a higher degree of resistance in the material evaluated. Differences in 
relative effects measure treatment differences. 
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CHAPTER 3. 
MATERIALS AND METHODS 
This research was divided into 6 sections, all of which were conducted in 
greenhouse conditions. The first three experiments were designed to evaluate and identify 
resistance to pathogenicity groups 3 and 4 of L. maculans in plant introductions from 
Brassica rapa, Brassica napus, and Brassica juncea collections. The following three 
experiments were designed to evaluate the reaction of 75 commercial canola cultivars to 
PG2, PG3 and PG4 and also to compare the effect of different sequences of inoculation on 
the reaction of ten commercial cultivars. 
The activities conducted in preparation for the actual screening, such as planting 
methods, inoculum preparations, growth conditions and the evaluation of disease reaction 
were common for all sections. The experiments were laid out using randomized complete 
block design (RCBD) with two replications and the experiments were conducted in 2009 
and 2010. The accessions were evaluated in trials, each of them containing 9 accessions 
and the commercial cultivar DK 3042 as a susceptible control. Finally, the 277 accessions 
of the B. rapa collection were evaluated in 31 trials, the 130 B. napus accessions in 15 
trials, and the 406 B. Juncea in 45 trials. For each accession a minimum of six plants were 
evaluated using a 0-9 scale developed by Delwiche (1980) where O to 3 correspond to the 
resistant category, 4 to 6 to the moderately resistant category and 7 to 9 to the susceptible 
category. According to their scores, individual plant materials showing a moderately 
resistant (MR) or resistant (R) were identified and transplanted into larger pots. They were 
then taken to flowering in order to evaluate disease reactions in the next generation after 
being self-pollinated. 
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3.1. Preparation of Plant Materials for Inoculation 
During the identification of sources of resistance it is recommended that greenhouse 
evaluations be accompanied by corresponding field trials. In this case, however, the limited 
geographic distribution and the low frequency of PGs 3 and 4 strains, in the most important 
canola production area in North Dakota, which include the north central counties 
Bottineau, Rollete, Towner, Cavalier, and neighboring areas, prevent us from conducting 
field trials. According to Pongam et al., 1999 isolates that belong to PG3 and PG4 in North 
Dakota were similar to those that exist in United Kingdom. PG4 strains were first detected 
in 2003 in a commercial field in Cavalier, ND (Chen and Fernando, 2006). 
Seeds of each accession were planted in one insert containing 6 cells. Ten inserts 
corresponding to 9 accessions plus the control constitute a trial (E.C.Geiger, Inc., 
Harleysville PA). Greenhouse artificial soilless mix (Professional Growing Mix 1 SunGro 
Horticulture Canada Seba Beach, AB, Canada) was used as subtract to grow the plants. The 
trials were watered daily, and the greenhouse room was illuminated with high pressure 
sodium lamps (1,000 µmol/m2s). The natural light, combined with artificial illumination, 
lasted for about 16 hours per day. The temperature inside the greenhouse room ranged 
between 20 and 25°C. At planting time, 3 seeds were sown in each cell and fertilized with 
3.3 g of 12-24-12 and 1 g/pot of insecticide imidacloprid was applied (Marathon, OHP 
Inc.). After germination, seedling populations were thinned down after 9 days in order to 
leave six plants per insert (one per cell). A total of21,336 plants that belong to the different 
Brassica collections and the commercial cultivars were screened in this study. The 
experiments were conducted as a RCBD, except the experiment that compared the effect of 
different sequences of inoculation where a CRD was used. All accessions and commercial 
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cultivars were inoculated using the cotyledon inoculation technique approximately 10 to 12 
days after planting. 
The plant materials used in this study were obtained from the National Plant 
Germplasm System USDA-ARS. The different Brassica spp collections are maintained at 
the North Central Regional Plant Introduction station in Ames, IA (http://www.ars-
grin.gov/ars/MidWest/Ames/). In this study, 277 accessions of Brassica rapa, 130 B. napus 
and 407 B. juncea accessions, were evaluated for their reaction to PG3 and PG4 of L. 
maculans. Additionally, 75 of the most commonly grown canola cul ti vars that were part of 
the NDSU field trials during 2008 were evaluated for their reaction to strains of the same L. 
maculans PGs. Arbitrarily, in order to have cultivars that represent the seed companies that 
are in the field trial evaluation of NDSU, a sample of 16 commercial cultivars were 
selected from the 75 cultivars, and also evaluated for their reaction to PG2 of L. maculans. 
For the same reason mentioned above, a sample of ten commercial cultivars (Table 2) 
selected from the 75 cultivars was also evaluated for their reaction to five different 
inoculation sequences during 2009 and 2010 with two replications. The disease reaction 
was evaluated after 12 days of inoculation, and the inoculation process was similar to the 
previous experiments described. 
3.2. Inoculum Production and Storage 
Four L. maculans isolates belonging to PG3, identified as BL 729, BL 730, BL 731, 
and BL 732, and isolate BL 736, belonging to PG4 were used in all studies reported in this 
thesis. All isolates were collected from plant residues from canola grown in North Dakota. 
Single spore cultures of L. maculans isolates belonging to PG3 and PG4 were 
grown in potato dextrose agar (Difeo; Becton, Dickinson and Company, Sparks, MD 
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USA). For PG3, a mixture of spores of four isolates was used. For PG4, only one isolate 
was used (the only one available). These cultures were transferred to V8 juice agar medium 
and supplemented with rose Bengal (0.05g/l) and CaC03 (3g/l) for spore production. 
Table 2. Characteristics of 10 commercial cul ti vars evaluated for their reaction to PG3 
and PG4 strains of blackleg inoculated alone or in different sequences. 
Company 
Cargill 
Canterra 
Integra Seed 
Brett Young 
Monsanto 
Mycogen Seeds 
Agriprogress 
Croplan Hyclass 
Bayer Invigor 
DKL 
Cultivar Type1 Blackleg Rating2 
V2018 H,HO MR 
30507-B6 H,TR MR 
IX08-7323R H,TR R 
6235RR H,TR MR 
G67012 H,TR R 
G2X0043 OP,HO R 
30412-B6 H,TR MR 
924 H,TR R 
5440 H,LL,TR R 
30-42 H, TR R 
Adapted from Kandel, 2008. 
10P-Open Pollinated, H-Hybrid, Syn-Synthetic. TR-Traditional Oil Type, HO-High Oleic Oil 
Type 
2Blackleg Rating: S = Susceptible, MS= Moderately Susceptible, MR= Moderately Resistant, R = 
Resistant, ratings are provided by the companies. 
Isolates were incubated for two weeks at 21 °C under 24 hours of light conditions. 
After incubation, the cultures were flooded with 5 ml of sterile distilled water, and their 
surface was gently rubbed with a bent glass rod to suspend the spores in the water. The 
spore concentrations were adjusted to 107 spores mr1and stored for future use in 1.5 ml 
polyethylene microcentrifuge capsules (VWR International, LLC, PA) at -20°C. To 
reduce variation among batches and to eliminate the repeated sub-culturing, all batches 
were inoculated using spores from the frozen stock. Viability of inocula was periodically 
checked by incubating spores in water and estimating spore germination after 24 h of 
incubation at 21 °C. 
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3.3. Inoculation and Incubation Procedures 
Cotyledon bioassay was used to select resistant plant materials (Rimmer and van 
den Berg, 1992). The methodology and reaction assessment were similar for all the 
experiments carried out for this study (Figure 2). 
Each seedling, simultaneously received inoculum from both PGs, but in separate 
cotyledon leaves approximately 10 days after planting. A tiny spot of red color was used to 
identify the cotyledon inoculated with PG4, whereas any mark was used to identify the 
cotyledon inoculated with PG3. Inoculum from each group was applied at a concentration 
of 10 7 spores per ml. Each cotyledon leaf was previously wounded lightly by gently 
pricking the center of each lobule with a needle. A 1 Oµl aliquot of the stock suspension was 
placed on top of each wound using a micropipette. A cool-mist machine was used to 
increase relative humidity in the greenhouse room for the 24 h after inoculation. The plants 
were incubated at 20°C in a greenhouse room. 
3.4. Disease Evaluation 
Ten to twelve days after inoculation, disease reaction was evaluated using a 0-9 
scale developed by Delwiche (1980) (Table 3 and Figure 3). 
Materials showing a resistant or moderately resistant reaction to both groups were 
transplanted into larger pots, taken to flowering, and self-pollinated to increase seed 
production. The seed obtained from those plants were planted and inoculated in a new 
round in order to prove the existence of resistance. 
Seedlings were considered resistant if their reaction scores were below 3 on the 
scale, partially resistant if their score ranged between 3 and 6, and susceptible when their 
scores were in the range of 6 to 9 (Delwiche, 1980). 
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Figure 2: Process of inoculum preparation and disease evaluation on seedling of Brassica 
spp using three Leptosphaeria maculans isolates of pathogenicity group 3 and one 
isolate of pathogenicity group 4 in greenhouse condition~. 
Table 3. Descriptions of symptoms and signs according to the Delwiche scale (1980). 
Categories Symptoms and signs description 
0 No darkening around wound, as in controls. 
1 
3 
5 
7 
9 
Limited blackening around wound, lesion diameter: 0.5-1.Smm, faint 
chlorotic halo may be present, sporulation absent 
Dark necrotic lesions, 1.5-3.0mm, chlorotic halo may be present, sporulation 
absent. · 
Non sporulating 3-6 mm lesions, sharply delimited ibY dark necrotic margin, 
may show grey-green tissue collapse as in IP 7 · and 9 or dark necrosis 
throughout. 
Grey-green tissue collapse 3-5 mm diameter, sharply delimited, non darkened 
mar~n. . 
Rapid tissue collapse at about 10 days, accompanied ;by profuse sporulation in 
large, more than 5 mm, lesions with diffuse margins. 
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Figure 3: Blackleg severity scale: No presence of lesions =O: Presence of dark necrotic 
lesions= 3: Collapse of grey-green tissue=6: Collapse of rapid tissue and lesions 
with diffuse margins=9. 
Individual plants that belonged to accessions with acceptable levels of resistance 
(<S in the Delwiche scale) were selected, transplanted and tak~n to flowering and seed 
production. The next generations were evaluated in subsequent rounds of inoculations. 
3.5. Experiments Conducted 
The screening process was similar for all plant introduction materials evaluated. As 
! 
outlined above, seedlings were inoculated simultaneously but in ~ifferent cotyledons, with 
spore suspensions of isolates that belonged to both PGs. Reactjons to inoculation were 
evaluated separately, and those accessions showing resistant reactions to both PGs were 
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advanced for evaluation in advanced generations. Resistant materials were self-pollinated 
and their S1 seeds were advanced to the second phase of the study, where they were 
inoculated again with both PGs. Plants showing a resistant reaction were taken to seed 
production. Resistant materials were self-pollinated and their progeny screened again to 
achieve S2 generation. 
3.5.1. Screening of Brassica rapa Plant Introduction Materials 
In this study the reaction of 277 B. rapa accessions to L. maculans isolates 
belonging to pathogenicity groups 3 and 4 were evaluated. Also, 33 plant introduction 
materials previously identified as having adequate levels of resistance to Sclerotinia 
sclerotiorum (Zabala, 2008) were evaluated. 
3.5.2. Screening of Brassica napus Plant Introduction Materials 
In this study, 130 B. napus accessions were evaluated for their reaction to L. 
maculans isolates belonging to pathogenicity groups 3 and 4. In addition, 21 plant 
introduction materials previously identified by Khot (2006) as having adequate levels of 
resistance to Sclerotinia sclerotiorum were also evaluated. 
3. 5. 3. Screening of Brassica Juncea Plant Introduction Materials 
A group of 406 B. juncea accessions were screened for their reaction to L. maculans 
isolates belonging to pathogenicity groups 3 and 4. 
3.5.4. Evaluation of Reaction of Commercial Cultivars to PG2 
In this study 16 commercial canola cultivars from ten seed companies were 
evaluated for their reaction to PG2 strains of L. maculans. This set of cultivars was a subset 
of the 75 commercial cultivars evaluated later for their reaction to PG3 and PG4. These 
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cultivars had been part of the NDSU 2008 variety trials (Kandel, 2008). PG2 is considered 
the most prevalent pathogenicity group in North Dakota. 
3.5.5. Evaluation of Reaction of Commercial Cultivars to PG3 and PG4 
In this study, the reactions of 75 commercial canola cultivars commonly grown in 
North Dakota to PG3 and PG4 strains of blackleg were assessed. These cultivars were 
produced by 12 seed companies and were chosen from the 2008 canola field trial 
evaluations (Kandel, 2008). These cultivars were considered either resistant (R) or 
moderately resistant (MR) to blackleg by the companies that produced them, although it is 
not clear whether the rating refers to a particular PG or is a blanket statement. 
3. 5. 6. Effect of Timing and Sequence of Inoculation on Reaction to Disease 
In this study, 10 commercial cultivars were evaluated for their reaction to different 
inoculation sequences during 2009 and 2010 with two replications. The objective of this 
study was to determine if there was synergism in the simultaneous inoculation of PG3 and 
PG4 and to detect other possible interactions between the cultivars and the inoculation 
methods. In all cases when seedlings were inoculated with spores of a second PG, either 
separately or simultaneously, the inoculum of the second PG was deposited in the 
cotyledon not inoculated with the first PG. In cases when a single PG was used, seedlings 
were inoculated in both cotyledons. 
In the first treatment, the cultivars were inoculated with a blend of four PG3 
isolates, and 24 h later with a PG4 isolate. In the second treatment, the cultivars were first 
inoculated with the PG4 isolate, and 24 h later with the blend of PG3 isolates. In the third 
treatment, cultivars were inoculated only with PG4. In the fourth treatment, cultivars were 
inoculated only with the blend of PG3 isolates. In the fifth treatment, cultivars were 
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inoculated with the blend of PG3 isolates and PG4 simultaneously. The process of 
inoculum preparation and disease evaluations were similar to those described for the other 
experiments. All treatments were incubated 24 h in the mist chamber. 
3.6. Statistical Analyses 
3. 6.1. Analyses of Reaction of Plant Introduction Materials and Commercial 
Cultivars 
Since disease data was collected using a categorical scale, median values rather 
than arithmetic means were calculated for each treatment and replication. The median 
values of the control materials used in each batch for each PG throughout the experiments 
were used to determine whether the batches were significantly different from each other, at 
a probability level of 5%, within a year and then between years. This was conducted 
running analyses of variances for each level. Upon confirmation that there were no 
statistical differences among batches, using a Bartlett chi-square test within a year and 
between years, the data from both years in each study were combined. Years were 
considered as random effects whereas accessions were considered as fixed effects. 
Treatment medians for each replication were ranked using PROC RANK from SAS v. 9.2 
(SAS Institute, Cary, NC) and the ranks analyzed using the ANOVA F-TEST option of 
PROC MIXED from SAS. PROC MIXED was used in order to deal with the random and 
the fixed effects and to have a better estimate of the standard error. The AN OVA F-TEST 
option runs an ANOV A-type analysis and calculates treatment relative effects (Shah and 
Madden, 2004). This test is equivalent to Friedman's non-parametric test and was used to 
determine whether the treatments were different or not. To discriminate among treatments, 
the estimated treatment relative effect and its 95% confidence interval were calculated 
using the Id ci.sas macro developed by Dr. E. Brunner (University of Gottingen, 
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Germany). According to Shah and Madden, 2004 "one can think of the relative treatment 
effects as a generalized expectation or mean". 
3. 6. 2. Analyses of Reaction of Commercial Cultivars to Blackleg Sequence 
Inoculations 
Data from the ten commercial canola cultivars was processed in similar manner, 
although there were no batches in this study. Median treatments values were ranked and 
analyzed as described using the ANOV A F-TEST option of PROC MIXED from SAS and 
single-degree-of-freedom ANOVA analysis was used to compare treatments. 
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CHAPTER 4. 
RESULTS 
4.1. Evaluation of Brassica rapa Accessions for their Reaction to PG3 Isolates of L. 
maculans 
Out of the 277 accessions evaluated for their reaction to PG3, none were selected 
based on the high values of median disease ratings according to the Delwiche scale. 
The median disease rating for PG3 varied between 5 and 9 (Figure 4) and the 
relative effect varied between 0.10 and 0.95. Most of the Brassica rapa accessions (160) 
representing 58% showed a median disease rating of 6. Nevertheless, 7 accessions, 
representing 2%, of the total evaluated had a median disease rating between 5 and 6. The 
remaining 110 accessions ( 40%) showed a median disease rating over 7. Treatment relative 
effects of the best 10% accessions are presented in Table 4. Data for the remaining 
accessions were placed in Appendix 1. 
Just 10 accessions representing 3.6% of the total evaluated had a relative effect 
below 0.2. Six of these accessions, Ames 9244, 340179, 169064, 370733, 173846, and 
171521 had an overall median disease rating of 5 in the 0-9 Delwiche scale (Table 4 ). The 
remaining accessions in this group had median of 6. Additionally, 20 accessions, 
representing 7 .2 % of the total evaluated showed a relative effect between 0.2 and 0.3. The 
remaining 246 accessions (89%) had a relative effect higher than 0.3. 
Based on the range of confidence intervals for each relative treatment effect, there 
is no overlap for estimated relative effects between accessions that scored 5 and those that 
scored 9. This means that those accessions are statistically different. There was no 
significant difference between accessions that scored 5, 6, 7 and 8 (Table 4 and Appendix 
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1 ), a confirmation that most accessions in the B. rapa collection are susceptible to PG3 and 
PG4 strains of blackleg. 
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Figure 4. Frequency distribution of the reaction of Brassica rapa accessions to inoculation 
with L. maculans isolates of the pathogenicity groups 3 and 4 (R=Resistant, R-
MR=Resistant to moderately resistant, MR=Moderately resistant, S=Susceptible). 
4.2. Evaluation of Brassica rapa Accessions for their Reaction to PG4 Isolate of L. 
maculans 
As a population, the 277 B. rapa accessions were more susceptible to PG4 than to 
PG3 (Figure 5). Of all materials evaluated only nine (3.2% of the population) were 
classified in the lower part of moderately resistant; the rest were considered susceptible. 
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Table 4. Median disease ratings, mean ranks, and estimated relative treatment effects for 
the severity of symptoms on 29 Brassica rapa plant introduction materials 
inoculated on seedling cotyledons with three Leptosphaeria maculans isolates 
of pathogenicitl group 3 in greenhouse conditions. 
Confidence Interval 
Treatment effect (95%) 
Median Treatment 
Accession Disease Mean relative Standard Lower Upper 
number Name Ratio!! Rank effect error Limit Limit 
3 Ames 9244 5 97.88 0.10 0.020 O.Q3 0.34 
32 Pl340179 5 69.75 0.11 0.020 0.03 0.33 
74 PI347596 6 149.50 0.11 0.020 0.03 0.33 
67 Ames 9741 6 13738 0.17 0.023 0.06 0.39 
209 PI 169064 5 117.75 0.17 0.023 0.06 0.39 
217 PI 370733 5 208.00 0.17 0.023 0.06 0.39 
248 PI 173846 5 191.00 0.17 0.023 0.06 0.39 
258 PI 173871 6 120.75 0.17 0.023 0.06 0.39 
247 Pl 171521 5 86.63 0.18 0.022 0.07 0.38 
51 PI 163947 6 150.38 0.19 0.039 0.04 0.57 
2 Pl 179863 7 145.25 0.21 0.054 O.D3 0.71 
13 Ames 9263 6 113.88 0.24 0.039 0.07 0.57 
27 Pl319413 5 117.50 0.24 0.020 0.13 0.40 
35 PI340181 6 91.38 0.24 0.039 0.07 0.57 
43 Ames 9474 6 205.88 0.24 0.039 0.07 0.57 
84 Pl347605 6 158.38 0.24 0.020 0.13 0.40 
95 PI 633173 6 120.75 0.24 0.020 0.13 0.40 
141 PI426177 6 163.25 0.24 0.020 0.13 0.40 
249 Pl 173848 6 138.50 0.24 0.020 0.13 0.40 
6 PI314137 6 86.25 0.25 0.018 0.15 0.39 
31 PI 175085 6 150.50 0.25 0.037 0.08 0.56 
33 PI426281 6 153.25 0.25 0.018 0. 15 0.39 
36 Ames 9396 6 68.63 0.25 0.018 0.15 0.39 
41 PI340184 6 134.00 0.25 0.018 0.15 0.39 
46 Pl340188 6 121.75 0.25 0.018 0.15 0.39 
50 Pl 340189 6 99.88 0.25 0.018 0.15 0.39 
55 Ames 9668 6 96.63 0.25 0.018 0.15 0.39 
56 PI340195 6 158.38 0.25 0.018 0.15 0.39 
207 Pl 169061 6 83.13 0.25 ( 0.018 ) 0.15 0.39 
Standard errors (se) are given in brackets after the estimates, which were determined based on 
output of the SAS macro. In general, if the SAS macro is not available, se can be roughly 
approximated by se I N, in which se is the standard error of the mean rank for the ithaccession 
(treatment) as determined in the MIXED procedure of SAS v.9.2 with the LSMEANS option (SAS 
Institute, Cary, NC). 
44 
Nine accessions, representing 3% of the population, had a median disease rating of 6; 
whereas 129 accessions (47%) had a median of 7. Almost one half of the population, 139 
accessions had a median disease rating of 8 or 9 (Figure 4). 
Treatment relative effect of the top 10% accessions is presented in Table 5; data for 
the remaining 244 accessions are in Appendix 2. The median disease rating for PG4 among 
the top 10% accessions ranged between 6 and 9, although only three accessions had ratings 
:::_8 and their relative effect between 0.05 and 0.23 (Table 5). When the entire population 
was considered, however, the treatment relative effect ranged between 0.5 and 0.91 
(Appendix 2). 
Just 3 accessions, representing 1 % of the accessions evaluated, had a relative effect 
below 0.1. Additionally, 14 accessions representing 5% of the total evaluated showed a 
relative effect between 0.1 and 0.2. There were 37 accessions, representing 13%, that 
showed relative effect between 0.2 and 0.3 The remaining 223 accessions, representing 
80% of the accessions evaluated, had a relative effect higher than 0.3 (Table 5 and 
Appendix 2). 
Contrary to what was observed with the PG3 inoculations, significant differences in 
reaction were observed among the top 10% accessions with PI34 7596 being statistically 
less susceptible than the rest of top 10% materials (Table 5). Besides this, however, and 
based on the range of confidence intervals for each relative treatment effect, there was 
overlap for estimated relative effects between most accessions, which means there was no 
significant difference between the median disease rating of 6 , 7 , 8 or 9 (Table 5 and 
Appendix 2). 
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4.3. Evaluation of Brassica napus Accessions for their Reaction to PG3 Isolates of 
L.maculans 
Response of the 130 accessions evaluated for their reaction to PG3 resembled that 
of the B. rapa collection. Most materials were considered susceptible with the highest 
proportion (63%) having a median disease rating ranging between 7 and 8 and the 
remaining accessions (37%) having a rating of 6 in the 0-9 scale of Delwiche (Figure 5). 
The best 29 accessions according had a treatment relative effect that ranged 
between 0.14 and 0.37 (Table 6). However, when the entire population was considered, the 
treatment relative effect extended up to 0.98 (Appendix 3). Forty nine accessions, 
representing 3 7% of the population evaluated had a median disease rating of 6 for disease 
reaction; these accessions had a treatment relative effect ranging between 0.18 and 0.7 
(Table 6). 
Just three accessions, 432392, Ames 25110, and 537010 had a relative effect value 
>0.20. Ten other accessions, representing 7.6% of the population, showed relative effect 
values between 0.25 and 0.30. The remaining 118 (90.1 %) accessions showed a relative 
effect higher than 0.32 (Table 6). 
There is no significant difference between estimated relative effects (pi) between 
the accessions that scored 6, 7 and those that scored 8, which was evaluated based on the 
range of confidence intervals for each relative treatment effect. 
4.4. Evaluation of Brassica napus Accessions for their Reaction to PG4 Isolate of L. 
maculans 
Just as in the case of PG3, none of the 130 B. napus accessions evaluated for their 
reaction to PG4 were considered resistant. The median disease rating for PG4 ranged 
between 6 and 9 (Figure 5). Only two accessions, representing 1 % of the accessions eva-
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Table 5. Median disease ratings, mean ranks, and estimated relative treatment effects for 
the severity of symptoms on 33 Brassica rapa plant introduction materials 
inoculated on seedling cotyledons with Leptosphaeria maculans isolates of 
Eathos;eniciti s;rouE 4 in greenhouse conditions. 
Treatment effect Confidence Interval ~95% ~ 
Accession Median Mean Treatment Standard Upper 
number Name Disease Rating Rank relative effect error Lower Limit Limit 
74 Pl347596 6 40.00 0.05 0.004 o.oz 0.08 
3 Ames 9244 6 300 0.09 0.019 0.02 0.32 
12 Pl263054 6 16.00 0.09 0.018 o.oz 0.30 
13 Ames 9263 6 3.00 0.10 0.018 0.03 0.30 
109 PI 633178 7 89.50 0.10 0.018 0.03 0.30 
46 Pl340188 6 89.50 0.12 0.016 0.05 0.27 
73 Ames 9888 6 16.00 0.15 0.022 0.05 0.36 
32 PI 340179 7 89.50 0.16 0.021 0.06 0.35 
58 Ames 9677 7 149.00 0.16 0.021 0.06 0.35 
99 PI347612 6 89.50 0.16 0.021 0.06 0.35 
116 Pl 426284 7 149.00 0.16 0.021 0.06 0.35 
119 Pl 352793 7 208.50 0.16 0.021 0.06 0.35 
75 Pl3476IO 7 149.00 0.17 0.019 0.08 0.34 
62 Pl347596 7 40.00 0.18 0.016 0.10 0.32 
67 Ames 9741 7 16.00 0.18 0.016 0.10 0.32 
71 Pl347595 7 89.50 0.18 0.016 0.10 0.32 
217 Pl 370733 8 208.50 0.18 0.034 0.05 0.51 
100 Pl370731 7 208.50 0.22 0.018 0.12 0.36 
222 Pl370735 9 208.50 0.22 0.018 0.12 0.36 
225 P1370736 8 89.50 0.22 0.018 0.12 0.36 
248 Pl 173846 7 89.50 0.22 0.018 0.12 0.36 
33 PI426281 7 208.50 0.23 0.014 0.15 0.34 
38 Ames 9411 7 89.50 0.23 0.014 0.15 0.34 
48 Pl 340187 7 89.50 0.23 0.033 0.08 0.51 
49 Ames 9495 7 40.00 0.23 0.014 0.15 0.34 
68 Pl340196 7 16.00 0.23 0.033 0.08 0.51 
81 Pl 347599 7 40.00 0.23 0.014 0.15 0.34 
82 Pl426290 7 40.00 0.23 0.014 0.15 0.34 
85 Pl 426261 7 208.50 0.23 0.014 0.15 0.34 
Ill PI352790 7 208.50 0.23 0.014 0.15 0.34 
115 PI 633181 7 16.00 0.23 0.014 0.15 0.34 
184 Pl3528I8 7 16.00 0.23 0.014 ) 0.15 0.34 
276 Pl 426263 7 89.50 0.23 ( 0.014 l 0.15 0.34 
Standard errors (se) are given in brackets after the estimates, which were determined based on 
output of the SAS macro. In general, if the SAS macro is not available, se can be roughly 
approximated by se I N, in which se is the standard error of the mean rank for the ithaccession 
(treatment) as determined in the MIXED procedure of SAS with the LSMEANS option (SAS 
Institute, Cary, NC). 
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luated had a value for median disease reaction of 6. The remaining 99% of the accessions 
evaluated had a rating score that ranged between 7 and 9, and were considered susceptible 
to PG4.The top 15 accessions, representing roughly 11 % of the population evaluated had 
estimated treatment relative effects ranging from 0.15 and 0.28 (Table 7). However, when 
the entire population was considered, that value extended to 0.99 (Appendix 4). 
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Figure 5. Frequency distribution of the reaction of Brassica napus accessions to inoculation 
with L. maculans isolates of the pathogenicity group 3 and group 4 (R = Resistant, 
R-MR=Resistant to moderately resistant, MR=Moderately resistant, 
S=Susceptible ). 
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Table 6. Median disease ratings, mean ranks, and estimated relative treatment effects for 
the severity of symptoms on 29 Brassica napus plant introduction materials 
inoculated on seedling cotyledons with Leptosphaeria maculans isolates of 
pathogenicity group 3 in greenhouse conditions. 
Treatment effect Confidence Interval !95%! 
Median Treatment 
Accession Disease relative Standard Lower Upper 
number Name Rating Mean Rank effect error Limit Limit 
105 Pl537010 7 66.75 0.18 0.020 0.09 0.36 
82 PJ458945 7 55.25 0.25 0.040 0.08 0.58 
12 Ames 21490 6 41.25 0.29 0.034 0.12 0.55 
56 Pl 311730 7 72.00 0.29 0.034 0.12 0.55 
73 Pl 436554 7 87.88 0.29 0.034 0.12 0.55 
81 Pl469882 7 38. 13 0.29 0.034 0.12 0.55 
92 Pl 469729 7 72.88 0.29 0.034 0.12 0.55 
95 PI469758 6 44.38 0.29 0.034 0.12 0.55 
114 Pl597828 7 87.88 0.29 0.034 0.12 0.55 
17 Ames 25113 6 35.75 0.30 0.039 0.11 0.60 
70 PI 432393 8 103.00 0.30 0.039 0.11 0.60 
77 Pl26637 7 72.88 0.32 0.054 0.09 0.71 
64 PJ43!571 7 95.75 0.33 0.053 0.09 0.71 
8 Ames 19202 6 44.38 0.34 0.032 0.16 0.57 
29 Ames 26169 6 45.63 0.34 0.032 0.16 0.57 
33 Ames 26653 6 46.50 0.34 0.032 0.16 0.57 
36 Pl 458941 6 46.50 0.34 0.032 0.16 0.57 
76 P1443015 7 55.25 0.34 0.032 0.16 0.57 
87 Pl458940 7 72.00 0.34 0.032 0.16 0.57 
91 Pl458954 6 46.50 0.34 0.032 0.16 0.57 
94 PI469756 7 56.00 0.34 0.032 0.16 0.57 
112 PI 537019 7 74.63 0.34 0.032 0.16 0.57 
117 Pl603024 7 52.63 0.34 0.032 0.16 0.57 
59 Pl 311733 7 72.00 0.37 0.047 0.14 0.69 
93 P1469730 7 63.25 0.37 0.058 0.10 0.76 
96 P1469761 6 39.25 0.37 0.024 0.23 0.54 
99 P1469814 6 39.25 0.37 0.048 0.13 0.69 
Standard errors (se) are given in brackets after the estimates, which were determined based on 
output of the SAS macro. In general, if the SAS macro is not available, se can be roughly 
approximated by se / N, in which se is the standard error of the mean rank for the ithaccession 
(treatment) as determined in the MIXED procedure of SAS with the LSMEANS option (SAS 
Institute, Cary, NC). 
From the top 11 % accessions, seven, showed a value for relative effect of >0.22, 
with the most resistant accessions, Ames 21490, having a disease rating of 6 and a 
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treatment relative effect of 0.15 (Table 7). Eight other accessions had relative treatment 
effects that ranged between 0.22 and 0.28. The remaining 88.5% of accessions had relative 
treatment effects higher than 0.30 (Appendix 4), with the most susceptible accession being 
Ames 211489. 
The confidence interval for the accessions that scored 6 varied between 0.06 and 
0.7. For the accessions that scored 7, the confidence interval was between 0.08 and 0.93, 
whereas the only accession that scored 9 had a confidence interval between 0.97 and 0.99. 
There was no significant difference between the accessions that scored 6, 7 and 8 (Table 7). 
Table 7. Median disease ratings, mean ranks, and estimated relative treatment effects for 
Accession 
number 
12 
105 
14 
29 
57 
82 
95 
34 
46 
114 
73 
85 
27 
92 
94 
the severity of symptoms on 15 Brassica napus plant introduction materials 
inoculated on seedling cotyledons with Leptosphaeria maculans isolates of 
pathogenicity group 4 in greenhouse conditions. 
Confidence Interval 
Treatment effect (95%) 
Median Treatment 
Disease Mean relative Standard Lower lipper 
Name Ratio~ Rank effect error Limit Limit 
Ames 21490 6 17.63 0.15 0.020 0.06 0.34 
PI 537010 8 93.25 0.18 0.018 0.09 0.33 
Ames 25110 7 25.50 0.21 0.025 0.09 0.42 
Ames 26169 7 26.00 0.21 0.025 0.09 0.42 
Pl 311731 8 94.75 0.21 0.025 0.09 0.42 
P1458945 7 64.00 0.21 0.025 0.09 0.42 
Pl 469758 7 46.63 0.21 O.Q25 0.09 0.42 
Pl 391553 7 31.38 0.23 0.022 0.11 0.40 
PI282571 7 58.50 0.23 0.022 0.11 0.40 
Pl 597828 7 78.75 0.23 0.022 0.11 0.40 
Pl 436554 7 70.63 0.25 0038 0.08 0.56 
PJ535865 7 74.13 0.25 0.018 0.15 0.38 
Ames 26167 7 35 13 0.28 0.022 0.16 0.44 
P1469729 7 58.88 0.28 ( 0.040 0.09 0.59 
Pl469756 8 83.75 0.28 ( 0.022 ) 0.16 0.44 
Standard errors (se) are given in brackets after the estimates, which were determined based on 
output of the SAS macro. In general, if the SAS macro is not available, se can be roughly 
approximated by se I N, in which se is the standard error of the mean rank for the ithaccession 
(treatment) as detennined in the MIXED procedure of SAS with the LSMEANS option (SAS 
Institute, Cary, NC). 
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4.5. Evaluation of Brassica juncea Accessions for their Reaction to PG3 Isolates of L. 
maculans 
The median disease rating for the 407 accessions (one control included) evaluated 
for their reaction to PG3 isolates of L. maculans varied between 4 and 8 (Figure 6). The 
general median disease rating of 44 accessions (11 %) showed values between 4 and 5, and 
were classified as moderately resistant; 277 accessions, representing 68% of all accessions, 
had a general median disease rating of 6. The remaining 86 accessions (21 %) showed a 
median disease rating higher than 6 and were classified as susceptible according to the 
Delwiche scale. 
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Figure 6. Frequency distribution of the reaction of Brassica juncea accessions to 
inoculation with L. maculans isolates of the pathogenicity group 3 and group 4 
(R=Resistant, R-MR=Resistant to moderately resistant, MR=Moderately 
resistant, S=Susceptible ). 
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The top 28 accessions according to the relative effect are reported in Table 8. These 
accessions, representing 7 % of the population, had a relative effect <0.2. The best material 
was PI426295. Of the remaining accessions 36 showed a relative effect between 0.2 and 
0.3 and 343 accessions, representing 84 % of the population, had a treatment relative effect 
>0.3 (Appendix 5). 
4.6. Evaluation of Brassica juncea Accessions for their Reaction to PG4 Isolate of L. 
maculans 
The B. Juncea population evaluated was considered as more sensitive to PG4 than 
to PG3 with roughly 12% of the materials being considered as moderately resistant (Figure 
6). The median disease rating for the 407 accessions evaluated varied between 5 and 8. Of 
these, 6 accessions (2%) showed a general median disease rating of 5 and were considered 
as moderately resistant. Of all accessions evaluated, 42 (10 %) showed a general median 
disease rating of 6, and the remaining 359 accessions (88 %) showed a median disease 
rating of 7 and 8 (Appendix 6). 
The 37 best accessions according to treatment relative effects are reported in Table 
9. The top accessions were PI 426295, which was also considered the best material for its 
reaction to PG3, Pl 426253, PI 390136, and PI 426343 (Table 9). 
4. 6.1. Development and Screening of F2 Plants 
Throughout this study, the reaction of individual plants was recorded allowing the 
selection of individual plants even if the reaction of the plant introduction as a group was 
not too promising. Of all Brassica juncea accessions evaluated in 2009 ( 406 accessions 
with 4,884 individual plants), 34 of them were identified as potential sources of resistance 
based on the low score that they had. These accessions had disease rating scores :::5 to the 
reaction of both PG3 and PG4. In 2009, these accessions had in some instances more than 
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Table 8. Median disease ratings, mean ranks, and estimated relative treatment effects for 
the severity of symptoms on 28 Brassica juncea plant introduction materials 
inoculated on seedling cotyledons with L. maculans isolates of pathogenicity 
sroue 3 in greenhouse conditions. 
Confidence Interval 
Treatment effect (95%) 
Median Treatment 
Accession Disease Mean relative Standard Lower Upper 
number Name Rating Rank effect error Limit Limit 
147 Pl426295 4 2.75 0.01 0.002 0.00 0.05 
155 Pl 426303 4 35.25 0.01 0.001 0.00 0.02 
189 Pl 426338 5 274.00 0.01 0.001 0.01 0.03 
103 Pl 340204 6 45.50 0.04 0.010 0.01 0.19 
126 PI 347619 5 45.50 0,04 0.010 0.01 0.19 
142 PI426253 6 6.75 0.04 0.006 0.02 0.11 
281 Pl 458934 5 I 13.00 0.04 0.010 0.01 0.19 
194 PI426343 5 11.00 0.05 0.009 0.01 0.16 
118 PI340220 6 45.50 0.08 0.001 0.07 0.09 
125 PI347618 7 45.50 0.08 0.001 0.07 0.09 
134 Pl 390136 6 1 LOO 0.08 0.001 007 0.09 
212 Pl 426361 6 37.75 0.08 0.001 0,07 0.09 
390 Pl 649115 6 45.50 0.08 0.001 0.07 0.09 
401 Pl 531272 6 45.88 0.10 0.011 0.05 0.20 
399 Pl 649124 6 113.00 0.12 0.012 0.06 0.23 
139 Pl390141 5 80.88 0.15 0.028 0.04 0.45 
335 Pl603012 6 136.63 0.15 0.026 0.04 0.43 
367 Pl633108 6 187.88 0.15 0.027 0.04 0.43 
374 PI 633115 6 127.00 0.15 0.027 0.04 0.43 
255 PI426406 6 274.00 0.16 0.002 0.15 0.18 
197 Pl 426346 6 242.25 0.17 0.025 0.06 0.41 
366 Pl633107 6 82.63 0.17 O.o25 0.06 0.41 
380 Pl 649105 6 240.13 0.17 0.026 0.05 0.43 
21 Pll75100 7 52.63 0.19 0.023 0.07 0.40 
78 Pl249555 7 141.25 0.19 0.024 0.08 0.41 
336 PI 603013 6 113.13 0.19 0.023 0.07 0.40 
338 Pl603015 6 108.25 0.19 ( 0.023 0.07 0.40 
392 Pl649117 6 106.50 0.19 ( 0.023 l 0.07 0.40 
Standard errors (se) are given in brackets after the estimates, which were determined based on 
output of the SAS macro. In general, if the SAS macro is not available, se can be roughly 
approximated by se I N, in which se is the standard error of the mean rank for the ithaccession 
(treatment) as determined in the MIXED procedure of SAS with the LSMEANS option (SAS 
Institute, Cary, NC). 
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Table 9. Median disease ratings, mean ranks, and estimated relative treatment effects for 
the severity of symptoms on 38 Brassica juncea plant introduction materials 
inoculated on seedling cotyledons with Leptosphaeria macu/ans isolates of 
eathos;enicitr groue 4 in greenhouse conditions. 
Confidence Interval 
Treatment effect (95%) 
Median Treatment 
Accession Disease Mean relative Standard Lower Upper 
number Name RatinG Rank effect error Limit Limit 
147 Pl 426295 5 2.75 0.00 0.001 0.00 0,02 
134 Pl 390136 6 11.00 0.02 0.002 0.01 0.04 
142 Pl426253 7 6.75 0.02 0.001 0.01 0,03 
194 Pl426343 5 11.00 0.02 0.002 0.01 0.04 
155 Pl 426303 5 35.25 0.06 0.016 0.01 0.32 
212 Pl426361 6 37.75 0.06 0.015 0.01 0.29 
252 Pl 426403 6 25.38 0.06 0.009 0,02 0.16 
103 PI 340204 7 45.50 0.07 0.013 0.02 0.23 
118 Pl340220 7 45.50 0.07 0.013 0.02 0.23 
125 P1347618 8 45.50 0.07 0.013 0.02 0.23 
126 Pl347619 6 45.50 0.07 0.013 0,02 0.23 
187 Pl426336 6 43.00 0.07 0.013 0.02 0.23 
390 Pl 649115 7 45.50 0,07 0.013 0,02 0.23 
130 PI370746 7 72.25 0.12 0.002 0.11 0.13 
132 PI387819 7 72.25 0.12 0.002 0.11 0.13 
133 Pl 390135 6 72.25 0.12 0.002 0.11 0.13 
144 PI 426292 6 72.25 0.12 0.002 0.11 0.13 
177 PI426326 6 72.25 0.12 0.002 0.1 I 0.13 
188 PI426337 6 72.25 0.12 0.002 0.11 0.13 
256 P1426407 6 45.88 0.12 0.002 0.11 0.13 
257 Pl426408 7 45.88 0.12 0.002 0.11 0.13 
301 Pl459008 6 45.88 0.12 0.002 0.11 0.13 
359 PI633100 7 61.63 0.12 0.014 0.05 0.26 
401 PI 531272 7 45.88 0.12 0.002 0.11 0.13 
21 PI 175100 7 52.63 0.15 0.010 0.10 0.23 
337 PI603014 7 50.88 0.15 0.010 0.10 0.23 
79 P1250130 7 41.63 0.16 0.017 O.o7 0.31 
162 PI 426311 6 43.00 0.16 0.016 0.08 0.30 
154 Pl426302 6 59.75 0.18 0.031 0.05 0.48 
214 Pl 426363 6 112.75 0.18 0.019 0.09 0.35 
281 Pl458934 6 113.00 0.18 0.019 0.09 0.35 
352 Pl633093 8 113.00 0.18 0.019 0.09 0.35 
399 Pl 649124 7 I 13.00 0.18 0.019 0.09 0.35 
366 Pl633107 7 82.63 0.20 0.032 0.06 0.50 
139 P[390141 7 80.88 0.21 0.027 0.08 0.45 
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Table 9. Continued 
Median 
Accession Disease Mean 
number Name Rating Rank 
283 Pl458943 6 80.88 
Treatment effect 
Treatment 
relative Standard 
effect error 
0.21 0.027 
Confidence Interval 
(95%) 
Lower 
Limit 
0.08 
Upper 
Limit 
0.45 
333 Pl 549282 7 76.63 0.2 I ( 0.027 ) 0.08 0.45 
Standard errors (se) are given in brackets after the estimates, which were determined based on 
output of the SAS macro. In general, if the SAS macro is not available, se can be roughly 
approximated by se / N, in which se is the standard error of the mean rank for the ithaccession 
(treatment) as determined in the MIXED procedure of SAS with the LSMEANS option (SAS 
Institute, Cary, NC). 
one plant that showed disease reaction scores .:S5. These plants were selected. As an 
example of this selection procedure, one plant from PI 426295, scored 3 for both PG 
groups in 2009. That plant, which is considered a parental line was identified as 147-6-2, 
where 147 stands for the entry number used to denominate PI 426295 in the study, 6 stands 
for the entry number used to denominate PI 426295 in the study, (61h in a group of six 
plant) and 2 stands for the replication in which that plant was grown. Plant 147-6-2 had a 
disease reaction of 3 for both PGs in the first round of selections. This plant was 
transplanted and allowed to produce seed by self-pollination. Twelve F I seeds from this 
plant were inoculated and scored. A median disease score rating was calculated for all the 
F, plants. F, plants had a score of 4 and 6 for the entire group and plant number 3 from the 
first replication had low disease score reaction of the group to both PG3 and PG4 and thus 
it was selected for seed production. The selected plant was identified as 147-6-2/3-1. The 
identity of this plant is a combination of the parental line (147-6-2) and the plant 
identification in the second screening: plant #3 of replication #1. Plant 147-6-2/3-1 was 
taken to seed production by self-pollination. Seeds by 147-6-2/3-1 constitute the F2 
generation. F2 seeds from 22 different accessions were produced and saved (Table 10). In 
most cases, the scores of the FI generation were similar to those produced by the parental 
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plant; however, in a few instances the FI generation tended to be slightly more sensitive 
than its parent as was the case of some plants from Pl. 
Table 10. Elite Brassicajuncea F2 lines derived through self-pollination of seedlings that 
survived cotyledon inoculations with strains of pathogenicity groups 3 and 4 of 
Le£!OsE_haeria maculans in s;reenhouse conditions. 
Disease reaction F o Disease reaction F 1 
Parental Line PG3 PG4 ID PG3 PG4 ID 
PI 340205 4 6 4 6 
104-5-1 3 3 104-5-1/5-1 3 4 104-5-1/5-1/2-2* 
PI340211 6 7 4 6 
109-4-1 4 4 109-7-1/4-1 
PI340221 5 6 4 5 
119-2-1 3 4 119-2-1/2-1 3 4 119-2-1/2-1/5-1 * 
119-2-1/2-1/6-2* 
PI 347619 5 6 3 5 
126-4-1 4 4 126-4-1 /2-2 3 4 126-4-1/2-2/5-1 * 
PI 358591 5 6 4 5 
127-2-1 4 4 127-2-1/1-2 3 4 127-2-1/1-2/1-1 * 
127-3-1 3 3 127-3-1/1-1 3 3 127-3-1/1-1/1-1 * 
PI379103 6 6 5 6 
131-4-2 4 5 131-4-2/2-2 3 3 131-4-2/2-2/2-2* 
131-5-2 3 3 131-5-2/1-2 4 5 131-5-2/1-2/6-2* 
PI 390135 6 6 5 7 
133-2-2 4 5 133-2-2/3-2 3 5 133-2-2/3-2/2-1 * 
PI390636 6 6 5 7 
134-4-1 3 3 134-4-1/6-1 
PI 390137 5 5 5 6 
135-3-1 4 4 135-3-1/5-1 
135-2-2 4 4 135-2-2/5-1 3 4 135-2-2/5-1 /5-2 * 
PI390140 6 6 4 5 
138-6-2 3 3 138-6-2/1-2 3 3 13 8-6-2/1-2/3-1 * 
PI426292 6 6 5 6 
144-3-2 4 4 144-3-2/2-1 2 4 144-3-2/2-1/3-1 * 
144-5-2 4 4 144-5-2/6-2 4 4 144-5-2/6-2/1-2* 
PI426295 4 4 5 6 
147-3-2 3 3 147-3-2/6-1 
147-4-1 3 4 147-4-1/6-2 
147-5-1 4 4 147-5-1/3-2 
147-5-2 3 4 147-5-2/1-1 4 4 147-5-2/1-1/1-1 * 
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Table 10. Continued 
Disease reaction Fo Disease reaction F 1 
Parental Line PG3 PG4 ID PG3 PG4 ID 
147-6-2 3 3 14 7-6-2/3-1 3 4 147-6-2/3-1/2-1 * 
PI426300 6 7 5 7 
152-3-2 3 4 152-3-2/6-2 3 5 152-3-2/6-2/1-2* 
PI426303 4 5 
155-1-2 4 4 155-1-2/1-2 4 5 155-1-2/1-2/4-2* 
155-4-2 3 3 155-4-2/6-1 4 4 155-4-2/6-1/6-1 * 
155-5-2 3 3 155-5-2/6-2 3 3 155-5-2/6-2/2-1 * 
PI426326 6 6 4 5 
177-1-1 4 5 177-1-1/2-1 
177-3-2 4 5 177-3-2/5-1 
PI 426336 5 6 4 5 
187-2-2 4 4 187-2-2/3-2 4 4 187-2-2/3-2/4-2 * 
187-3-3 4 5 187-3-3/2-1 4 4 187-3-3/2-1/3-1 * 
PI426337 6 6 5 5 
188-5-2 3 4 188-5-2/6-2 4 4 
PI426338 4 7 6 6 
189-5-2 3 3 189-5-2/3-1 3 4 189-5-2/3-1/3-2* 
PI 426341 8 8 6 6 
192-1-2 3 3 192-1-2/1-1 4 4 192-1-2/1-1/5-2* 
PI426343 5 5 5 6 
194-6-1 4 5 194-6-1/2-1 4 4 194-6-1/2-1/6-2* 
194-5-2 4 4 194-5-2/1-1 4 4 194-5-2/1-1/5-2* 
PI426352 6 7 6 7 
203-3-1 3 3 203-3-1/1-1 4 4 203-3-1/1-1/4-1 * 
PI426361 5 5 6 7 
212-2-1 3 4 212-2-1/1-2 
PI426363 6 6 5 6 
214-5-1 3 3 214-5-1/3-1 3 4 214-5-1/3-1 /1-2* 
PI426367 6 6 4 5 
218-6-2 4 4 218-6-2/1-2 3 4 218-6-2/1-2/2-1 * 
PI426384 6 7 
234-4-2 2 4 234-4-2/1-2 
PI426406 5 7 6 6 
255-6-2 4 5 255-6-2/1-2 4 3 255-6-2/1-2/1-2* 
PI458934 4 6 
281-2-1 4 4 281-2-1 /5-2 
PI458996 7 8 
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Table 10. Continued 
Disease reaction Fo Disease reaction F 1 
Parental Line PG3 PG4 ID PG3 PG4 ID 
289-4-2 3 3 289-4-2/2-2 
PI478332 5 7 
313-2-2 3 3 313-2-2/1-2 
PI 633092 5 6 4 5 
351-2-1 4 4 351-2-1/4-1 3 4 351-2-1/4-1/3-1 * 
PI 633098 4 5 
357-2-1 4 4 357-2-1/3-2 
PI 649113 7 7 4 5 
388-2-1 2 3 388-2-1/3-1 4 4 388-2-1/3-1/3-2* 
PI 649114 5 6 
389-3-1 3 4 389-3-1/6-2 
PI 649123 5 6 
398-4-1 4 5 398-4-1/1-1 
Those plants were not advanced to the next generation 
*Elite materials selected that showed resistance to PG3 and PG4 
4.7. Evaluation of 16 Commercial Cultivars for their Reaction to 3 PG2 Isolates L. 
maculans 
The median disease ratings for the 16 commercials cultivars evaluated for their 
reaction to PG2 varied between 1 and 4 (Table 11 ), with treatment relative effect values 
that varied between 0.09 and 0.85. These results are, for the most part, consistent with the 
blackleg disease rating advertised by the seed companies that produced the cultivars. Those 
cultivars were classified in the lower part of the Delwiche scale as resistant and moderately 
resistant (Table 11 ). 
4.8. Evaluation of 75 Commercial Cultivars for their Reaction to PG3 Isolates of L. 
maculans 
The 75 commercial canola cultivars evaluated in this study, were representative of 
the genotypes currently in use by growers in North Dakota. The reaction of these genotypes 
to inoculation with PG3 and PG4 was one of almost complete susceptibility with 84% and 
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97% of genotypes scoring between 7 and 9 in the Delwiche scale (Figure 7). Only 12 
genotypes were considered moderately resistant to PG3, but none to PG4. 
Table 11. Median disease ratings, mean ranks, and estimated relative treatment effects for 
the severity of symptoms on 16 commercial canola cultivars inoculated with 
Leptosphaeria maculans isolates of pathogenicity group2 in greenhouse 
conditions. 
Confidence 
Treatment effect Interval !95%! 
Blackleg 
rating 
provided Median 
by Disease Proposed Mean Treatment relative Standard Lower Upper 
Cultivars comeani' Rating reaction' Rank Effect error Limit Limit 
Dekalb IS3057 R R 2.00 0.09 0.004 0.06 0.14 
Mycogen Seeds ONO 
51505 R R 2.00 0.09 0.004 0.06 0.14 
Canterra SWK5352RR MR R 3.75 0.22 0.025 0.08 0.54 
Croplan Hyclass 712 R 2 R 6.00 0.34 0.050 0.08 0.80 
Agriprogress 30214-
C7 R 2 R 6.50 0.35 0.008 0.28 0.43 
Croplan Hyclass 906P R 2 R 6.50 0.35 0.008 0.28 0.43 
Monsanto 072021 R 2 R 6.50 0.35 0.008 0.28 0.43 
Mycogen Seeds 
Nexera 830CL R 2 R 6.50 0.35 0.008 0.28 0.43 
Bayer Invigor 5630 R 2 R 8.75 0.47 0.022 0.28 0.67 
Bayer Invigor 8440 R 2 R 8.75 0.47 0.012 0.36 0.58 
Cargill V2018 MR 3 R 12.00 0.68 0.002 0.66 0.70 
Agriprogress 30509-
C7 MR 4 R-MR 13.75 0.78 0.013 0.64 0.87 
Brett Young 6235RR MR 4 R-MR 15.00 0.85 0.004 0.81 0.89 
lntegra Seed 
IX08712IR R 4 R-MR 15.00 0.85 0.004 0.81 0.89 
Pioneer 45 H26 R 4 R-MR 15.00 0.85 0.004 0.81 0.89 
Dekalb 3042 R 4 R-MR 16.25 0.92 ( 0.011 ) 0.67 0.96 
Standard errors (se) are given in brackets after the estimates, which were determined based on 
output of the SAS macro. In general, if the SAS macro is not available, se can be roughly 
approximated by se I N, in which se is the standard error of the mean rank for the ithaccession 
(treatment) as determined in the MIXED procedure of SAS with the LSMEANS option (SAS 
Institute, Cary, NC). 
1 R=Resistant MR=Moderately Resistant R-MR= Resistant to moderately resistant 
When inoculated with PG 3, commercial cultivars had a median disease rating that 
varied between 5 and 8. Data from the best 21 materials are presented in table 12. Among 
them, the best cultivar was Brett Young's 6051 RR with a median disease rating of 5 that 
placed it in the moderately resistant part of the scale. However, when one considers the 
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confidence intervals for the treatment relative effect. It is clear that there are not significant 
differences among cultivars. Data from the remaining 56 materials is presented in appendix 
7. 
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Figure 7. Frequency distribution of the reaction of 75 commercials cultivars to inoculation 
with L. maculans isolates of the pathogenicity group 3 and group 4 (R=Resistant, 
R-MR=Resistant to moderately resistant, MR=Moderately resistant, 
S=Susceptible ). 
4.9. Evaluation of 75 Commercial Cultivars for their Reaction to PG4 Isolates of L. 
maculans 
For PG4 the median disease rating varied between 6 and 9 (Figure 7). Of the 75 
materials evaluated in this study, 28 had a median disease rating of 7; 40 had a median 
disease rating of 8, and 5 had a median disease rating of 9. 
The 27 accessions with the lowest estimated treatment relative treatment effect are 
reported in Table 13 whereas the remaining 48 accessions are in Appendix 8. According to 
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the confidence interval values there was no overlapping between the median disease rating 
values for the cultivars rate 6, 7, 8, and the median disease rating for the cultivars rate 9. 
That means there was significant difference between those groups (Table 13). There was no 
significant difference between the median disease rating 8 and 9. 
Table 12. Median disease ratings, mean ranks and estimated relative treatment effects for 
the severity of symptoms on 21 commercial canola cultivars inoculated with 
Leptosphaeria maculans isolates of pathogenicity group 3 m greenhouse 
conditions. 
Name 
Agriprogress H7385 
Brett Young 6051 RR 
Agriprogress 302 I 6-C7 
Agriprogress 30509-C7 
Mycogen Seeds G2X0054 
Brett Young 6235RR 
Cargill 04H272 
Proseed 2030 
Bayer lnvigor 5550 
Pioneer 45 H26 
Agriprogress 30522-C7 
Agriprogress H6 I 95 
Canterra 305 07 
Interstate I 005 
Integra Seed IX08-7323R 
Proseed 50 Caliber 
Agriprogress 30422-C7 
Bayer Invigor 5630 
Croplan Hyclass 940 
Bayer lnvigor 5440 
Median 
Disease Proposed 
Rating reaction1 
7 S 
5 MR 
6 MR-S 
6 MR-S 
7 S 
7 S 
6 MR-S 
7 S 
6 MR-S 
7 S 
7 S 
6 MR-S 
6 MR-S 
6 MR-S 
7 S 
6 MR-S 
7 S 
7 S 
6 MR-S 
6 MR-S 
Treatment effect 
Treatment 
Mean relative 
Rank effect 
7.38 0.09 
7.88 0.10 
I 1.50 0.14 
11.50 0.14 
10.88 0.14 
12.50 0.16 
14.50 0.18 
14.50 0.18 
17.25 0.23 
18.13 0.23 
19.88 0.25 
18.00 0.25 
18.00 0.25 
18.50 0.25 
19.25 0.25 
18.63 0.25 
19.88 0.25 
20.13 0.26 
19.25 0.27 
22.13 0.29 
Standard 
error 
0.0167 
0.0163 
0.0116 
0.0116 
0.0116 
0.0170 
0.0134 
0.0134 
0.0323 
0.0328 
0.0293 
0.0293 
0.0293 
0.0293 
0.0293 
0.0293 
0.0293 
0.0045 
0.0490 
0.0258 
Confidence Interval 
(95%) 
Lower Upper 
Limit Limit 
0.03 0.29 
0.03 0.29 
0.08 0.24 
0.08 0.24 
0.08 0.24 
0.08 0.32 
0.11 0.29 
0.11 0.29 
0.08 0.51 
0.08 0.52 
0.10 0.50 
0.10 0.50 
0.10 0.50 
0.10 0.50 
0.10 0.50 
0.10 0.50 
0.10 0.50 
0.23 0.29 
0.07 0.67 
0.15 0.49 
Mycogen Seeds G2X0039 7 S 22.50 0.29 ( 0.0258 ) 0.15 0.49 
Standard errors (se) are given in brackets after the estimates, which were determined based on 
output of the SAS macro. In general, if the SAS macro is not available, se can be roughly 
approximated by se / N, in which se is the standard error of the mean rank for the ithaccession 
(treatment) as determined in the MIXED procedure of SAS with the LSMEANS option (SAS 
Institute, Cary, NC). 
1MR=Moderately Resistant MR-S=moderately resistant to susceptible S=susceptible 
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A summary of all the Brassica collection and commercial cultivars screened and 
evaluated in this experiment for their reaction to L. maculans pathogenicity group 3 and 
group 4 are presented in Table 13. 
Table 13. Summary table for all the Brassica collections and commercial cultivars 
evaluated for their reaction to Leptosphaeria maculans isolates of pathogenicity 
grou2 3 and group 4 in greenhouse conditions. 
B. rap_a B. nap_us B. juncea Commercials cultivars 
Proposed 
Scale Reaction1 PG3 PG4 PG3 PG4 PG3 PG4 PG3 PG4 
0 R 0 0 0 0 0 0 0 0 
1 R 0 0 0 0 0 0 0 0 
2 R 0 0 0 0 0 0 0 0 
3 R-MR 0 0 0 0 0 0 0 0 
4 MR 0 0 0 0 2 0 0 0 
5 MR 7 0 0 0 20 5 1 0 
6 MR-S 160 9 49 2 299 43 11 2 
7 s 89 129 76 85 81 296 43 28 
8 s 19 120 6 43 5 63 20 40 
9 s 2 19 0 1 0 0 0 5 
1R=Resistant R-MR=Resistant to moderately resistant MR=Moderately resistant 
MR-S=Moderately resistant to susceptible S=Susceptible 
4.10. Evaluation of the Effect oflnoculation Sequence on Plant Reaction 
According to the analysis of variance, there are significant differences only for the 
inoculation factor (p=0.01) and the cultivar factor (p=0.04). There was no interaction 
between inoculation sequences and cultivars (p=0.8). 
There were significant differences between the median disease ratings of the 10 
cultivars evaluated, although all ratings ranked in the susceptible range of the Delwiche 
scale (1980) (Table 14). Cultivars Cargill V2018 and Mycogen Seeds G2X0043 with 
medians of 7 and 7.3 showed less susceptibility than Croplan Hyclass 924, and Canterra 
30507-B6. 
The effect of sequence of inoculations on the reaction of plants was studied using 
single-degree ANOV A analysis (Table 15). 
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Results indicate that plants inoculated with PG3 alone were less susceptible than 
those challenged with PG3 after the plants had been inoculated with PG4 or those that were 
inoculated simultaneously with PG3 and PG4 (Table 16). The difference between 
inoculation with PG3 only and inoculation of PG3 after PG4 was significant (p=0.007) 
whereas the difference between inoculation with PG3 only and inoculation with PG3 and 
PG4 simultaneously was not significant (p=0.09). The same result was observed for PG4 
only. Plants inoculated with PG4 alone were less susceptible than those challenged with 
PG4 after the plants had been inoculated with PG3 (p=0.004) or those that were inoculated 
simultaneously with PG3 and PG4 (p=0.04) (Table 16). This increased sensitivity, 
however, was not observed with the simultaneous inoculation. Plants inoculated with PG3 
and PG4 simultaneously were equally susceptible than those challenged with PG4 after 
plants had been inoculated with PG3 (p=0.07) or those that were inoculated with PG3 after 
plant had been inoculated with PG4 (p=0.38). The industry denomination of resistant or 
moderately resistant to blackleg did not apply for the reaction of the commercial cultivars 
to inoculations with PG3 (p=0.26) and/or PG4 (p=0.6). All cultivars were equally 
susceptible to both and the sequence in which these plants were inoculated did not 
significantly affect their reaction to blackleg (Table 16). 
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Table 14. Median disease ratings, mean ranks, and estimated relative treatment effects for 
the severity of foliar symptoms on 27 commercials canola cultivars inoculated 
on seedling cotyledons with Leptosphaeria maculans isolates of pathogenicity 
~rouE 4 in ~reenhouse conditions. 
Confidence 
Treatment effect Interval (95%) 
Median Treatment 
Accession Disease Proposed Mean relative Standard Lower Upper 
number Name RatinG reaction1 Rank effect error Limit Limit 
16 Bayer lnvigor 5630 6 MR-S 3.13 0.04 0.002 0.02 0.05 
77 Proseed 2030 7 s 7.00 0.09 0.006 0.06 0.14 
Agriprogress H7385 7 s 8.50 0.10 0.017 0.04 0.29 
23 Brett Young 6235RR 7 s 8.25 0.11 0.016 0.04 0.28 
9 Agriprogress 302 I 6-C7 7 s 9.88 0.13 0.014 0.06 0.26 
24 Cargill 04H272 7 s I 0.50 0.13 0.014 0.06 0.26 
65 Mycogen Seeds G2X0054 7 s 11.00 0.15 0.012 0.09 0.25 
82 Pioneer 45 H26 7 s 13.00 0.15 0.019 0.06 0.34 
14 Agriprogress 30509-C7 7 s 13.50 0.17 0.017 0.09 0.32 
49 lntegra Seed IX08-7323 R 7 s 13.25 0.17 0.017 0.09 0.32 
6 Agriprogress 30522-C7 7 s 15.88 0.19 0.013 0.12 0.30 
22 Brett Young 6051 RR 7 s 14.88 0.20 0.032 0.06 0.50 
80 Agriprogress 30422-C7 8 s 15.00 0.20 0.032 0.06 0.50 
61 Mycogen Seeds G2X0039 7 s 17.00 0.21 0.017 0.12 0.35 
21 Brett Young4414RR 8 s 17.75 0.24 0.031 0.09 0.50 
35 Croplan Hyclass 940 7 s 19.00 0.26 0.028 0.11 0.49 
29 Canterra SWK5352RR 7 s 21.00 0.27 0.004 0.25 0.30 
75 Monsanto DKL52-4 I Plus 7 s 21.00 0.27 0.004 0.25 0.30 
8 Agriprogress H6195 7 s 25.25 0.34 O.ot8 0.23 0.47 
13 Agriprogress 306 l 1-C7 7 s 26.13 0.34 O.ot8 0.23 0.47 
19 Bayer lnvigor 5550 6 MR-S 26.13 0.34 0.034 0.16 0.59 
25 Cargill V2018 7 s 26.13 0.34 0.018 0.23 0.47 
34 Canterra 30507 8 s 25.50 0.34 0.018 0.23 0.47 
41 Crop Ian Hyclass 410 7 s 26.13 0.34 0.018 0.23 0.47 
71 Monsanto 072003 7 s 26.13 0.34 0.018 0.23 0.47 
31 Canterra 1818 8 s 26.88 0.36 0.029 0.19 0.57 
37 Croelan H~class 906P 7 s 26.63 0.36 ( 0.029 ) 0.19 0.57 
Standard errors (se) are given in brackets after the estimates, which were determined based on 
output of the SAS macro. In general, if the SAS macro is not available, se can be roughly 
approximated by se IN, in which se is the standard error of the mean rank for the ithaccession 
(treatment) as determined in the MIXED procedure of SAS with the LSMEANS option (SAS 
Institute, Cary, NC). 1MR-S=moderately resistant to susceptible S=susceptible 
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Table 15. Median disease rating of the 10 cultivars evaluated. 
Brand cultivar Median disease rating 
Croplan Hyclass 924 
Canterra 30507-B6 
DKL 30-42 
Agriprogress 30412-B6 
Brett Young 6235RR 
Monsanto 067012 
Bayer Invigor 5440 
Integra Seed IX08-7323R 
Cargill V2018 
Mycogen Seeds G2X0043 
Least significant difference 
(LSD) 
PG3 only 
8.3 
8.0 
7.5 
7.0 
7.4 
7.8 
8.1 
5.8 
5.6 
5.6 
ns 
PG4 only 
8.6 
8.0 
8.6 
8.5 
7.6 
7.5 
6.6 
7.5 
7.9 
8.9 
Ns 
PG3 and 
PG4 
9.0 
8.0 
8.5 
7.8 
7.9 
7.5 
7.8 
8.0 
7.3 
7.4 
ns 
Table 16. ANOVA of median of different inoculation sequences with isolates from 
blackleg pathogenicity groups 3 and 4 on cotyledon leaves. 
Contrast Median 11 Median 2 Pr> F 
PG3 vs.: 
PG3 after PG4 7.1 7.7 0.007 
PG3 simultaneous with PG4 
PG4 vs.: 
PG4 after PG3 
PG4 simultaneous with PG3 
PG4 and PG3 simultaneous vs.: 
PG3 after PG4 
PG4 after PG3 
Resistant vs. moderately resistant 
PG3 
PG4 
7.1 
8.0 
8.0 
7.9 
8.5 
7.8 
7.9 
8.4 
8.5 
7.7 
8.4 
7.9 
0.093 
0.004 
0.043 
0.073 
0.378 
0.258 
0.596 
1 Median 1 represents median value of term to the left of the vs. term; median 2 represents the 
median value of the term to the right of the vs. term 
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CHAPTERS. 
DISCUSSION 
This study was conducted to identify potential sources of resistance against, and to 
characterize the reaction of commonly planted canola cultivars to, Leptosphaeria maculans 
pathogenicity groups 3 and 4. The second objective was intended to be a means to estimate 
the potential risk the discovery of new pathogenicity groups represent to the canola 
industry of the region. To fulfill the first objective, seedlings from three different plant 
introduction collections, Brassica rapa, B. napus, and B. juncea were screened at the 
cotyledon stage using pycnidiospores suspension of strains from both PGs. For the second 
objective 75 commercial canola cultivars were screened using similar inoculation protocol. 
All screening procedures were conducted in greenhouse conditions. While field trials to 
validate the reaction of germplasm at any and all stages of the screening process are highly 
desirable (Khot et al., 2011 ), in this case it was impractical. The geographic distribution of 
pathogenicity groups 3 and 4 in North Dakota is still limited and would be almost 
impossible to identify fields that only have one PG and not the other (Chen and Fernando, 
2006). Further, to raise seedlings from all accessions to get to the flowering stage would 
have required far more greenhouse space than what is available to the canola pathology 
program at this time. Nevertheless we had the opportunity to observe some of the selected 
materials get to produce seeds. During the growth of these materials, which come from 38 
accessions, plants from only 22 accessions (representing 40% of the selections) survived 
long enough to produce seed, this is an indication that resistance against one of the races 
(PG3 or PG4) at the seedling stage does not translate directly into adult plant resistance. 
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The cotyledon inoculation technique used allowed us to characterize the reaction of 
genotypes at the seedling stage (Zhu and Rimmer, 2003). Wounding seedlings before 
inoculation allows to evaluate disease reaction faster and increases disease development. 
Also, testing disease reaction at the cotyledon stage, when the seedlings exhibit less 
differentiated tissue and highest degree of sensitivity is advantageous because the 
morphological differences between accessions are smaller than at the adult stage (Sjodin 
and Glimelius, 1988). Further, cotyledon inoculations have been used successfully by other 
researchers who proved its effectiveness to screen for resistance to L. maculans in large 
number of plants (McNabb et al., 1993). 
After screening the accessions from the three collections, just 22 B. juncea 
accessions were deemed as moderately resistant to PG3 and PG4 according to the 
Delwiche scale (Delwiche, 1980). B. juncea has been known to be a source of resistance 
against blackleg (Mengistu et al., 1991 ). 
None of the B. rapa accessions was considered to have useful levels of resistance, 
especially to PG4, since the most resistant materials were grouped bordering susceptibility 
in the Delwiche scale; this finding is in agreement with findings of other researchers 
(Delourme et al., 2006). No resistant materials were found among the B. napus accessions 
evaluated either. However, the number of accessions tested from this species was relatively 
small and was the result of our desire to verify whether some of the accessions deemed to 
be resistant to Sclerotinia sclerotiorum (Khot et al., 2011) also were resistant to blackleg. 
The lack of correspondence in the reaction of these accessions to both pathogens is not 
surprising since both organisms interact with plants in different manners; S. sclerotiorum is 
a known necrotroph (Bolton et al., 2006) whereas L. maculans acts as a biotroph at least in 
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the initial stages of infection (Howlett et al., 2001). No attempts were made to evaluate 
these B. napus accessions for their reaction to PG2 strains since resistance to this group is 
no longer needed. 
All commercial cultivars evaluated for their reaction to pathogenicity group 2 
proved to be resistant or moderately resistant to it. PG2 has been the most prevalent 
blackleg strain in North Dakota until recently (Chen and Fernando, 2006). The reaction 
recorded was consistent with the information provided by the seed companies that 
produced these materials. However, when these cultivars were tested for their reaction to 
PG3 and PG4, they all proved to be very susceptible. This suggests that blackleg company 
ratings are related to reaction to PG2 L. maculans only. While it is very likely that seed 
companies are already actively testing for resistance against these new strains in confined 
environments; it is less likely they are doing field verification since distribution of these 
PGs is still limited and because characterization of these PGs requires the use of a 
differential set (Mengistu et al., 1991 ). 
All commercials cultivars evaluated under greenhouse conditions for their reaction 
to PG3 and PG4 were highly susceptible. This is a clear indication of the magnitude of the 
threat these new strains represent to the canola industry of the state and country since more 
than 90% of the canola produced in the US is planted in North Dakota (USDA, 2010). 
Until the time resistance is incorporated in commercial cultivars growers will need to go 
back to classic disease management practices such as longer crop rotations, crop residue 
management, and fungicide use (West et al., 2001). Development of strains with new 
pathogenicity profiles, races, or pathogenicity groups, is not foreign to L. maculans 
(Balesdent et al., 2005; Chen and Fernando, 2006; Mengistu et al, 1991). In the past, 
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rape/canola producing areas have been troubled by these shifts in population (Bokor et al., 
1975; Rouxel et al., 2003), This ability has reduced the time a vertical gene could be used 
from several years to a few growing seasons (Sprague et al., 2006) and is the best example 
of why horizontal resistance is needed. Incorporation of horizontal resistance into 
commercial cultivars is more difficult and advances at a much slower rate than 
incorporation of vertical genes, however, it is also longer lasting (Oliver and Solomon, 
2010) 
While the levels of resistance found in the materials evaluated are not very high, 
they represent an opportunity that should be explored in mode depth; an example of this 
would be the development and evaluation of lines produced by crosses made between the 
best materials identified in this study (good by good cross). The process of moving genes 
from lines at pre-breeding status into advanced breeding lines will take some time, that 
could be shorten if tissue culture techniques are used because homozygosity can be 
achieved more quickly than traditional breeding techniques (Roy, 1984; Su, 2009) and if a 
more intensive collaboration between the university and the seed industry is established. 
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APPENDIX TABLES 
A.I. Median, mean rank and estimated relative treatment effects for the severity of foliar 
symptoms on 227 Brassica rapa accessions based on their reaction to inoculation with 
three L. maculans isolates of PG3. 
Confidence Interval 
Treatment effect !95°/oi 
Median Treatment 
Accession Disease Mean relative Standard Lower Upper 
number Name Rating Rank effect error Limit Limit 
14 Pl 319693 6 131.00 0.28 0.050 0.07 0.68 
12 Pl263054 6 74.75 0.29 0.050 0.07 0.68 
4 Ames 9251 6 151.88 0.31 0.002 0.29 0.33 
48 Pl340187 6 67.13 0.31 0.002 0.29 0.33 
64 Ames 9731 6 151.88 0.31 0.002 0.29 0.33 
71 Pl347595 6 182.38 0.31 0.002 0.29 0.33 
75 Pl347610 6 138.63 0.31 0.002 0.29 0.33 
80 Pl 347612 6 161.25 0.31 0.002 0.29 0.33 
91 Pl352817 6 134.00 0.31 0.002 0.29 0.33 
94 Pl352821 6 99.88 0.31 0.002 0.29 0.33 
99 Pl347612 6 171.63 0.31 0.033 0.14 0.56 
115 Pl63318l 6 206.38 0.31 0.002 0.29 0.33 
118 Pl 597831 6 143.50 0.31 0.033 0.14 0.56 
167 Pl3528l2 6 94.50 0.31 0.002 0.29 0.33 
210 Pl458615 6 136.50 0.31 0.002 0.29 0.33 
237 Pl370740 6 138.50 0.31 0.002 0.29 0.33 
242 Pl 169096 6 84.63 0.31 0.033 0.14 0.56 
253 PI426234 6 137.00 0.31 0.002 0.29 0.33 
265 Pl 174796 6 150.38 0.31 0.002 0.29 0.33 
276 PI 426263 6 117.75 0.31 0.002 0.29 0.33 
5 Pl 183019 6 141.50 0.32 0.031 0.15 0.55 
7 Pl319413 6 140.00 0.32 0.031 0.15 0.55 
103 Pl430601 6 179.13 0.32 0.031 0.15 0.55 
Ill Pl352790 6 135.63 0.32 0.031 0.15 0.55 
116 Pl 426284 6 172.25 0.32 0.031 0.15 0.55 
208 Pl370729 6 68.38 0.32 0.031 0.15 0.55 
25 Pl426276 6 195.88 0.35 0.044 0.13 0.67 
59 Ames 9706 6 174.75 0.35 0.044 0.13 0.67 
63 Pl340194 6 137.38 0.35 0.044 0.13 0.67 
69 Pl347607 6 16700 0.35 0.044 0.13 0.67 
73 Ames 9888 6 116.50 0.35 0.044 0.13 0.67 
98 Pl633174 7 185.50 0.35 0.044 0.13 0.67 
109 Pl633178 6 141.88 0.35 0.044 0.13 0.67 
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A.1. Continued 
Confidence Interval 
Treatment effect !95%~ 
Median Treatment 
Accession Disease Mean relative Standard Lower Upper 
number Name Ratio& Rank effect error Limit Limit 
113 PI352791 6 I 95.38 0.35 0.044 0.13 0.67 
215 PI370732 6 105.88 0.35 0.044 0.13 0.67 
226 PI426282 6 120.75 0.35 0.044 0.13 0.67 
37 PI340182 6 140.00 0.36 0.042 0.14 0.66 
65 PI347602 6 192.25 0.36 0.042 0.14 0.66 
105 PI347614 6 120.75 0.36 0.042 0.14 0.66 
127 Pl 419212 6 144.38 0.36 0.042 0.14 0.66 
9 PI 183391 7 188.13 0.38 0.039 0.17 0.65 
38 Ames9411 6 169.63 0.38 0.020 0.26 0.52 
42 Ames 9416 6 133.25 0.38 0.020 0.26 0.52 
49 Ames 9495 6 120.75 0.38 0.020 0.26 0.52 
70 Ames 9744 6 137.38 0.38 0.020 0.26 0.52 
77 PI426265 6 150.38 0.38 0.020 0.26 0.52 
78 PI 3476! I 6 !37.38 0.38 0.020 0.26 0.52 
79 P1426257 6 147.38 0.38 0.020 0.26 0.52 
82 PI426290 6 120.75 0.38 0.020 0.26 0.52 
85 PI426261 6 117.75 0.38 0.020 0.26 0.52 
[21 PI352794 6 89.13 0.38 0.020 0.26 0.52 
122 PI419063 6 120.13 0.38 0.039 0.17 0.65 
216 PI426249 6 87.63 0.38 0.020 0.26 0.52 
250 PI426175 6 83.25 0.38 0.020 0.26 0.52 
261 ?1537002 6 94.50 0.38 0.020 0.26 0.52 
264 ?1426288 7 120.75 0.39 0.053 0.12 0.74 
194 Pl 164542 6 212.13 0.40 0.051 0.13 0.74 
P1312903 6 117.25 0.42 0.033 0.23 0.65 
24 PI314137 7 78.63 0.42 0.033 0.23 0.65 
29 Pl 198061 6 151.88 0.42 0.033 0.23 0.65 
39 PI207465 6 154.75 0.42 0.033 0.23 0.65 
45 Ames 15492 6 140.13 0.42 0.033 0.23 0.65 
52 Ames 9624 6 237.25 0.42 0.033 0.23 0.65 
61 Pl426273 6 157.13 0.42 0.033 0.23 0.65 
62 Pl 347596 6 120.75 0.42 0.033 0.23 0.65 
76 Pl633166 7 86.63 0.42 0.033 0.23 0.65 
87 Pl426264 6 165.13 0.42 0.033 0.23 0.65 
100 Pl370731 6 99.88 0.42 0.033 0.23 0.65 
102 Pl 347613 6 120.75 0.42 0.033 0.23 0.65 
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Confidence Interval 
Treatment effect !95%~ 
Median Treatment 
Accession Disease Mean relative Standard Lower Upper 
number Name Rating Rank effect error Limit Limit 
114 Pl391554 6 158.38 0.42 0.033 0.23 0.65 
117 Pl352792 6 169.00 0.42 0.033 0.23 0.65 
154 Pl 426238 6 125.50 0.42 0.033 0.23 0.65 
175 Pl426280 7 196.88 0.42 0.033 0.23 0.65 
195 PI 179642 6 172.63 0.42 0.033 0.23 0.65 
221 PI 169082 6 86.63 0.42 0.033 0.23 0.65 
231 PI 370738 7 172.63 0.42 0.033 0.23 0.65 
235 PI 169094 6 171.63 0.42 0.033 0.23 0.65 
240 Pl370741 7 102.50 0.42 0.033 0.23 0.65 
259 PI 174793 6 [04.50 0.42 0.033 0.23 0.65 
260 PI426242 6 151.88 0.42 0.033 0.23 0.65 
198 PI352823 6 181.00 0.43 0.044 0.18 0.72 
58 Ames 9677 7 151.88 0.45 0.023 0.30 0.61 
68 PI340196 6 160.63 0.45 0.023 0.30 0.61 
220 PI432375 6 147.38 0.45 0.023 0.30 0.61 
66 Pl 340195 6 147.63 0.46 0.043 0.21 0.73 
130 Pl 426172 6 137.50 0.46 0.043 0.21 0.73 
212 Pl 169070 6 86.63 0.46 0.038 0.23 0.71 
223 PI 169088 7 99.00 0.46 0.043 0.21 0.73 
IOI PI 633175 6 147.38 0.47 0.052 0.17 0.78 
147 PI426235 6 218.00 0.47 0.052 0.17 0.78 
165 Pl 426270 6 47.00 0.47 0.057 0.16 0.81 
197 PI426266 6 I 07.38 0.47 0.052 0.18 0.78 
222 Pl 370735 7 106.38 0.47 0.047 0.20 0.76 
192 Pl352821 6 226.00 0.48 0.050 0.19 0.78 
II PI319417 7 140.00 0.49 0.032 0.29 0.70 
18 PI 319694 7 117.75 0.49 0.032 0.29 0.70 
30 Ames 9304 7 170.25 0.49 0.032 0.29 0.70 
34 Ames 9390 6 131.00 0.49 0.032 0.29 0.70 
54 PI340189 7 80.00 0.49 0.032 0.29 0.70 
81 Pl347599 6 168.50 0.49 0.032 0.29 0.70 
90 PI347609 6 135.50 0.49 0.032 0.29 0.70 
92 PI 426255 6 120.75 0.49 0.032 0.29 0.70 
96 Pl 370728 6 191.00 0.49 0.032 0.29 0.70 
104 PI 633176 6 103.88 0.49 0.032 0.29 0.70 
108 Pl370737 6 124.25 0.49 0.032 0.29 0.70 
112 Pl 633180 6 8150 0.49 0.032 0.29 0.70 
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A.1. Continued 
Confidence Interval 
Treatment effect (95%) 
Median Treatment 
Accession Disease Mean relative Standard Lower Upper 
number Name Rating Rank effect error Limit Limit 
183 Pl431573 6 168.13 0.49 0.032 0.29 0.70 
184 PI352818 6 143.38 0.49 0.032 0.29 0.70 
219 Pl 458972 6 107.38 0.49 0.032 0.29 0.70 
227 PI458976 7 227.13 0.49 0.032 0.29 0.70 
232 Pl 169093 6 154.38 0.49 0.032 0.29 0.70 
239 Pl458984 7 86.63 0.49 0.032 0.29 0.70 
243 Pl370742 6 124.25 0.49 0.032 0.29 0.70 
245 Pl 170032 7 118.25 0.49 0.032 0.29 0.70 
255 Pl426236 6 135.13 0.49 0.032 0.29 0.70 
262 Pl 174799 6 104.50 0.49 0.032 0.29 0.70 
166 Pl 135821 7 44.38 0.50 0.058 0.17 0.83 
178 Pl 426292 6 146.88 0.50 0.058 0.17 0.83 
107 P1352789 7 86.63 0.52 0.020 0.38 0.65 
196 Pl352822 6 129.38 0.52 0.020 0.38 0.65 
17 Ames 9264 7 98.00 0.54 0.038 0.29 0.76 
19 Pl 183917 7 117.25 0.54 0.038 0.29 0.76 
22 Pl 323939 8 85.00 0.54 0.044 0.26 0.80 
23 Ames 9285 7 151.88 0.54 0.038 0.29 0.76 
28 Ames 9286 6 181.50 0.54 0.038 0.29 0.76 
57 Pl34192 7 181.50 0.54 0.038 0.29 0.76 
83 Ames 15943 7 161.38 0.54 0.038 0.29 0.76 
86 Pl 633170 6 209.13 0.54 O.Q38 0.29 0.76 
88 Pl352807 6 98.00 0.54 0.038 0.29 0.76 
97 ?1426287 7 151.38 0.54 0.038 0.29 0.76 
110 Pl391547 7 102.50 0.54 O.Q38 0.29 0.76 
119 Pl352793 6 182.13 0.54 O.Q38 0.29 0.76 
129 PI352798 7 251.13 0.54 O.Q38 0.29 0.76 
144 Pl426286 7 144.50 0.54 O.Q38 0.29 0.76 
146 Pl352805 6 178.00 0.54 O.Q38 0.29 0.76 
156 Pl426277 7 137.50 0.54 0.038 0.29 0.76 
172 Pl426259 6 117.25 0.54 0.038 0.29 0.76 
181 Pl 163498 6 106.38 0.54 O.Q38 0.29 0.76 
189 Pl 164468 6 178.00 0.54 0.038 0.29 0.76 
190 Pl352820 6 102.75 0.54 0.038 0.29 0.76 
193 Pl436560 6 245.25 0.54 0.038 0.29 0.76 
218 Pl 169081 6 138.50 0.54 0.038 0.29 0.76 
225 Pl370736 6 103.75 0.54 0.038 0.29 0.76 
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Confidence Interval 
Treatment effect !95%~ 
Median Treatment 
Accession Disease Mean relative Standard Lower Upper 
number Name Rating Rank effect error Limit Limit 
241 PI459020 6 86.63 0.54 0.038 0.29 0.76 
244 PI 169097 7 138.50 0.54 0.044 0.26 0.80 
254 PI 175608 6 127.13 0.54 0.038 0.29 0.76 
263 Pl 426244 7 150.38 0.54 0.038 0.29 0.76 
269 Pl537010 7 107.38 0.54 0.038 0.29 0.76 
270 Pl426248 6 140.50 0.54 0.044 0.26 0.80 
275 PI426254 7 151.88 0.54 0.038 0.29 0.76 
277 Pl 174805 7 136.50 0.54 0.038 0.29 0.76 
148 PI 115885 6 117.75 0.55 0.065 0.17 0.88 
257 Pl 426238 8 65.75 0.55 0.046 0.26 0.81 
157 Pl 125798 7 158.75 0.56 0.027 0.38 0.73 
170 Pl352813 6 212.13 0.56 0.027 0.38 0.73 
206 Pl370028 7 140.50 0.56 0.027 0.38 0.73 
238 Pl 169095 7 98.00 0.56 0.027 0.38 0.73 
252 Pl 426173 6 116.25 0.56 0.027 0.38 0.73 
143 Pl352804 6 135.63 0.57 0.044 0.28 0.82 
180 Pl458989 6 148.38 0.57 0.044 0.28 0.82 
142 Pl352803 6 106.00 0.59 0.047 0.27 0.84 
149 Pl329025 7 151.38 0.59 0.047 0.27 0.84 
161 Pl 352810 6 151.38 0.59 0.047 0.27 0.84 
163 Pl 134692 7 160.25 0.59 0.050 0.26 0.85 
169 Pl 135871 6 107.38 0.59 0.047 0.27 0.84 
179 PI352816 6 188.75 0.59 0.047 0.27 0.84 
182 PI352817 6 125.25 0.59 0.047 0.27 0.84 
204 PI365643 7 74.88 0.59 0.004 0.57 0.62 
236 P1458983 8 116.25 0.59 0.047 0.27 0.84 
267 Pl537009 7 156.25 0.59 0.047 0.27 0.84 
228 P1370737 7 158.25 0.60 0.060 0.22 0.89 
47 Ames 9492 7 169.63 0.61 0.031 0.39 0.79 
60 Pl340193 7 206.38 0.61 0.031 0.39 0.79 
135 Pl 175054 6 172.13 0.61 0.049 0.28 0.86 
136 PI426174 6 143.38 0.61 0.038 0.35 0.82 
199 Pl 165595 7 138.50 0.61 0.031 0.39 0.79 
133 PI352799 6 159.63 0.62 0.052 0.27 0.88 
155 Pl426240 6 134.13 0.62 0.052 0.27 0.88 
203 Pl 165608 8 103.88 0.62 0.052 0.27 0.88 
159 PI426241 6 194.38 0.63 0.054 0.26 0.89 
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Confidence Interval 
Treatment effect (95%~ 
Median Treatment 
Accession Disease Mean relative Standard Lower Upper 
number Name Rating Rank effect error Limit Limit 
164 Pl 426262 6 182.25 0.63 0.054 0.26 0.89 
202 Pl 426260 8 135.50 0.63 0.054 0.26 0.89 
213 Pl370731 8 202.25 0.63 0.054 0.26 0.89 
89 Pl633171 7 137.38 0.65 0.033 0.41 0.83 
150 Pl 175050 7 192.88 0.65 0.033 0.41 0.83 
168 Pl426275 7 148.38 0.65 0.033 0.41 0.83 
233 Pl 458982 7 117.50 0.65 0.033 0.41 0.83 
256 Pl 173868 7 218.63 0.65 0.033 0.41 0.83 
266 Pl426246 7 181.50 0.65 0.033 0.41 0.83 
273 Pl I 74804 7 117.25 0.65 0.033 0.41 0.83 
274 Pl426252 7 140.50 0.65 0.033 0.41 0.83 
131 Pl633156 6 148.88 0.66 0.039 0.37 0.86 
153 Ol 352807 6 161.25 0.66 0.039 0.37 0.86 
174 Pl 162778 8 120.75 0.66 0.039 0.37 0.86 
200 PI 443023 7 151.38 0.66 0.039 0.37 0.86 
229 Pl 169092 7 86.63 0.66 0.039 0.37 0.86 
230 Pl 458977 7 86.63 0.66 0.039 0.37 0.86 
40 PI426289 7 174.75 0.68 0.015 0.57 0.77 
120 Pl 419036 7 134.13 0.68 0.015 0.57 0.77 
128 PI426268 6 172.25 0.68 0.041 0.37 0.88 
26 Pl324507 7 104.50 0.69 0.037 0.40 0.88 
72 Pl347609 7 160.63 0.69 0.037 0.40 0.88 
145 Pl 633159 7 189.00 0.69 0.037 0.40 0.88 
173 Pl352814 7 141.50 0.69 0.037 0.40 0.88 
211 Pl 175052 7 141.50 0.69 0.037 0.40 0.88 
224 PI458975 6 100.38 0.69 0.037 0.40 0.88 
10 Pl 183395 7 174.13 0.70 0.039 0.39 0.89 
93 Pl347610 8 161.38 0.70 0.039 0.39 0.89 
171 Pl426728 7 154.38 0.70 0.039 0.39 0.89 
186 Pl 164398 8 224.00 0.70 0.045 0.35 0.91 
205 Pl 269445 6 89.13 0.70 0.039 0.39 0.89 
271 Pl 426250 8 195.38 0.70 0.039 0.39 0.89 
124 Pl470042 7 242.00 0.71 0.041 0.39 0.90 
234 Pl370739 7 69.75 0.71 0.022 0.55 0.84 
139 Pl 633158 7 154.63 0.72 0.040 0.40 0.91 
140 Ames 21757 7 161.38 0.72 0.013 0.63 0.80 
188 PI436552 7 205.38 0.72 0.013 0.63 0.80 
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Confidence Interval 
Treatment effect (95%) 
Median Treatment 
Accession Disease Mean relative Standard Lower Upper 
number Name Rating Rank effect error Limit Limit 
126 Pl352797 6 192.00 0.73 0.042 0.39 0.92 
137 Pl426175 7 161.25 0.73 0.042 0.39 0.92 
177 Pl 163496 7 110.25 0.73 0.042 0.39 0.92 
158 PI352809 7 160.25 0.75 0.044 0.38 0.93 
160 PI 127440 6 112.38 0.75 0.044 0.38 0.93 
162 PI426242 7 131.50 0.75 0.044 0.38 0.93 
272 PI 53701 I 8 86.63 0.75 0.044 0.38 0.93 
15 Pl 183664 7 118.25 0.76 0.003 0.75 0.78 
16 Dk 3042 7 140.00 0.76 0.003 0.75 0.78 
106 Pl370736 9 69.75 0.76 0.045 0.37 0.94 
123 PI419180 7 88.75 0.76 0.003 0.75 0.78 
251 PI 173852 7 117.25 0.76 0.003 0.75 0.78 
268 PI 174803 7 140.00 0.76 0.018 0.61 0.86 
134 PI633157 7 159.63 0.77 0.044 0.38 0.95 
138 PI352802 7 170.50 0.77 0.046 0.36 0.95 
132 PI426173 7 86.88 0.78 0.024 0.58 0.90 
151 PI 116021 6 205.38 0.78 0.045 0.37 0.96 
44 PI340185 7 I 71.25 0.79 0.021 0.61 0.90 
125 PI352796 7 125.50 0.80 0.024 0.60 0.92 
191 Pl 164494 7 162.25 0.80 0.024 0.60 0.92 
20 Ames 9267 8 132.00 0.81 0.014 0.70 0.89 
185 Pl 432364 7 107.38 0.83 0.012 0.74 0.90 
246 Pl 419063 8 106.38 0.85 0.014 0.72 0.92 
152 Pl 125795 8 151.38 0.86 0.016 0.71 0.94 
201 PJ443024 8 47.00 0.86 0.016 0.71 0.94 
214 Pl 169074 9 68.38 0.88 0.019 0.68 0.96 
21 Pl i83919 8 116.25 0.90 0.013 0.77 0.96 
53 PI340191 8 120.75 0.91 0.014 0.76 0.97 
187 Pl352819 8 191.88 0.91 0.014 0.76 0.97 
176 Pl426258 7 191.13 0.92 0.015 0.74 0.98 
8 Ames 9260 8 146.88 0.95 ( 0.005 l 0.90 0.98 
Standard errors (se) are given in brackets after the estimates, which were determined based on 
output of the SAS macro. In general, if the SAS macro is not available, se can be roughly 
approximated by se I N, in which se is the standard error of the mean rank for the ith accession 
(treatment) as determined in the MIXED procedure of SAS with the LSMEANS option (SAS 
Institute, Cary, NC). 
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A.2. Median, mean rank and estimated relative treatment effects for the severity of foliar 
symptoms on 227 Brassica rapa accessions based on their reaction to inoculation 
with one L. maculans isolate of PG 4. 
Confidence Interval 
Treatment effect {95%) 
Median Treatment 
Accession Disease Mean relative Standard Lower Upper 
number Name Rating Rank effect error Limit Limit 
PJ312903 7 89.50 0.28 0.003 0.26 0.30 
2 Pl 179863 7 89.50 0.28 0.003 0.26 0.30 
9 PI 183391 6 16.00 0.28 0.029 0.13 0.51 
27 PI 319413 7 89.50 0.28 0.050 0.07 0.67 
51 Pl 163947 7 208.50 0.28 0.050 0.07 0.67 
57 PI34192 7 89.50 0.28 0.003 0.26 0.30 
60 PI 340193 7 16.00 0.28 0.003 0.26 0.30 
72 PI347609 7 3.00 0.28 0.003 0.26 0.30 
88 PI352807 7 89.50 0.28 0.003 0.26 0.30 
94 PI352821 7 149.00 0.28 0.029 0.13 0.51 
103 PI430601 7 40.00 0.28 0.003 0.26 0.30 
198 PI352823 7 270.50 0.28 0.003 0.26 0.30 
204 Pl365643 7 89.50 0.28 0.003 0.26 0.30 
216 PI426249 7 40.00 0.28 0.003 0.26 0.30 
79 PI426257 8 16.00 0.29 0.048 0.08 0.66 
98 PI 633174 7 16.00 0.29 0.048 0.08 0.66 
192 PI352821 8 89.50 0.29 0.048 0.08 0.66 
56 Pl340195 7 89.50 0.30 0.026 0.15 0.50 
63 Pl 340194 7 40.00 0.30 0.026 0.15 0.50 
78 Pl34761 I 7 89.50 0.30 0.026 0.15 0.50 
96 Pl370728 7 40.00 0.30 0.026 0.15 0.50 
5 Pl183019 8 149.00 0.34 0.034 0.16 0.60 
7 Pl319413 7 16.00 0.34 0.034 0.16 0.60 
23 Ames 9285 7 270.50 0.34 0.018 0.23 0.47 
28 Ames 9286 7 89.50 0.34 0.034 0.16 0.60 
30 Ames 9304 7 16.00 0.34 0.034 0.16 0.60 
35 Pl340181 7 208.50 0.34 0.018 0.23 0.47 
37 ?1340182 7 40.00 0.34 0.018 0.23 0.47 
61 ?1426273 7 89.50 0.34 0.034 0.16 0.60 
80 Pl347612 8 89.50 0.34 0.044 0.12 0.66 
87 Pl426264 7 89.50 0.34 0.044 0.12 0.66 
89 PI633171 7 89.50 0.34 O.ot8 0.23 0.47 
90 Pl347609 7 149.00 0.34 0.018 0.23 0.47 
91 PI352817 7 208.50 0.34 0.018 0.23 0.47 
105 ?1347614 8 89.50 0.34 0.018 0.23 0.47 
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Confidence Interval 
Treatment effect (95%} 
Median Treatment 
Accession Disease Mean relative Standard Lower Upper 
number Name Ratin& Rank effect error Limit Limit 
107 Pl352789 7 89.50 0.34 0.018 0.23 0.47 
183 Pl431573 7 89.50 0.34 0.034 0.16 0.60 
206 PJ370028 7 208.50 0.34 0.018 0.23 0.47 
235 Pll69094 7 149.00 0.34 O.oJ8 0.23 0.47 
241 Pl459020 7 40.00 0.34 0.044 0.12 0.66 
253 Pl426234 8 208.50 0.34 0.018 0.23 0.47 
273 Pll74804 6 149.00 0.34 0.044 0.12 0.66 
10 Pll 83395 8 40.00 0.35 0.041 0.14 0.65 
50 Pl340189 7 16.00 0.35 0.041 0.14 0.65 
194 Pll64542 7 89.50 0.35 0.041 0.14 0.65 
249 Pll 73848 8 89.50 0.35 0.041 0.14 0.65 
41 Pl340184 8 208.50 0.36 0.031 0.18 0.58 
83 Amesl5943 7 149.00 0.36 0.031 0.18 0.58 
104 PI633176 7 89.50 0.36 0.031 0.18 0.58 
117 Pl352792 7 208.50 0.36 0.031 0.18 0.58 
6 Pl314137 8 208.50 0.37 0.048 0.12 0.70 
31 Pit 75085 7 89.50 0.40 0.045 0.16 0.71 
66 Pl340195 8 40.00 0.40 O.Q35 0.20 0.64 
69 P1347607 8 89.50 0.40 0.061 0.11 0.79 
70 Ames 9744 7 40.00 0.40 0.035 0.20 0.64 
108 Pl370737 8 40.00 0.40 0.035 0.20 0.64 
150 PI! 75050 8 270.50 0.40 O.Q35 0.20 0.64 
207 PI169061 8 208.50 0.40 0.035 0.20 0.64 
226 Pl426282 7 208.50 0.40 0.035 0.20 0.64 
4 Ames 9251 7 89.50 0.41 0.021 0.28 0.55 
114 PI391554 7 40.00 0.41 0.021 0.28 0.55 
14 P1319693 7 40.00 0.42 0.042 0.18 0.70 
34 Ames 9390 7 89.50 0.42 0.042 0.18 0.70 
64 Ames 9731 8 149.00 0.42 0.056 0.13 0.78 
242 Pll69096 7 89.50 0.42 0.042 0.18 0.70 
15 Pll 83664 7 89.50 0.46 0.033 0.26 0.68 
26 Pl324507 7 208.50 0.46 0.033 0.26 0.68 
29 Pll 98061 7 16.00 0.46 0.033 0.26 0.68 
47 Ames 9492 7 16.00 0.46 0.033 0.26 0.68 
52 Ames 9624 7 208.50 0.46 0.033 0.26 0.68 
93 ?1347610 7 149.00 0.46 0.033 0.26 0.68 
102 ?1347613 8 89.50 0.46 0.033 0.26 0.68 
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Confidence Interval 
Treatment effect {95%! 
Median Treatment 
Accession Disease Mean relative Standard Lower Upper 
number Name Ratin~ Rank effect error Limit Limit 
113 PI352791 7 149.00 0.46 0.052 0.17 0.78 
145 PI633159 7 254.50 0.46 0.033 0.26 0.68 
175 PI426280 8 270.50 0.46 0.052 0.17 0.78 
178 Pl426292 8 208.50 0.46 0.052 0.17 0.78 
208 Pl370729 7 40.00 0.46 0.033 0.26 0.68 
211 Pll 75052 7 149.00 0.46 0.033 0.26 0.68 
212 Pll69070 8 208.50 0.46 0.033 0.26 0.68 
215 Pl370732 8 89.50 0.46 0.033 0.26 0.68 
220 PI432375 8 89.50 0.46 0.052 0.17 0.78 
231 PI370738 8 149.00 0.46 0.033 0.26 0.68 
237 PI370740 7 149.00 0.46 0.033 0.26 0.68 
265 Pil74796 7 89.50 0.46 0.052 0.17 0.78 
275 PI426254 7 40.00 0.46 0.033 0.26 0.68 
84 PI347605 8 89.50 0.47 0.018 0.35 0.59 
127 PI419212 8 254.50 0.47 0.049 0.19 0.77 
159 P1426241 8 254.50 0.47 0.049 0.19 0.77 
180 Pl458989 8 208.50 0.47 0.049 0.19 0.77 
218 PI169081 8 208.50 0.47 0.049 0.19 0.77 
223 Pl169088 8 208.50 0.47 0049 0.19 0.77 
232 Pl169093 8 208.50 0.47 0.018 0.35 0.59 
182 PI352817 7 16.00 0.48 0.041 0.23 0.73 
133 Pl352799 8 208.50 0.51 0.044 0.24 0.77 
193 PI436560 8 40.00 0.51 0.044 0.24 0.77 
256 Pl173868 7 208.50 0.51 0.044 0.24 0.77 
25 Pl426276 7 149.00 0.52 0.040 0.27 0.76 
55 Ames 9668 8 40.00 0.52 0.040 0.27 0.76 
86 Pl633170 8 16.00 0.52 0.040 0.27 0.76 
101 PI633175 8 149.00 0.52 0.040 0.27 0.76 
185 Pl432364 8 149.00 0.52 0.050 0.22 0.81 
195 PII 79642 8 149.00 0.52 0.040 0.27 0.76 
230 Pl458977 8 149.00 0.52 0.040 0.27 0.76 
250 Pl426175 7 208.50 0.52 0.040 0.27 0.76 
264 PI426288 7 16.00 0.52 0.047 0.23 0.79 
268 Pil74803 7 89.50 0.52 0.040 0.27 0.76 
16 Dk 3042 7 149.00 0.53 0.003 0.51 0.55 
17 Ames 9264 7 208.50 0.53 0.028 0.34 0.71 
19 Pll83917 7 149.00 0.53 0028 0.34 0.71 
90 
A.2. Continued 
Confidence Interval 
Treatment effect ~95%} 
Median Treatment 
Accession Disease Mean relative Standard Lower Upper 
number Name Rating Rank effect error Limit Limit 
39 Pl207465 8 149.00 0.53 0.028 0.34 0.71 
40 Pl426289 7 149.00 0.53 0.028 0.34 0.71 
44 PI340185 8 254.50 0.53 0.028 0.34 0.71 
65 PI347602 7 208.50 0.53 0.028 0.34 0.71 
76 PI633166 8 208.50 0.53 0.028 0.34 0.71 
92 PI426255 8 149.00 0.53 0.028 0.34 0.71 
95 PI633 l73 8 40.00 0.53 0.028 0.34 0.71 
97 PI426287 8 16.00 0.53 0.059 0.18 0.85 
122 PI419063 8 270.50 0.53 0.028 0.34 0.71 
188 PI436552 8 149.00 0.53 0.028 0.34 0.71 
190 Pl352820 8 254.50 0.53 0.028 0.34 0.71 
209 PI169064 7 149.00 0.53 0.059 0.18 0.85 
210 Pl458615 7 89.50 0.53 0.028 0.34 0.71 
259 Pll 74793 7 89.50 0.53 0.028 0.34 0.71 
203 Pll65608 7 89.50 0.54 0.046 0.25 0.80 
22 Pl323939 7 89.50 0.56 0.068 0.16 0.89 
205 Pl269445 8 89.50 0.56 0.048 0.26 0.83 
165 Pl426270 7 208.50 0.57 0.039 0.31 0.79 
II PI319417 8 208.50 0.58 0.033 0.36 0.78 
18 Pl319694 7 149.00 0.58 0.033 0.36 0.78 
36 Ames 9396 7 89.50 0.58 0.033 0.36 0.78 
77 Pl426265 8 89.50 0.58 0.033 0.36 0.78 
110 Pl391547 7 89.50 0.58 0.033 0.36 0.78 
121 Pl352794 8 149.00 0.58 0.033 0.36 0.78 
140 Ames21757 8 208.50 0.58 0.033 0.36 0.78 
154 PI426238 8 270.50 0.58 0.033 0.36 0.78 
162 Pl426242 8 208.50 0.58 0.033 0.36 0.78 
166 Pil35821 8 254.50 0.58 0.033 0.36 0.78 
169 Pil35871 8 254.50 0.58 0.033 0.36 0.78 
172 Pl426259 8 208.50 0.58 0.033 0.36 0.78 
179 PI352816 8 208.50 0.58 0.033 0.36 0.78 
189 Pll64468 8 149.00 0.58 0.033 0.36 0.78 
228 Pl370737 8 208.50 0.58 0.042 0.30 0.82 
234 PI370739 7 149.00 0.58 0.033 0.36 0.78 
238 PJl69095 8 89.50 0.58 0.033 0.36 0.78 
240 Pl37074l 7 89.50 0.58 0.033 0.36 0.78 
244 Pll69097 7 208.50 0.58 0.050 0.25 0.85 
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A.2. Continued 
Confidence Interval 
Treatment effect {95%) 
Median Treatment 
Accession Disease Mean relative Standard Lower Upper 
number Name Rating Rank effect error Limit Limit 
252 Pl426173 8 149.00 0.58 0.033 0.36 0.78 
255 Pl426236 8 149.00 0.58 0.033 0.36 0.78 
258 Pll 73871 7 149.00 0.58 0.033 0.36 0.78 
260 Pl426242 7 149.00 0.58 0.050 0.25 0.85 
261 Pl537002 8 208.50 0.58 0.033 0.36 0.78 
266 PI426246 7 89.50 0.58 0.050 0.25 0.85 
272 Pl53701 l 7 16.00 0.58 0.050 0.25 0.85 
274 Pl426252 7 89.50 0.58 0.033 0.36 0.78 
59 Ames 9706 7 89.50 0.59 0.017 0.47 0.70 
158 PI352809 8 208.50 0.59 0.049 0.27 0.85 
224 Pl458975 8 89.50 0.59 0.049 0.27 0.85 
197 Pl426266 8 89.50 0.61 0.060 0.22 0.90 
170 PI352813 8 208.50 0.62 0.058 0.24 0.90 
200 PI443023 7 208.50 0.62 0.058 0.23 0.90 
269 PI537010 8 208.50 0.62 0.056 0.24 0.89 
131 PI633 I 56 8 270.50 0.63 0.041 0.34 0.84 
135 Pll 75054 8 208.50 0.63 0.041 0.34 0.84 
146 Pl352805 8 254.50 0.63 0.041 0.34 0.84 
160 Pil27440 8 208.50 0.63 0.041 0.34 0.84 
24 PI314137 7 89.50 0.64 0.043 0.33 0.86 
54 Pl340189 8 89.50 0.64 0.035 0.39 0.83 
112 Pl633180 8 208.50 0.64 0.035 0.39 0.83 
120 Pl4 I 9036 7 208.50 0.64 0.035 0.39 0.83 
124 PI470042 8 254.50 0.64 0.035 0.39 0.83 
130 PI426172 8 254.50 0.64 0.035 0.39 0.83 
173 Pl352814 8 208.50 0.64 0.035 0.39 0.83 
174 PI162778 8 16.00 0.64 0.043 0.33 0.86 
202 Pl426260 7 149.00 0.64 0.035 0.39 0.83 
219 Pl458972 8 208.50 0.64 0.035 0.39 0.83 
221 P!l69082 9 89.50 0.64 0.043 0.33 0.86 
227 Pl458976 7 89.50 0.64 0.035 0.39 0.83 
239 Pl458984 8 149.00 0.64 0.035 0.39 0.83 
243 PI370742 8 89.50 0.64 0.035 0.39 0.83 
247 Pll71521 7 16.00 0.64 0.035 0.39 0.83 
254 Pil75608 8 208.50 0.64 0,035 0.39 0.83 
42 Ames 9416 8 149.00 0.65 0.019 0.51 0.76 
43 Ames 9474 8 89.50 0.65 0.019 0.51 0.76 
118 Pl59783 l 7 16.00 0.65 0.019 0.51 0.76 
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A.2. Continued 
Confidence Interval 
Treatment effect {95%1 
Median Treatment 
Accession Disease Mean relative Standard Lower Upper 
number Name Ratio& Rank effect error Limit Limit 
156 Pl426277 8 208.50 0.65 0.019 0.51 0.76 
161 PI352810 8 149.00 0.65 0.019 0.51 0.76 
168 Pl426275 8 208.50 0.65 0.019 0.51 0.76 
233 Pl458982 8 89.50 0.65 0.019 0.51 0.76 
263 Pl426244 7 89.50 0.65 0.056 0.26 0.90 
45 Ames15492 9 40.00 0.68 0.040 0.38 0.88 
144 Pl426286 7 89.50 0.68 0.040 0.38 0.88 
148 Pll 15885 9 208.50 0.68 0.048 0.32 0.90 
236 P1458983 7 89.50 0.68 0.048 0.32 0.90 
271 Pl426250 7 89.50 0.68 0.048 0.32 0.90 
196 Pl352822 8 1.00 0.69 0.028 0.48 0.84 
20 Ames 9267 8 208.50 0.70 0.017 0.58 0.80 
53 PI340191 8 208.50 0.70 0.042 0.37 0.90 
106 Pl370736 7 89.50 0.70 0.042 0.37 0.90 
126 Pl352797 9 208.50 0.70 0.042 0.37 0.90 
129 Pl352798 8 208.50 0.70 0.017 0.58 0.80 
132 Pl426173 9 254.50 0.70 0.042 0.37 0.90 
142 PI352803 9 270.50 0.70 0.042 0.37 0.90 
164 Pl426262 8 149.00 0.70 0.042 0.37 0.90 
171 PI426728 9 208.50 0.70 0.042 0.37 0.90 
181 Pil63498 8 40.00 0.70 0.017 0.58 0.80 
186 Pl164398 8 254.50 0.70 0.017 0.58 0.80 
199 Pll65595 8 254.50 0.70 0.042 0.37 0.90 
229 Pll69092 8 208.50 0.70 0.017 0.58 0.80 
267 Pl537009 7 89.50 0.70 0.042 0.37 0.90 
277 Pll 74805 7 149.00 0.70 0.042 0.37 0.90 
257 Pl426238 8 149.00 0.73 0.044 0.37 0.92 
245 Pll 70032 7 208.50 0.74 0.046 0.36 0.93 
136 PI426174 8 270.50 0.75 0.024 0.56 0.87 
138 PI352802 9 270.50 0.75 0.047 0.35 0.94 
147 Pl426235 8 254.50 0.75 0.024 0.56 0.87 
157 Pll25798 8 208.50 0.75 0.024 0.56 0.87 
163 Pl 134692 8 270.50 0.75 0.024 0.56 0.87 
167 Pl352812 8 149.00 0.75 0.024 0.56 0.87 
201 PI443024 7 208.50 0.75 0.047 0.35 0.94 
246 Pl419063 8 208.50 0.75 0.024 0.56 0.87 
137 PI426175 8 270.50 0.76 0.026 0.54 0.89 
149 PI329025 8 89.50 0.76 0.002 0.74 0.78 
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A.2. Continued 
Confidence Interval 
Treatment effect !95%) 
Median Treatment 
Accession Disease Mean relative Standard Lower Upper 
number Name Rating Rank effect error Limit Limit 
155 Pl426240 9 149.00 0.76 0.026 0.54 0.89 
262 P1174799 8 40.00 0.76 0.002 0.74 0.78 
270 Pl426248 8 149.00 0.76 0.026 0.54 0.89 
128 Pl426268 9 208.50 0.79 0.027 0.55 0.92 
21 Pll83919 8 254.50 0.80 0.012 0.71 0.87 
187 Pl352819 8 89.50 0.80 0.012 0.71 0.87 
139 Pl633158 9 208.50 0.81 0.031 0.52 0.94 
214 Pl169074 8 208.50 0.81 0.031 0.52 0.94 
177 PII 63496 9 208.50 0.82 0.016 0.69 0.90 
125 PI352796 8 208.50 0.85 0.014 0.72 0.92 
134 Pl633 I 57 8 254.50 0.85 0.014 0.72 0.92 
153 01352807 8 89.50 0.85 0.014 0.72 0.92 
143 Pl352804 9 254.50 0.86 0.016 0.71 0.94 
176 PJ426258 9 270.50 0.86 0.016 0.71 0.94 
251 PII 73852 8 208.50 0.86 0.016 0.71 0.94 
8 Ames 9260 8 208.50 0.87 0.018 0.69 0.95 
213 Pl37073 I 8 208.50 0.87 0.018 0.69 0.95 
191 Pll64494 9 89.50 0.89 0.012 0.77 0.95 
123 Pl419180 9 208.50 0.90 0.014 ) 0.76 0.96 
I 51 Pll 16021 9 208.50 0.90 0.014 ) 0.76 0.96 
152 Pll25795 9 254.50 0.91 ( 0.015 ) 0.75 0.97 
Standard errors (se) are given in brackets after the estimates, which were determined based on 
output of the SAS macro. In general, if the SAS macro is not available, se can be roughly 
approximated by se I N, in which se is the standard error of the mean rank for the ithaccession 
(treatment) as determined in the MIXED procedure of SAS with the LSMEANS option (SAS 
Institute, Cary, NC). 
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A.3. Median, mean rank and estimated relative treatment effects for the severity of foliar 
symptoms on 80 Brassica napus accessions based on their reaction to inoculation 
with three L. maculans isolates of PG 3. 
Confidence Interval 
Treatment effect (95%) 
Median Treatment 
Accession Disease Mean relative Standard Lower Upper 
number Name Rating Rank effect error Limit Limit 
5 Ames 19198 7 55.25 0.41 0.039 0.19 0.67 
20 Ames25116 7 56.00 0.41 0.039 0.19 0.67 
39 PI 169080 7 55.25 0.41 0.039 0.19 0.67 
45 Pl271452 7 99.63 0.41 0.039 0.19 0.67 
46 Pl 282571 6 55.25 0.41 0.039 0.19 0.67 
48 Pl286418 7 79.13 0.41 0.026 0.25 0.58 
63 PI409022 7 92.00 0.41 0.039 0.19 0.67 
72 Pl432395 7 37.38 0.41 0.039 0.19 0.67 
78 Pl 458924 7 69.88 0.41 0.039 0.19 0.67 
79 Pl458935 8 103.00 0.41 0.039 0.19 0.67 
85 Pl535865 6 39.25 0.41 0.039 0.19 0.67 
86 PI458949 6 27.13 0.41 0.039 0.19 0.67 
90 PI 469930 7 55.13 0.41 0.039 0.19 0.67 
98 PI469803 6 44.38 0.41 0.039 0.19 0.67 
130 Pl 649145 7 61.25 0.41 0.039 0.19 0.67 
4 Ames 19197 6 65.38 0.44 0.060 0.13 0.80 
60 PI365644 7 72.88 0.45 0.064 0.13 0.82 
74 PI436556 6 56.00 0.45 0.032 0.26 0.66 
104 PI490024 7 43.88 0.45 0.064 0.13 0.82 
3 Ames 18935 7 60.38 0.46 0.033 0.25 0.67 
18 Ames 25114 7 60.38 0.46 0.033 0.25 0.67 
19 Ames 25115 7 67.38 0.46 0.033 0.25 0.67 
28 Ames 26168 7 60.38 0.46 0.033 0.25 0.67 
34 Pl 391553 7 63.25 0.46 0.033 0.25 0.67 
41 Pl250135 7 87.88 0.46 0.033 0.25 0.67 
42 Pl26635 7 63.25 0.46 0.033 0.25 0.67 
51 Pl 305281 8 118.88 0.46 0.033 0.25 0.67 
89 Pl458952 7 56.00 0.46 0.033 0.25 0.67 
106 Pl537011 7 98.63 0.46 0.033 0.25 0.67 
123 Pl 633163 7 98.63 0.46 0.033 0.25 0.67 
128 Pl 633169 7 60.38 0.46 0.033 0.25 0.67 
129 Pl649141 7 98.25 0.46 0.065 0.13 0.83 
40 PI221971 6 39.25 0.47 0.025 0.31 0.63 
24 Ames 25120 7 69.88 0.48 0.053 0.18 0.79 
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A.3. Continued 
Confidence Interval 
Treatment effect (95%) 
Median Treatment 
Accession Disease Mean relative Standard Lower Upper 
number Name Rating Rank effect error Limit Limit 
25 Ames 26165 6 63.13 0.48 0.053 0.18 0.79 
31 Ames 26626 6 63.13 0.48 0.053 0.18 0.79 
100 PI469832 6 42.75 0.48 0.053 0.18 0.79 
35 PI 399418 7 72.88 0.49 0.057 0.18 0.81 
58 PI311732 6 39.25 0.49 0.057 0.18 0.81 
88 Pl 458951 7 80.00 0.49 0.057 0.18 0.81 
97 Pl469791 6 56.13 0.49 0.045 0.22 0.76 
125 PI633165 7 82.38 0.49 0.045 0.22 0.76 
10 Ames 19205 7 74.63 0.50 0.024 0.35 0.66 
113 PI537020 7 I 01.75 0.50 0.024 0.35 0.66 
115 PI603020 7 87.88 0.50 0.024 0.35 0.66 
Ames 19204 7 72.00 0.53 0.034 0.31 0.73 
6 Ames 19199 7 72.00 0.53 0.034 0.31 0.73 
15 Ames25111 7 72.00 0.53 0.034 0.31 0.73 
27 Ames 26167 7 72.00 0.53 0.034 0.3 I 0.73 
30 Ames 26171 7 72.00 0.53 0.034 0.31 0.73 
37 PI 458944 7 72.00 0.53 0.034 0.31 0.73 
43 Pl251614 6 60.38 0.53 0.034 0.31 0.73 
53 Pl 311727 7 63.25 0.53 1)_034 0.31 0.73 
54 PI 311728 7 93.75 0.53 0.034 0.31 0.73 
55 Pl311729 7 72.00 0.53 0.034 0.31 0.73 
57 PI 311731 7 72.00 0.53 0.034 0.31 0.73 
80 PI458939 6 44.38 0.53 0.034 0.31 0.73 
83 Pl 458946 7 56.00 0.53 0.034 0.31 0.73 
103 Pl469863 6 56.00 0.53 0.034 0.31 0.73 
65 Pl431572 7 55.25 0.55 0.055 0.22 0.84 
2 Ames I 73847 7 76.25 0.57 0.021 0.43 0.70 
47 PI284859 7 55.25 0.57 O.o21 0.43 0.70 
102 Pl469857 7 61.25 0.57 0.038 0.32 0.79 
107 PI537012 7 85.38 0.57 0.021 0.43 0.70 
Ill Pl 469920 7 60.38 0.57 0.021 0.43 0.70 
l 16 Pl26628 7 79.13 0.57 0.021 0.43 0.70 
127 Pl 633168 7 88.88 0.57 0.038 0.32 0.79 
61 PI383422 6 45.25 0.59 0.055 0.24 0.87 
126 PI 633167 7 87.88 0.59 0.045 0.30 0.83 
66 PI431574 7 38.50 0.61 0.048 0.29 0.85 
120 PI633160 7 74.63 0.61 0.048 0.29 0.85 
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A.3. Continued 
Confidence Interval 
Treatment effect (95%) 
Median Treatment 
Accession Disease Mean relative Standard Lower Upper 
number Name Rating Rank effect error Limit Limit 
122 Pl 633162 6 48.50 0.61 0.048 0.29 0.85 
38 Pl 169075 7 87.88 0.64 0.004 0.62 0.67 
71 Pl432394 6 10.13 0.64 0.004 0.62 0.67 
75 Pl 436557 6 39.25 0.64 0.033 0.41 0.82 
84 Pl458947 7 72.00 0.64 0.033 0.41 0.82 
109 Pl 537014 7 67.75 0.64 0.004 0.62 0.67 
110 Pl537015 6 22.25 0.64 0.004 0.62 0.67 
119 PI603027 6 39.25 0.64 0.033 0.41 0.82 
121 PI633161 7 79.13 0.64 0.004 0.62 0.67 
52 PI305282 7 113.38 0.65 0.036 0.39 0.85 
32 Ames 26627 7 93.75 0.66 0.051 0.30 0.90 
26 Ames 26166 8 96.25 0.67 0.053 0.29 0.91 
44 Pl269449 7 72.00 0.67 0.053 0.29 0.91 
7 Ames 19201 7 98.63 0.71 0.020 0.56 0.82 
13 Ames 25109 7 IO 1. 75 0.71 0.020 0.56 0.82 
21 Ames 25117 7 95.75 0.71 0.020 0.56 0.82 
62 Pl384536 6 60.75 0.71 0.020 0.56 0.82 
67 Pl432373 7 75.13 0.71 0.020 0.56 0.82 
101 Pl 469836 7 56.00 0.71 0.020 0.56 0.82 
108 PI 537013 7 71.13 0.71 0.020 0.56 0.82 
118 Pl603026 7 74.63 0.71 0.020 0.56 0.82 
9 Ames 19203 7 94.75 0.72 0.041 0.40 0.91 
16 Ames 25112 7 100.13 0.72 0.024 0.54 0.85 
124 PT 26641 7 84.13 0.72 0.024 0.54 0.85 
22 Ames 25118 7 110.63 0.74 0.043 0.39 0.92 
23 Ames 25119 7 102.38 0.78 0.023 0.59 0.89 
68 Pl 432391 7 82.38 0.81 0.027 0.56 0.93 
50 Pl 305279 7 56.00 0.84 0.020 0.67 0.93 
49 P!305278 7 57.25 0.87 0.023 0.63 0.96 
131 Dk 3042 8 132.13 0.97 0.001 ) 0.95 0.98 
11 Ames 21489 8 133.50 0.98 { 0.002 ) 0.95 0.99 
Standard errors (se) are given in brackets after the estimates, which were determined based on 
output of the SAS macro. In general, if the SAS macro is not available, se can be roughly 
approximated by se I N, in which se is the standard error of the mean rank for the i1haccession 
(treatment) as determined in the MIXED procedure of SAS with the LSMEANS option (SAS 
Institute, Cary, NC). 
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A.4. Median, mean rank and estimated relative treatment effects for the severity of foliar 
symptoms on 80 Brassica napus accessions based on their reaction to inoculation 
with one L. maculans isolate of PG 4. 
Confidence Interval 
Treatment effect (95%) 
Median Treatment 
Accession Disease Mean relative Standard Lower lipper 
number Name Rating Rank effect error Limit Limit 
20 Ames 25116 7 44.63 0.33 0.055 0.09 0.72 
89 ?1458952 7 35.75 0.33 0.055 0.09 0.72 
43 Pl251614 7 60.25 0.35 0.004 0.32 0.38 
48 ?1286418 7 76.63 0.35 0.022 0.22 0.51 
54 Pl 311728 8 74.38 0.35 0.004 0.32 0.38 
59 Pl 311733 7 25.50 0.35 0.034 0.16 0.60 
83 Pl458946 8 88.25 0.35 0.052 0.11 0.72 
91 Pl 458954 7 64.00 0.35 0.034 0.16 0.60 
97 PI469791 7 64.63 0.35 0.034 0.16 0.60 
129 Pl 649141 8 103.13 0.36 0.064 0.08 0.78 
8 Ames 19202 7 52.75 0.37 0.029 0.20 0.58 
18 Ames 25114 7 52.75 0.37 0.029 0.20 0.58 
19 Ames 25115 7 49.13 0.37 0.045 0.14 0.68 
33 Ames 26653 7 51.00 0.37 0.029 0.20 0.58 
117 Pl603024 7 70.63 0.37 0.029 0.20 0.58 
123 Pl 633163 8 87.63 0.37 0.029 0.20 0.58 
127 Pl 633168 8 82.38 0.37 0.029 0.20 0.58 
128 Pl 633169 7 49.13 0.37 0.029 0.20 0.58 
96 Pl469761 7 35.88 0.38 O.o35 0.18 0.62 
70 Pl 432393 8 68.88 0.39 0.041 0.17 0.67 
77 Pl26637 8 88.25 0.39 0.052 0.13 0.73 
41 PI 250135 8 98.00 0.40 0.060 0.12 0.78 
72 ?1432395 7 51.63 0.40 0.060 0.12 0.78 
17 Ames 25113 7 55.13 0.41 0.049 0.15 0.72 
24 Ames 25120 7 58.00 0.41 0.049 0.15 0.72 
45 ?1271452 7 83. 13 0.41 0.049 0.15 0.72 
88 Pl458951 8 97.13 0.41 0.049 0.15 0.72 
98 ?1469803 7 38.88 0.41 0.049 0.15 0.72 
125 ?1633165 7 70.50 0.41 0.049 0.15 0.72 
130 Pl649145 7 50.63 0.41 0.049 0.15 0.72 
4 Ames 19197 7 55.00 0.42 0.040 0.19 0.68 
25 Ames 26165 7 56.63 0.42 0.021 0.29 0.56 
26 Ames 26166 7 56.63 0.42 0.021 0.29 0.56 
42 Pl26635 7 56.38 0.42 0.021 0.29 0.56 
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A.4. Continued 
Confidence Interval 
Treatment effect (95%) 
Median Treatment 
Accession Disease Mean relative Standard Lower Upper 
number Name Rating Rank effect error Limit Limit 
104 Pl490024 7 64.38 0.42 0.040 0.19 0.68 
Ill Pl469920 8 100.13 0.42 0.021 0.29 0.56 
113 Pl 537020 8 87.13 0.42 0.021 0.29 0.56 
116 Pl26628 7 60.25 0.42 0.021 0.29 0.56 
76 Pl 443015 7 55.13 0.43 0.044 0.18 0.71 
126 Pl633167 8 106.88 0.43 0.044 0.18 0.71 
53 Pl 311727 8 87.63 0.44 O.o35 0.24 0.67 
93 Pl 469730 7 44.63 0.46 0.068 0.12 0.84 
56 Pl 311730 7 48.50 0.48 0.037 0.26 0.71 
58 Pl 311732 7 62.50 0.48 0.051 0.19 0.78 
64 Pl 431571 8 75.75 0.48 0.037 0.26 0.71 
78 Pl 458924 6 35.88 0.48 0.037 0.26 0.71 
87 Pl458940 7 50.50 0.48 0.037 0.26 0.71 
110 Pl 537015 7 20.00 0.48 0.037 0.26 0.71 
120 Pl 633160 7 73.13 0.48 0.064 0.14 0.84 
99 Pl 469814 7 25.50 0.49 0.024 0.34 0.65 
112 Pl 537019 7 83.50 0.49 0.024 0.34 0.65 
28 Ames 26168 7 69.13 0.50 0.046 0.23 0.77 
75 Pl436557 7 35.88 0.50 0.1)36 0.28 0.72 
81 Pl469882 7 48.88 0.50 0.046 0.23 0.77 
115 Pl603020 7 67.63 0.51 0.036 0.29 0.73 
40 Pl 221971 7 41.00 0.52 0.030 0.32 0.70 
74 Pl436556 7 56.63 0.52 0.036 0.30 0.74 
68 Pl432391 8 91.75 0.53 0.058 0.19 0.84 
103 PI469863 7 58.88 0.53 0.058 0.19 0.84 
7 Ames 19201 7 75.75 0.55 0.036 0.32 0.76 
30 Ames 26171 7 75.75 0.55 0.036 0.32 0.76 
31 Ames 26626 7 75.75 0.55 0.036 0.32 0.76 
35 Pl 399418 8 80.13 0.55 0.053 0.23 0.84 
39 Pl 169080 8 78.88 0.55 0.036 0.32 0.76 
47 Pl 284859 7 31.88 0.55 0.036 0.32 0.76 
52 Pl 305282 8 108.38 0.55 0.036 0.32 0.76 
60 PI365644 7 65.75 0.55 0.036 0.32 0.76 
62 PI384536 7 75.38 0.55 0.036 0.32 0.76 
65 Pl 431572 7 82.13 0.55 0.036 0.32 0.76 
71 PI432394 8 81.75 0.55 0.036 0.32 0.76 
10 Ames 19205 7 74.75 0.56 0.021 0.42 0.69 
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A.4. Continued 
Confidence Interval 
Treatment effect (95%) 
Median Treatment 
Accession Disease Mean relative Standard Lower Upper 
number Name Ratin& Rank effect error Limit Limit 
109 Pl 537014 7 53.63 0.56 0.021 0.42 0.69 
38 Pl 169075 7 85.25 0.58 0.044 0.29 0.82 
69 Pl432392 8 112.13 0.60 0.055 0.25 0.87 
90 Pl 469930 7 78.00 0.60 0.055 0.25 0.87 
122 Pl633162 7 51.38 0.60 0.055 0.25 0.87 
3 Ames 18935 7 87.63 0.61 0.043 0.32 0.83 
22 Ames 25118 8 87.63 0.61 0.043 0.32 0.83 
44 Pl269449 7 48.50 0.61 0.043 0.32 0.83 
51 Pl 305281 8 90.63 0.61 0.043 0.32 0.83 
86 Pl458949 7 25.50 0.61 0.043 0.32 0.83 
118 Pl 603026 7 56.63 0.61 0.043 0.32 0.83 
Ames 19204 8 83.50 0.62 0.030 0.41 0.79 
6 Ames 19199 7 81.00 0.62 0.030 0.41 0.79 
36 Pl 458941 7 82.13 0.62 0.030 0.41 0.79 
63 Pl409022 8 93.38 0.62 0.030 0.41 0.79 
79 Pf 458935 8 98.00 0.62 0.049 0.29 0.87 
107 Pf 537012 8 107.38 0.62 0.030 0.41 0.79 
108 Pl 537013 8 72.00 0.62 0.030 0.41 0.79 
9 Ames 19203 8 89.38 0.65 0038 0.38 0.85 
100 Pf 469832 7 53.50 0.66 0.054 0.28 0.90 
5 Ames 19198 7 88.38 0.68 O.Q35 0.42 0.86 
13 Ames 25109 8 95.38 0.68 0.035 0.42 0.86 
49 Pl 305278 7 57.50 0.68 0.035 0.42 0.86 
61 Pl 383422 7 46.63 0.68 0.035 0.42 0.86 
66 Pl431574 7 62.50 0.68 0.035 0.42 0.86 
2 Ames! 73847 8 93.88 0.69 0.017 0.57 0.79 
37 Pl 458944 8 93.88 0.69 0.017 0.57 0.79 
55 Pl 311729 7 63.13 0.69 0.017 0.57 0.79 
80 Pl458939 7 61.00 0.69 0.017 0.57 0.79 
IOI PI469836 7 56.38 0.69 0.017 0.57 0.79 
32 Ames26627 8 99.88 0.71 0.056 0.29 0.94 
84 PI458947 8 94.75 0.73 0.037 0.44 0.90 
124 Pl 26641 8 100.13 0.73 0.037 0.44 0.90 
21 Ames25117 8 102.63 0.74 0.019 0.60 0.85 
106 Pl 53701 I 8 93.88 0.74 0.019 0.60 0.85 
119 PI603027 7 31.38 0.74 0.019 0.60 0.85 
15 Ames 25111 8 104.25 0.78 0.026 0.56 0.90 
100 
A.4. Continued 
Median 
Accession Disease Mean 
number Name Rating Rank 
102 Pl469857 7 46.88 
121 PI 633161 7 58.88 
16 Ames 25112 8 109.75 
50 Pl305279 7 35. 13 
67 PI 432373 7 75.38 
23 Ames 25119 8 117.13 
131 Dk 3042 8 117.13 
Treatment effect 
Treatment 
relative Standard 
effect error 
0.78 0.026 
0.78 0.026 
0.80 0.017 
0.80 0.017 
0.83 0.021 
0.86 0.003 
0.87 0.003 
Confidence Interval 
(9S%) 
Lower Upper 
Limit Limit 
0.56 0.90 
0.56 0.90 
0.67 0.89 
0.67 0.89 
0.64 0.93 
0.84 0.88 
0.82 0.88 
11 Ames21489 9 135.38 0.99 ( 0.001 0.98 1.00 
Standard errors (se) are given in brackets after the estimates, which were determined based on 
output of the SAS macro. In general, if the SAS macro is not available, se can be roughly 
approximated by se / N, in which se is the standard error of the mean rank for the ithaccession 
(treatment) as determined in the MIXED procedure of SAS with the LSMEANS option (SAS 
Institute, Cary, NC). 
101 
A.5. Median, mean rank and estimated relative treatment effects for the severity of foliar 
symptoms on 356 Brassica juncea accessions based on their reaction I to inoculation 
with three L. maculans isolates of PG 3. 
Confidence Interval 
Treatment effect !95%} 
Median Treatment 
Accession Disease Mean relative Standard Lower Upper 
number Name Rating Rank effect error Limit Limit 
133 Pl 390135 6 72.25 0.22 0.059 0.03 0.76 
137 Pl390139 6 157.50 0.22 0.059 0.03 0.76 
186 Pl426335 6 131.88 0.22 0.033 0.07 0.52 
187 Pl426336 5 43.00 0.22 0.058 0.03 0.74 
79 Pl250130 6 41.63 0.24 0.031 0.09 0.51 
162 Pl 426311 6 43.00 0.24 0.031 0,09 0.51 
340 Pl633077 6 128.75 0.24 0.032 0.08 0.51 
400 Pl649125 6 189.75 0.24 0.032 0.08 0.51 
56 Pl 181034 6 151.25 0.25 O.o28 0.11 0.49 
130 Pl370746 6 72.25 0.25 0.049 0.05 0.67 
132 PI387819 6 72.25 0.25 0.049 0.05 0.67 
138 PI390140 5 194.50 0.25 0.028 0.1 I 0.49 
144 P1426292 6 72.25 0.25 0.049 0.05 0.67 
188 Pl426337 6 72.25 0.25 0.049 0.05 0.67 
204 Pl 426353 6 128.50 0.25 0.028 0.11 0.49 
210 Pl426359 6 132.00 0.25 0.028 0.11 0.49 
218 Pl426367 6 128.25 0.25 0.049 0.05 0.67 
252 P1426403 6 25.38 0.25 0.028 0.11 0.49 
304 Pl470082 6 83.38 0.25 0.028 0.11 0.49 
313 Pl478332 6 274.00 0.25 0.049 0.05 0.67 
316 PI478335 6 197.88 0.25 0.028 0.11 0.49 
330 PI537008 6 154.25 0.25 0.028 0.11 0.49 
352 PI633093 6 113.00 0.25 0.049 0.05 0.67 
357 Pl 633098 6 148.75 0.25 0.028 0.11 0.49 
387 Pl649112 6 197.88 0.25 0.028 0.11 0.49 
394 Pl649119 6 218.50 0.25 0.028 0.11 0.49 
154 Pl426302 6 59.75 0.26 0.030 0.10 0.50 
347 Pl633088 6 113.00 026 0.029 0.11 0.50 
181 P1426330 6 124.88 028 0.025 0.14 0.48 
334 PI 603011 5 100.25 0.28 0.025 0.14 0.48 
356 Pl633097 6 238.50 0.28 0.025 0. 14 0.48 
364 Pl633 I05 6 100.25 0.28 0.025 0.14 0.48 
396 PI649121 6 163.75 0.28 0.025 0.14 0.48 
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A.5. Continued 
Confidence Interval 
Treatment effect {95%) 
Median Treatment 
Accession Disease Mean relative Standard Lower Upper 
number Name Rating Rank effect error Limit Limit 
117 PI340219 6 194.50 0.30 0.022 0.17 0.46 
177 Pl426326 6 72.25 0.30 0.037 0.11 0.59 
327 Pl537005 6 83.63 0.30 0.022 0.17 0.46 
322 Pl 531268 6 208.50 0.31 0.045 0.09 0.66 
209 Pl426358 6 174.50 0.32 0.042 0.11 0.65 
248 Pl426399 6 111.63 0.32 0.042 0.11 0.65 
286 Pl458993 6 182.75 0.32 0.042 0.11 0.65 
342 Pl633083 6 119.25 0.32 0.030 0.16 0.55 
359 PI633 IOO 6 61.63 0.32 0.042 0.11 0.65 
5 Pl2 l 754 6 126.00 0.33 0.029 0.16 0.55 
373 PI 633114 6 151.88 0.33 0.043 0.11 0.65 
55 Pll81033 7 132.00 0.34 0.025 0.20 0.53 
160 Pl426308 6 186.75 0.34 O.o25 0.20 0.53 
207 PI426356 6 111.63 0.34 0.040 0.13 0.64 
263 PI432381 6 174.50 0.34 0.025 0.20 0.53 
312 Pl47833 I 6 197.88 0.34 0.025 0.20 0.53 
324 PI531270 6 197.88 0.34 O.o25 0.20 0.53 
326 Pl537004 6 174.50 0.34 0.025 0.20 0.53 
328 PI537006 6 182.75 0.34 0.025 0.20 0.53 
333 PI549282 6 76.63 0.34 0.015 0.20 0.53 
337 PI603014 5 50.88 0.34 0.025 0.20 0.53 
348 Pl633089 6 240.50 0.34 0.025 0.20 0.53 
372 PI633 l 13 6 193.88 0.34 O.o25 0.20 0.53 
385 PI6491 IO 6 126.00 0.34 0.025 0.20 0.53 
391 Pl 649116 6 123.63 0.34 0.025 0.20 0.53 
397 Pl649122 6 155.25 0.34 0.025 0.20 0.53 
32 Pll79644 6 258.25 0.36 0.019 0.24 0.50 
I 16 Pl340218 6 172.25 0.36 0.019 0.24 0.50 
131 Pl 379103 6 224.00 0.36 0.019 0.24 0.50 
201 Pl426350 6 213.00 0.36 0.019 0.24 0.50 
216 PI426365 6 271.00 0.36 0.051 0.11 0.72 
268 PI432386 6 238.50 0.36 0.051 0.11 0.72 
272 PI432390 6 216.75 0.36 0.019 0.24 0.50 
282 PI458942 6 124.38 0.36 0.051 0.1 I 0.72 
318 PI478337 6 123.50 0.36 0.036 0.16 0.63 
339 PI 603016 6 178.63 0.36 0.019 0.24 0.50 
362 PI633103 6 281.25 0.36 0.019 0.24 0.50 
211 Pl426360 6 98.25 0.38 0.049 0. 13 0.72 
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A.5. Continued 
Confidence Interval 
Treatment effect (95%} 
Median Treatment 
Accession Disease Mean relative Standard Lower Upper 
number Name Ratin& Rank effect error Limit Limit 
277 PI449439 6 172.25 0.38 0.049 0.13 0.72 
283 P1458943 6 80.88 0.38 0.049 0.13 0.72 
25 P1179183 7 192.25 0.39 0.050 0.13 0.74 
196 P1426345 6 244.38 0.39 0.060 0.10 0.79 
254 P1426405 6 181.38 0.39 0.050 0.13 0.74 
344 Pt633085 6 161.25 0.39 0.060 0.10 0.79 
329 PI537007 6 215.00 0.40 0.045 0.15 0.71 
156 PI426304 6 152.25 0.41 0.036 0.20 0.66 
198 PI426347 6 198.25 0.41 0.036 0.20 0.66 
247 P1426398 6 238.25 0.41 0.036 0.20 0.66 
262 Pl432380 6 257.13 0.41 0.036 0.20 0.66 
294 Pl459001 6 146.25 0.41 0.036 0.20 0.66 
311 Pl478330 6 104.63 0.41 0.036 0.20 0.66 
378 Pl649103 7 174.50 0.41 0.036 0.20 0.66 
45 Pll 80264 6 245.00 0.43 0.002 0.41 0.44 
67 Pll 92936 6 85.88 0.43 0.002 0.41 0.44 
104 PI340205 5 141.63 0.43 0.002 0.41 0.44 
106 PI340207 6 257.50 0.43 0.002 0.41 0.44 
108 Pl340210 6 193.50 0.43 0.002 0.41 0.44 
111 Pl 340213 6 218.50 0.43 0.002 0.41 0.44 
113 PI340215 6 202.38 0.43 0.002 0.41 0.44 
119 PI34022I 5 245.00 0.43 0.002 0.41 0.44 
127 PI358591 5 265.75 0.43 0.002 0.41 0.44 
128 PI370744 6 265.75 0.43 0.002 0.41 0.44 
129 Pl370745 6 154.25 0.43 0.002 0.41 0.44 
136 Pl390138 6 194.50 0.43 0.002 0.41 0.44 
145 P1426293 6 240.50 0.43 0.002 0.41 044 
152 Pl426300 6 198.00 0.43 0.002 0.41 0.44 
182 Pl426331 6 139.00 0.43 0.031 0.24 0.64 
190 PI426339 6 152.25 0.43 0.002 0.41 0.44 
195 PI426344 6 154.25 0.43 0.002 0.41 0.44 
203 P1426352 6 303.00 0.43 0.002 0.41 0.44 
214 ?1426363 6 112.75 0.43 0.002 0.41 0.44 
256 PI426407 6 45.88 0.43 0.002 0.41 0.44 
257 PI426408 6 45.88 0.43 0.002 0.41 0.44 
260 PI432378 6 194.50 0.43 0.002 0.4[ 0.44 
267 PI432385 6 244.75 0.43 0.002 0.41 0.44 
278 PI458927 6 276.25 0.43 0.002 0.41 0.44 
104 
A.5. Continued 
Confidence Interval 
Treatment effect (95%! 
Median Treatment 
Accession Disease Mean relative Standard Lower Upper 
number Name Rating Rank effect error Limit Limit 
279 PI458928 6 194.50 0.43 0.002 0.41 0.44 
284 Pl458978 6 103.63 0.43 0.002 0.41 044 
290 Pl458997 6 124.00 0.43 0.002 0.41 0.44 
292 PI458999 6 152.25 0.43 0.002 0.41 0.44 
301 Pl459008 6 45.88 0.43 0.002 0.41 0.44 
341 Pl633078 6 151.88 0.43 0.002 0.41 0.44 
345 PJ633086 6 116.88 0.43 0.031 0.24 0.64 
358 PI633099 6 157.50 0.43 0.002 0.41 0.44 
375 PI633116 7 257.13 0.43 0.031 0.24 0.64 
402 Pl 163497 6 214.25 0.43 0.002 0.41 0.44 
85 Pl250!40 7 194.25 0.45 0.044 0.19 0.74 
86 PI251239 6 151.88 0.45 0.044 0.19 0.74 
97 PI288725 7 228.38 0.45 0.044 0.19 0.74 
115 PI340217 6 187.25 0.45 0.044 0.19 0.74 
146 Pl426294 6 147.63 0.45 0.054 0.15 0.79 
171 Pl426320 6 182.38 0.45 0.044 0.19 0.74 
172 Pl426321 6 142.13 0.45 0.054 0.15 0.79 
174 PJ426323 6 146.25 0.45 0.044 0.19 0.74 
215 Pl426364 6 106.13 0.45 0.044 0.19 0.74 
223 PI426373 6 201.63 0.45 0.044 0.19 0.74 
274 PI449436 6 174.50 0.45 0.044 0.19 0.74 
314 Pl478333 6 131.88 0.45 0.044 0.19 0.74 
315 PI478334 6 157.63 0.45 0.044 0.19 0.74 
320 PI500675 6 127.25 0.45 0.044 0.19 0.74 
331 PI5370I8 6 154.25 0.45 0.054 0.15 0.79 
343 PI633084 6 148.50 0.45 0.044 0.19 0.74 
365 Pl633106 5 158.88 0.45 0.044 0.19 0.74 
377 PI649102 6 107.63 0.45 0.044 0.19 0.74 
383 Pl649108 7 232.25 0.45 0.044 0.19 0.74 
65 Pll 831 I 7 7 202.38 0.46 0.062 0.13 0.83 
285 PI458992 6 98.25 0.46 0.062 0.13 0.83 
323 PI531269 6 111.63 0.46 0.062 0.13 0.83 
8 Pll 63494 7 157.63 0.47 0.040 0.22 0.73 
10 PI169077 7 215.88 0.47 0.040 0.22 0.73 
17 Pll 73874 6 174.00 0.47 0.050 0.18 0.78 
41 Pl 179857 7 232.25 0.47 0.040 0.22 0.73 
44 PI! 79862 6 241.38 0.47 0.040 0.22 0.73 
84 PI250139 6 229.13 0.47 0.040 0.22 0.73 
105 
A.5. Continued 
Confidence Interval 
Treatment effect ~95%! 
Median Treatment 
Accession Disease Mean relative Standard Lower Upper 
number Name Rating Rank effect error Limit Limit 
105 PI340206 6 197.88 0.47 0.040 0.22 0.73 
149 Pl426297 6 157.63 0.47 0.040 0.22 0.73 
158 PI426306 6 152.25 0.47 0.040 0.22 0.73 
179 Pl426328 6 132.00 0.47 0.040 0.22 0.73 
180 PI426329 6 127.75 0.47 0.040 0.22 0.73 
222 PI426372 6 142.13 0.47 0.040 0.22 0.73 
226 PI426376 6 263.38 0.47 0.040 0.22 0.73 
270 Pl432388 6 190.25 0.47 0.040 0.22 0.73 
271 Pl432389 6 220.75 0.47 0.040 0.22 0.73 
309 Pl478328 6 194.50 0.47 0.040 0.22 0.73 
346 PI633087 6 144.50 0.47 0.040 0.22 0.73 
19 Pil75068 6 232.25 0.48 0.059 0.15 0.83 
398 Pl 649123 5 222.13 0.48 0.071 0.1 I 0.87 
403 PI 175608 5 302.50 0.48 0.041 0.22 0.74 
6 Plll3310 7 210.88 0.50 0.019 0.37 0.63 
61 Pl 181043 7 145.00 0.50 0.036 0.27 0.73 
72 Pl211000 7 144.00 0.50 0.019 0.37 0.63 
76 Pl 215636 7 126.50 0.50 0.019 0.37 0.63 
107 Pl340209 6 174.50 0.50 0.019 0.37 0.63 
110 Pl340212 6 212.50 0.50 0.019 0.37 0.63 
114 Pl340216 6 190.50 0.50 0.019 0.37 0.63 
135 Pl 390137 5 257.13 0.50 0.019 0.37 0.63 
163 PI426312 6 166.00 0.50 0.019 0.37 0.63 
170 PI426319 6 225.00 0.50 0.019 0.37 0.63 
236 PI426386 6 172.25 0.50 0.019 0.37 0.63 
237 P!426387 6 118.50 0.50 0.056 0.18 0.83 
265 P!432383 6 251.00 0.50 0.019 0.37 0.63 
288 PI458995 6 163.75 0.50 0.019 0.37 0.63 
317 PI478336 6 168.38 0.50 0.068 0.13 0.87 
349 PI633090 7 221.38 0.50 0.019 0.37 0.63 
351 Pl633092 6 194.50 0.50 0.019 0.37 0.63 
386 Pl6491 I 1 6 202.50 0.50 0.019 0.37 0.63 
389 Pl 649114 5 238.00 0.50 0.096 om 0.94 
37 Pll 79654 6 178.00 0.51 0.048 0.22 0.80 
219 Pl426369 6 162.25 0.51 0.048 0.22 0.80 
266 PJ432384 6 355.63 0.51 0.048 0.22 0.80 
306 Pl478325 6 227.00 0.51 0.048 0.22 0.80 
382 Pl649107 6 147.63 0.51 0.048 0.22 0.80 
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A.5. Continued 
Confidence Interval 
Treatment effect !95%i 
Median Treatment 
Accession Disease Mean relative Standard Lower Upper 
number Name Rating Rank effect error Limit Limit 
388 PI649113 6 169.88 0.51 0.048 0.22 0.80 
393 PI649118 6 224.75 0.51 0.048 0.22 0.80 
95 PI2864!7 7 304.25 0.52 0.065 0.15 0.87 
29 Pll 79636 7 162.38 0.53 0.029 0.33 0.72 
35 PII 79651 7 202.38 0.53 0.029 0.33 0.72 
42 PII 79858 7 151.88 0.53 0.029 0.33 0.72 
50 Pil 80420 7 258.25 0.53 0.029 0.33 0.72 
64 PI183115 7 152.25 0.53 0.043 0.26 0.79 
73 PI212082 6 274.88 0.53 0.029 0.33 0.72 
80 Pl 250131 6 244.38 0.53 0.029 0.33 0.72 
88 PI257240 7 307.38 0.53 0.029 0.33 0.72 
98 PI288727 6 242.75 0.53 0.029 0.33 0.72 
99 PT288730 6 200.13 0.53 0.029 0.33 0.72 
109 PI340211 6 242.75 0.53 0.029 0.33 0.72 
120 Pl340223 6 190.25 0.53 0.029 0.33 0.72 
121 PI346876 6 172.25 0.53 0.029 0.33 0.72 
123 Pl347616 6 265.75 0.53 0.029 0.33 0.72 
143 Pl426291 6 227.00 0.53 0.029 0.33 0.72 
161 PI426310 6 111.63 0.53 0.029 0.33 0.72 
168 Pl426317 6 255.25 0.53 0.029 0.33 0.72 
175 PI426324 6 154.25 0.53 0.029 0.33 0.72 
[83 PI426332 6 139.00 0.53 0.029 0.33 0.72 
184 PI426333 6 154.25 0.53 0.029 0.33 0.72 
185 PI426334 6 131.88 0.53 0.029 0.33 0.72 
202 PI426351 6 204.75 0.53 0.029 0.33 0.72 
221 Pl426371 6 244.25 0.53 0.029 0.33 0.72 
227 Pl426377 6 242.25 0.53 0.029 0.33 0.72 
230 PI426380 6 162.13 0.53 0.029 0.33 0.72 
238 Pl426388 6 131.88 0.53 0.043 0.26 0.79 
240 PI426390 6 182.13 0.53 0.029 0.33 0.72 
241 Pl426391 6 227.00 0.53 0.029 0.33 0.72 
242 Pl426393 6 194.50 0.53 0.029 0.33 0.72 
245 Pl426396 6 308.75 0.53 0.029 0.33 0.72 
264 PI432382 6 204.75 0.53 0.029 0.33 0.72 
273 Pl436559 6 !74.50 0.53 0.029 0.33 0.72 
280 PI458929 6 240.50 0.53 0.029 0.33 0.72 
291 PI458998 6 132.00 0.53 0.029 0.33 0.72 
293 Pl459000 6 111.63 0.53 0.043 0.26 0.79 
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A. 5. Continued 
Confidence Interval 
Treatment effect !95%) 
Median Treatment 
Accession Disease Mean relative Standard Lower Upper 
number Name Rating Rank effect error Limit Limit 
302 Pl459009 6 111.63 0.53 0.029 0.33 0.72 
310 PI478329 6 218.25 0.53 0.029 0.33 0.72 
319 Pl50065 I 6 111.63 0.53 0.043 0.26 0.79 
355 Pl633096 6 332.50 0.53 0.029 0.33 0.72 
363 P1633104 6 288.50 0.53 0.029 0.33 0.72 
368 P1633109 6 194.50 0.53 0.029 0.33 0.72 
371 Pl633112 6 257.13 0.53 0.029 0.33 0.72 
395 Pl649120 6 103.75 0.53 0.029 0.33 0.72 
404 P1207465 6 271.00 0.53 0.029 0.33 0.72 
89 Pl269432 7 306.50 0.55 0.052 0.22 0.84 
148 Pl426296 7 253.63 0.55 0.055 0.21 0.85 
151 PI 426299 6 151.88 0.55 0.052 0.22 0.84 
169 P1426318 6 132.00 0.55 0.052 0.22 0.84 
205 PI426354 6 172.38 0.55 0.052 0.22 0.84 
213 PI426362 6 157.63 0.55 0.052 0.22 0.84 
251 PJ426402 6 157.63 0.55 0.052 0.22 0.84 
234 Pl426384 6 222.50 0.56 0.113 0.05 0.97 
246 PI426397 6 212.50 0.56 0.022 0.41 0.71 
30 PII 79637 7 201.63 0.57 0.039 0.30 0.80 
49 Pll80417 7 306.50 0.57 0.047 0.26 0.84 
102 PI323270 6 182.00 0.57 0.047 0.26 0.84 
122 Pl347615 6 111.63 0.57 0.047 0.26 0.84 
141 P1426178 7 213.63 0.57 0.039 0.30 0.80 
275 Pl449437 6 280.25 0.57 0.047 0.26 0.84 
297 Pl459004 6 194.50 0.57 0.047 0.26 0.84 
153 P!426301 6 296.00 0.58 0.058 0.21 0.88 
369 Pl6331 IO 7 246.50 0.58 0.057 0.21 0.87 
38 Pll 79850 6 308.75 0.60 0.052 0.25 0.87 
51 Pl 180421 6 172.25 0.60 0.029 0.39 0.78 
60 Pil81042 6 216.25 0.60 0.029 0.39 0.78 
70 P1209021 7 212.50 0.60 0.029 0.39 0.78 
75 P!212970 7 194.50 0.60 0.029 0.39 0.78 
100 P!311726 6 151.25 0.60 0.029 0.39 0.78 
112 PI340214 6 214.25 0.60 0.029 0.39 0.78 
140 Pl418956 5 182.13 0.60 0.029 0.39 0.78 
157 PI426305 6 111.63 0.60 0.029 0.39 0.78 
166 Pl426315 6 162.25 0.60 0.029 0.39 0.78 
173 P1426322 6 154.25 0.60 0.029 0.39 0.78 
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A.5. Continued 
Confidence Interval 
Treatment effect {95%! 
Median Treatment 
Accession Disease Mean relative Standard Lower Upper 
number Name Rating Rank effect error Limit Limit 
199 Pl426348 6 257.13 0.60 0.029 0.39 0.78 
220 PI426370 6 244.25 0.60 0.029 0.39 0.78 
225 PI426375 6 142.13 0.60 0.029 0.39 0.78 
229 PI426379 6 132.00 0.60 0.029 0.39 0.78 
232 P1426382 6 224.63 0.60 0.029 0.39 0.78 
243 Pl426394 6 224.63 0.60 0.029 0.39 0.78 
269 P1432387 6 174.50 0.60 0.029 0.39 0.78 
287 Pl458994 7 182.00 0.60 0.029 0.39 0.78 
295 Pl459002 6 194.25 0.60 0.029 0.39 0.78 
325 Pl531271 7 244.38 0.60 0.029 0.39 0.78 
208 PI426357 6 271.00 0.62 0.052 0.26 0.88 
321 PI531267 6 244.38 0.62 0.052 0.26 0.88 
361 Pl633102 6 284.50 0.62 0.063 0.20 0.91 
235 Pl426385 6 227.00 0.63 0.036 0.37 0.83 
3 Amesl5649 6 142.13 0.64 0.034 0.39 0.83 
12 Pll69085 7 201.63 0.64 0.034 0.39 0.83 
14 Pll 73865 6 244.25 0.64 0.034 0.39 0.83 
16 PII 73873 7 240.50 0.64 0.034 0.39 0.83 
18 Pll74801 7 257.13 0.64 0.034 0.39 0.83 
20 Pll 75082 6 I 41.88 0.64 0.034 0.39 0.83 
23 PII 75607 6 184.63 0.64 0.034 0.39 0.83 
24 PII 76884 7 198.25 0.64 0.034 0.39 0.83 
28 Pll79635 7 276.75 0.64 0.034 0.39 0.83 
33 PI! 79647 7 335.00 0.64 0.034 0.39 0.83 
36 Pl 179653 7 287.63 0.64 0.034 0.39 0.83 
43 Pll 79859 6 258.25 0.64 0.034 0.39 0.83 
53 Pll81017 6 132.00 0.64 0.034 0.39 0.83 
54 Pll81026 7 220.50 0.64 0.034 0.39 0.83 
58 Pll8l040 6 258.25 0.64 0.034 0.39 0.83 
59 PII81041 7 232.75 0.64 0.034 0.39 0.83 
62 Pll 82921 6 228.75 0.64 0.034 0.39 0.83 
66 Pl 183437 6 I I 1.63 0.64 0.034 0.39 0.83 
68 Pll95553 6 290.38 0.64 0.034 0.39 0.83 
69 Pl208734 7 256.50 0.64 0.034 0.39 0.83 
81 Pl 250133 7 268.75 0.64 0.034 0.39 0.83 
82 Pl250134 7 293.00 0.64 0.034 0.39 0.83 
83 PI250I37 7 285.13 0.64 0.034 0.39 0.83 
90 Pl269448 6 195.88 0.64 0.034 0.39 0.83 
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A.5. Continued 
Confidence Interval 
Treatment effect {95%! 
Median Treatment 
Accession Disease Mean relative Standard Lower Upper 
number Name Rating Rank effect error Limit Limit 
91 PI 271442 7 320.88 0.64 0.034 0.39 0.83 
92 ?1271453 7 259.88 0.64 0.034 0.39 0.83 
93 Pl271455 6 284.25 0.64 0.034 0.39 0.83 
IOI Pl311734 6 177.00 0.64 0.034 0.39 0.83 
159 Pl426307 7 182.13 0.64 0.034 0.39 0.83 
165 PI426314 6 142. 13 0.64 0.034 0.39 0.83 
!67 Pl426316 6 264.00 0.64 0.034 0.39 0.83 
193 PI426342 7 257.13 0.64 0.058 0.24 0.91 
200 P1426349 7 310.13 0.64 0.034 0.39 0.83 
206 Pl426355 7 274.63 0.64 0.034 0.39 0.83 
224 Pl426374 7 206.25 0.64 0.034 0.39 0.83 
228 Pl426378 6 111.63 0.64 0.034 0.39 0.83 
231 PJ426381 6 228.38 0.64 0.034 0.39 0.83 
239 PI426389 6 196.38 0.64 0.034 0.39 0.83 
259 Pl432377 7 148.75 0.64 0.034 0.39 0.83 
261 Pl432379 7 172.25 0.64 0.034 0.39 0.83 
276 ?1449438 7 293.00 0.64 0.034 0.39 0.83 
296 Pl459003 6 111.63 0.64 0.034 0.39 0.83 
298 Pl459005 6 257.13 0.64 0.034 0.39 0.83 
299 ?1459006 6 174.50 0.64 0.0>4 0.39 0.83 
308 Pl478327 6 194.SO 0.64 0.034 0.39 0.83 
332 PI53702l 6 I 54.25 0.64 0.034 0.39 0.83 
350 Pl633091 6 227.00 0.64 0.034 0.39 0.83 
354 PI633095 6 324.88 0.64 0.034 0.39 0.83 
360 Pl633l0l 7 290.75 0.64 0.046 0.3 I 0.87 
381 PI649l06 6 172.25 0.64 0.034 0.39 0.83 
384 PI649l09 6 172.25 0.64 0.034 0.39 0.83 
Ames 9914 7 236.25 0.65 0.054 0.26 0.9! 
II Pl!69078 6 204.50 0.67 O.Q25 0.48 0.81 
15 Pll73872 6 272.00 0.67 0.o40 0.36 0.88 
3! Pl 179640 6 220.50 0.67 0.040 0.36 0.88 
39 Pll 79854 6 327.25 0.67 0.040 0.36 0.88 
52 Pll80422 6 262.25 0.67 0.040 0.36 0.88 
57 Pll8l035 6 196.25 0.67 0.040 0.36 0.88 
74 Pl2!2594 7 292.38 0.67 0.040 0.36 0.88 
94 PI280637 6 264.50 0.67 0.039 0.37 0.87 
!24 Pl347617 6 275.38 0.67 0.025 0.48 0.81 
164 Pl426313 7 221.88 0.67 0.040 0.36 0.88 
110 
A.5. Continued 
Confidence Interval 
Treatment effect !95%} 
Median Treatment 
Accession Disease Mean relative Standard Lower Upper 
number Name Rating Rank effect error Limit Limit 
22 Pll 75602 6 197.88 0.68 0.048 0.31 0.90 
379 Pl649104 5 215.00 0.68 0.048 0.31 0.90 
249 PI426400 7 317.88 0.70 0.028 0.49 0.86 
250 P1426401 7 240.50 0.70 0.028 0.49 0.86 
289 Pl458996 7 363.25 0.70 0.076 0.16 0.96 
300 PI459007 7 245.00 0.70 0.028 0.49 0.86 
303 Pl459010 7 194.50 0.70 O.o28 0.49 0.86 
305 PI470241 7 257.13 0.70 0.028 0.49 0.86 
353 PI633094 7 281.25 0.70 0.028 0.49 0.86 
376 Pl649101 6 194.50 0.70 0.044 0.35 0.91 
7 Pl120923 6 284.50 0.71 0.051 0.30 0.93 
71 Pl209781 6 321.00 0.71 0.052 0.30 0.93 
34 Pll 79649 6 312.13 0.73 0.033 0.46 0.90 
63 Pll83112 6 305.63 0.73 0.033 0.46 0.90 
4 Ames21749 8 278.88 0.74 0.029 0.50 0.89 
87 PI254361 6 275.00 0.74 0.029 0.50 0.89 
40 Pl l 79855 7 204.88 0.77 0.033 0.48 0.92 
258 Pl432367 7 242.75 0.77 0.012 0.68 0.85 
217 PI426366 7 355.63 0.78 0.034 0.47 0.93 
233 Pl426383 7 257.13 0.78 0.0]4 0.47 0.93 
47 Pll 80267 6 319.25 0.80 0.018 0.65 0.90 
96 Pl288724 6 233.13 0.80 0.036 0.46 0.95 
370 PI633111 6 329.38 0.80 0.018 0.65 0.90 
46 PI 180266 6 264.13 0.81 0.010 0.73 0.87 
77 Pl217516 6 257.13 0.81 0.037 0.44 0.96 
307 Pl478326 7 257. 13 0.81 0.010 0.73 0.87 
191 PI426340 7 307.50 0.82 0.038 0.43 0.96 
253 PI426404 7 347.13 0.83 0.022 0.63 0.93 
13 Pil73857 6 314.63 0.84 0.016 0.70 0.93 
26 Pl 179191 7 301.13 0.84 0.016 0.70 0.93 
27 Pll79192 6 301.13 0.84 0.015 0.70 0.92 
2 Amesl5645 6 293.13 0.85 0.002 0.83 0.86 
9 Pll 69076 6 304.25 0.85 0.002 0.83 0.86 
48 Pll 80269 7 257.13 0.88 0.008 0.80 0.92 
406 Pl649162 6 314.63 0.88 0.008 0.80 0.92 
244 Pl426395 8 347.13 0.91 0.011 0.80 0.97 
405 Pl 426281 5 325.75 0.91 0.01 l 0.80 0.97 
150 Pl426298 7 348.50 0.92 0.012 0.79 0.97 
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A.5. Continued 
Confidence Interval 
Treatment effect !95%) 
Median Treatment 
Accession Disease Mean relative Standard Lower Upper 
number Name Rating Rank effect error Limit Limit 
176 Pl426325 8 268.38 0.92 0.012 0.79 0.97 
178 PI426327 8 268.38 0.92 0.012 0.79 0.97 
407 Dk 3042 8 358.38 0.98 ( 0.001 0.98 0.99 
192 PI426341 7 385.75 0.99 ( 0.002 ) 0.96 1.00 
Standard errors (se) are given in brackets after the estimates, which were detennined based on 
output of the SAS macro. In general, if the SAS macro is not available, se can be roughly 
approximated by se / N, in which se is the standard error of the mean rank for the ithaccession 
(treatment) as determined in the MIXED procedure of SAS with the LSMEANS option (SAS 
Institute, Cary, NC). 
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A.6. Median, mean rank and estimated relative treatment effects for the severity of foliar 
symptoms on 356 Brassica juncea accessions based on their reaction to inoculation 
with one L. maculans isolate of PG 4. 
Confidence Interval 
Treatment effect !95%) 
Median Treatment 
Accession Disease Mean relative Standard Lower Upper 
number Name Rating Rank effect error Limit Limit 
67 PI! 92936 7 85.88 0.25 O.D25 0.1 I 0.46 
304 PI 470082 6 83.38 0.25 0.025 0.11 0.46 
364 PI633105 7 100.25 0.25 0.047 0.06 0.66 
392 PI649117 7 106.50 0.25 0.025 0.11 0.46 
218 PI426367 7 128.25 0.26 0.067 0.03 0.80 
327 Pl537005 7 83.63 0.26 0.039 0.08 0.59 
338 PI603015 7 108.25 0.27 0.045 O.D7 0.64 
181 Pl 426330 7 124.88 0.28 0.035 0.11 0.57 
211 PI426360 7 98.25 0.28 0.035 0.11 0.57 
215 Pl426364 6 106.13 0.28 0.022 0.15 0.46 
284 PI458978 7 103.63 0.28 0.022 0.15 0.46 
285 Pl 458992 6 98.25 0.28 0.035 0.11 0.57 
311 Pl478330 7 104.63 0.28 O.D35 0.11 0.57 
334 Pl60301 l 7 100.25 0.28 0.022 0.15 0.46 
347 Pl633088 7 113.00 0.28 0.035 0 11 0.57 
395 Pl649120 7 103.75 0.28 0.022 0.15 0.46 
66 Pl 183437 7 111.63 0.31 0.031 0.14 0.55 
76 Pl 215636 7 126.50 0.31 0.018 0.21 0.44 
122 Pl347615 7 111.63 0.31 0.031 0.14 0.55 
137 Pl390139 7 157.50 0.31 0.054 0.07 0.72 
157 Pl426305 7 111.63 0.31 0.031 0.14 0.55 
161 P4263 JO 7 111.63 0.31 0.031 0.14 0.55 
207 Pl426356 7 111.63 0.31 0.031 0.14 0.55 
228 Pl426378 7 111.63 0.31 0.031 0.14 0.55 
248 Pl426399 7 111.63 0.31 0.031 0.14 0.55 
290 Pl458997 7 124.00 0.31 0.018 0.21 0.44 
293 Pl459000 7 111.63 0.31 0.031 0.14 0.55 
296 Pl459003 7 111.63 0.31 0.031 0.14 0.55 
302 Pl 459009 6 111.63 0.31 0.031 0.14 0.55 
318 Pl478337 7 123.50 0.31 0.031 0.14 0.55 
319 Pl500651 7 111.63 0.31 0.031 0.14 0.55 
323 ?1531269 7 111.63 0.31 0.031 0.14 0.55 
340 PI633077 7 128.75 0.31 0.031 0.14 0.55 
342 ?1633083 7 119.25 0.31 0.031 0.14 0.55 
345 Pl633086 7 116.88 0.31 0.031 0.14 0.55 
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A.6. Continued 
Confidence Interval 
Treatment effect {95%~ 
Median Treatment 
Accession Disease Mean relative Standard Lower lipper 
number Name Rating Rank effect error Limit Limit 
358 PI 633099 6 157.50 0.31 0.054 0.07 0.72 
377 PI649102 6 107.63 0.31 0.033 0.14 0.57 
237 Pl426387 7 118.50 0.32 0.032 0.14 0.57 
336 Pl 603013 6 113.13 0.32 0.055 0.08 0.73 
5 P12 I 754 7 126.00 034 0.027 0.18 0.54 
53 Pil81017 7 132.00 0.34 0.027 0.18 0.54 
55 Pil81033 7 132.00 0.34 0.027 0.18 0.54 
78 PI249555 7 141.25 0.34 0.052 0.10 0.72 
169 Pl426318 7 132.00 0.34 0.027 0.18 0.54 
179 Pl426328 7 132.00 0.34 0.027 0.18 0.54 
180 PI426329 7 127.75 0.34 0.052 0.10 0.72 
185 PI426334 7 131.88 0.34 0.027 0.18 0.54 
186 Pl426335 7 131.88 0.34 0.027 0.18 0.54 
210 PI426359 7 132.00 0.34 0.027 0.18 0.54 
229 Pl426379 7 132.00 0.34 0.027 0.18 0.54 
238 ?1426388 7 131.88 0.34 0.027 0.18 0.54 
291 PI458998 7 132.00 0.34 0.027 0.18 0.54 
314 Pl478333 7 131.88 0.34 0.027 0.18 0.54 
335 Pl603012 7 136.63 0.34 0.052 0.10 0.72 
385 Pl6491 IO 7 126.00 0.34 0.027 0.18 0.54 
391 PI 649116 6 123.63 0.34 0.027 0.18 0.54 
204 PI426353 6 128.50 0.35 0.048 0.11 0.70 
282 Pl458942 6 124.38 035 0.060 0.08 0 77 
320 Pl 500675 6 127.25 0.35 0.048 0.11 0.70 
346 Pl633087 7 144.50 035 0.048 0.11 0.70 
374 PI633 I 15 8 127.00 0.35 0.060 0.08 0.77 
3 Amesl5649 7 142.13 0.37 0.044 0.14 0.68 
20 Pll 75082 7 141.88 037 0.044 0.14 0.68 
64 Pil83115 7 152.25 0.37 0.020 0.25 0.52 
72 PI211000 8 144.00 037 0.020 0.25 0.52 
108 Pl340210 7 193.50 0.37 0.035 0.18 0.63 
152 Pl426300 7 198.00 0.37 0.035 0.18 0.63 
156 PI 426304 7 152.25 037 0.020 0.25 0.52 
158 PI426306 7 152.25 0.37 0.020 0.25 0.52 
165 Pl426314 7 142.13 0.37 0.044 0.14 0.68 
172 PI426321 7 142.13 0.37 0.044 0.14 0.68 
174 Pl426323 7 146.25 0.37 0.020 0.25 0.52 
182 PI42633 I 7 139.00 0.37 0.044 0. 14 0.68 
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A.6. Continued 
Confidence Interval 
Treatment effect (95%} 
Median Treatment 
Accession Disease Mean relative Standard Lower Upper 
number Name Rating Rank effect error Limit Limit 
183 PI426332 7 139.00 0.37 0.044 0.14 0.68 
190 Pl426339 7 152.25 0.37 0.020 0.25 0.52 
222 Pl426372 7 142.13 0.37 0.044 0.14 0.68 
225 Pl426375 7 142.13 0.37 0.044 0.14 0.68 
259 Pl432377 7 148.75 0.37 0.020 0.25 0.52 
292 Pl458999 7 152.25 0.37 0.020 0.25 0.52 
294 Pl459001 7 146.25 0.37 0.020 0.25 0.52 
343 Pl633084 7 148.50 0.37 0.044 0.14 0.68 
357 P1633098 6 148.75 0.37 0.020 0.25 0.52 
61 PI 181043 7 145.00 038 0.045 0.14 0.70 
146 Pl 426294 7 147.63 0.38 0.044 0.14 0.69 
382 Pl649107 7 147.63 0.38 0.044 0.14 0.69 
8 Pl163494 7 157.63 0.40 0.052 0.13 0.75 
29 Pl179636 8 162.38 0.40 0.039 0.18 0.68 
42 Pll 79858 7 151.88 0.40 0.027 0.24 0.59 
56 PI 181034 7 151.25 0.40 0.052 0.13 0.75 
86 Pl251239 7 151.88 0.40 0.027 0.24 0.59 
100 Pl3 I 1726 7 151.25 0.40 0.052 0.13 0.75 
129 Pl370745 7 154.25 0.40 0.027 0.24 0.59 
149 PI426297 7 157.63 0.40 0.052 0.13 0.75 
151 Pl426299 7 151.88 0.40 0.027 0.24 0.59 
166 Pl 426315 7 162.25 0.40 0.039 0.18 0.68 
173 Pl426322 7 154.25 0.40 0.027 0.24 0.59 
175 Pl426324 7 154.25 0.40 0.027 0.24 0.59 
184 Pl426333 7 154.25 0.40 0.027 0.24 0.59 
195 Pl426344 7 154.25 0.40 0.027 0.24 0.59 
213 PI426362 7 157.63 0.40 0.052 0.13 0.75 
219 Pl426369 7 162.25 0.40 0.039 0.18 0.68 
230 Pl426380 7 162.13 0.40 0.039 0.18 0.68 
251 Pl426402 7 157.63 0.40 0.052 0.13 0.75 
288 Pl458995 7 163.75 0.40 0.027 0.24 0.59 
315 Pl478334 7 157.63 0.40 0.052 0.13 0.75 
330 PI537008 7 154.25 0.40 0.027 0.24 0.59 
331 PI537018 7 154.25 0.40 0.027 0.24 0.59 
332 PI537021 7 154.25 0.40 0.027 0.24 0.59 
341 PI633078 6 151.88 0.40 0.027 0.24 0.59 
344 Pl633085 7 161.25 0.40 0.052 0.13 0.75 
365 Pl 633106 6 158.88 0.40 0.052 0.13 0.75 
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A.6. Continued 
Confidence Interval 
Treatment effect !95%} 
Median Treatment 
Accession Disease Mean relative Standard Lower Upper 
number Name RatinG Rank effect error Limit Limit 
373 PI633114 7 151.88 0.40 0.027 0.24 0.59 
396 Pl64912l 7 163.75 0.40 0.027 0.24 0.59 
397 PI649122 7 155.25 0.40 0.039 0.18 0.68 
205 PI426354 7 172.38 0.43 0.052 0.15 0.77 
37 PI179654 7 178.00 0.44 0.048 0.17 0.75 
51 PI 180421 7 172.25 0.44 0.018 0.32 0.56 
IOI P13 I I 734 7 177.00 0.44 0.034 0.23 0.67 
107 P1340209 7 174.50 0.44 0.018 0.32 0.56 
116 P1340218 7 172.25 0.44 0.018 0.32 0 56 
121 PI346876 7 172.25 0.44 0.018 0.32 0.56 
163 P1426312 7 166.00 0.44 0.034 0.23 0.67 
209 PI426358 7 174.50 0.44 0.018 0.32 0.56 
236 Pl426386 7 172.25 0.44 0.018 0.32 0.56 
261 P1432379 7 172.25 0.44 0.018 0.32 0.56 
263 Pl432381 7 174.50 0.44 O.oI8 0.32 0.56 
269 P1432387 7 174.50 0.44 0.018 0.32 0.56 
273 Pl436559 7 174.50 0.44 0.018 0.32 0.56 
274 P[449436 7 174.50 0.44 0.018 0.32 0.56 
277 P[449439 7 I 72.25 0.44 O.oI8 0.32 0.56 
286 PI458993 7 182.75 0.44 0.0'.14 0.23 0.67 
299 Pl459006 7 174.50 0.44 0.018 0.32 0.56 
326 Pl 537004 6 174.50 0.44 0.018 0.32 0.56 
328 Pl537006 7 182.75 0.44 0.034 0.23 0.67 
378 P1649I03 7 174.50 0.44 0.018 0.32 0.56 
381 Pl649106 7 172.25 0.44 0.018 0.32 0.56 
384 Pl649109 7 172.25 0.44 0.018 0.32 0.56 
317 PI478336 6 168.38 0.45 0.072 0.10 0.86 
23 Pll 75607 7 184.63 0.46 0.053 0.16 0.79 
254 Pl426405 7 l 8 l.38 0.46 0.070 0.11 0.86 
17 Pll 73874 7 174.00 0.47 0.037 0.24 0.71 
24 Pll 76884 7 198.25 0.47 0.043 0.22 0.74 
57 PIJ81035 7 196.25 0.47 0.043 0.22 0.74 
140 Pl 418956 6 182.13 0.47 0.037 0.24 0.71 
159 Pl426307 7 182. 13 0.47 0.037 0.24 0.71 
171 Pl426320 7 182.38 0.47 0.037 0.24 0.71 
198 PI426347 7 198.25 0.47 0.043 0.22 0.74 
240 Pl426390 7 182.13 0.47 0.037 0.24 0.71 
339 P1603016 7 178.63 0.47 0.058 0.15 0.81 
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Confidence Interval 
Treatment effect {95%! 
Median Treatment 
Accession Disease Mean relative Standard Lower Upper 
number Name RatinG Rank effect error Limit Limit 
388 PI649113 7 169.88 0.47 0.037 0.24 0.71 
400 PI 649125 6 189.75 0.47 0.037 0.24 0.71 
367 Pl633108 7 187.88 0.49 0.063 0.15 0.85 
12 PI169085 8 201.63 0.50 0.063 0.15 0.85 
22 PJI 75602 7 197.88 0.50 0.044 0.23 0.77 
25 Pll 79183 7 192.25 0.50 0.041 0.24 0.76 
30 Pll79637 7 201.63 0.50 0.063 0.15 0.85 
75 Pl212970 8 194.50 0.50 0.002 0.48 0.51 
85 Pl250140 7 194.25 0.50 0.029 0.31 0.69 
90 Pl269448 7 195.88 0.50 0.044 0.23 0.77 
102 Pl323270 7 182.00 0.50 0.044 0.23 0.77 
104 Pl340205 6 141.63 0.50 0.039 0.18 0.68 
105 Pl340206 7 197.88 0.50 0.044 0.23 0.77 
115 Pl340217 7 187.25 0.50 0.049 0.20 0.80 
117 Pl340219 7 194.50 0.50 0.002 0.48 0.51 
120 PJ340223 7 190.25 0.50 0.029 0.31 0.69 
136 P1390138 7 194.50 0.50 0.002 0.48 0.51 
138 PJ390140 7 194.50 0.50 0.002 0.48 0.51 
160 Pl426308 7 186.75 0.50 0.044 0.23 0.77 
201 PI426350 7 213.00 0.50 0.041 0.24 0.76 
202 P!426351 7 204.75 0.50 0.029 0.31 0.69 
223 Pl426373 7 201.63 0.50 0.063 0.15 0.85 
224 PI426374 7 206.25 0.50 0.053 0.19 0.81 
234 Pl426384 7 222.50 0.50 0.109 0.05 0.95 
242 Pl426393 7 194.50 0.50 0.002 0.48 0.5[ 
260 P!432378 7 194.50 0.50 0.002 0.48 0.51 
264 Pl432382 7 204.75 0.50 0.029 OJI 0.69 
270 Pl432388 7 190.25 0.50 0.029 0.31 0.69 
279 PI458928 7 194.50 0.50 0.002 0.48 0.51 
287 Pl458994 7 182.00 0.50 0.044 0.23 0.77 
295 Pl459002 7 194.25 0.50 0.029 OJI 0.69 
297 ?1459004 7 194.50 0.50 0.002 0.48 0.51 
303 Pl459010 7 194.50 0.50 0.002 0.48 0.51 
308 Pl478327 7 194.50 0.50 0.002 0.48 0.51 
309 Pl478328 7 194.50 0.50 0.002 0.48 0.51 
312 Pl47833 I 7 197.88 0.50 0.044 0.23 0.77 
316 PI478335 7 197.88 0.50 0.044 0.23 0.77 
324 Pl531270 7 197.88 0.50 0.044 0.23 0.77 
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A.6. Continued 
Confidence Interval 
Treatment effect !95%! 
Median Treatment 
Accession Disease Mean relative Standard Lower Upper 
number Name Rating Rank effect error Limit Limit 
351 PJ633092 6 194.50 0.50 0.002 0.48 0.51 
368 PI633109 7 194.50 0.50 0.002 0.48 0.51 
376 PI649101 7 194.50 0.50 0.002 0.48 0.51 
386 Pl6491 ll 7 202.50 0.50 0.029 OJI 0.69 
387 Pl649112 7 197.88 0.50 0.044 0.23 0.77 
389 PI649!14 6 238.00 0.50 0.002 0.48 0.51 
322 Pl531268 7 208.50 0.51 0.063 0.16 0.86 
114 Pl340216 7 190.50 0.52 0.050 0.22 0.81 
372 PI633113 7 193.88 0.52 0.057 0.18 0.84 
11 Pll69078 7 204.50 0.53 0.042 0.26 0.78 
31 Pl 179640 7 220.50 0.53 0.037 0.29 0.76 
35 Pll 79651 8 202.38 0.53 0.037 0.29 0.76 
54 Pl!81026 8 22050 0.53 0.037 0.29 0.76 
60 Pll8!042 7 216.25 0.53 0.037 0.29 0.76 
99 PI288730 7 200.13 0.53 0.042 0.26 0.78 
111 Pl340213 7 218.50 0.53 0.037 0.29 0.76 
113 Pl340215 7 202.38 0.53 0.037 0.29 0.76 
239 Pl426389 7 196.38 0.53 0.037 0.29 0.76 
310 Pl478329 7 218.25 0.53 0.037 0.29 0.76 
329 Pl537007 7 215.00 0.53 0.042 0.26 0.78 
379 PI649104 7 215.00 0.53 0.042 0.26 0.78 
394 Pl649119 7 218.50 0.53 0.037 0.29 0.76 
62 Pll 82921 7 228.75 0.54 0.047 0.24 0.81 
65 Pll83117 8 202.38 0.54 0.054 0.21 0.84 
164 PI426313 7 221.88 0.54 0.058 0.19 0.85 
6 Pll 13310 8 210.88 0.56 0.043 0.27 0.81 
10 Pll69077 8 215.88 0.56 0.048 0.25 0.83 
40 Pll 79855 8 204.88 0.56 0.043 0.27 0.81 
70 Pl209021 8 212.50 0.56 0.018 0.44 0.68 
96 Pl288724 8 233.13 0.56 0.062 0.18 0.88 
97 Pl288725 7 228.38 0.56 0.048 0.25 0.83 
110 Pl340212 7 212.50 0 56 0.018 0.44 0.68 
112 Pl340214 7 214.25 0.56 0.018 0.44 0.68 
141 Pl426178 7 213.63 0.56 0.044 0.27 0.81 
170 Pl426319 7 225.00 0.56 0.018 0.44 0.68 
231 Pl426381 7 228.38 0.56 0.048 0.25 0.83 
246 Pl426397 7 212.50 0.56 0.018 0.44 0.68 
271 PI432389 7 220.75 0.56 0.034 0.33 0.77 
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Confidence Interval 
Treatment effect ~9S%! 
Median Treatment 
Accession Disease Mean relative Standard Lower Upper 
number Name Rating Rank effect error Limit Limit 
349 Pl633090 7 221.38 0.56 0.043 0.27 0.81 
393 PI649118 7 224.75 0.56 0.018 0.44 0.68 
402 Pll63497 7 214.25 0.56 0.018 0.44 0.68 
197 P1426346 7 242.25 0.57 0.052 0.23 0.85 
227 ?1426377 7 242.25 0.57 0.052 0.23 0.85 
131 ?1379103 6 224.00 0.59 0.052 0.24 0.86 
Ames 9914 8 236.25 0.60 0.040 0.32 0.82 
14 Pll 73865 7 244.25 0.60 0.052 0.25 0.87 
16 PII 73873 8 240.50 0.60 0.028 0.40 0.77 
59 Pil8 l041 7 232.75 0.60 0.052 0.25 0.87 
143 ?1426291 7 227.00 0.60 0.028 0.40 0.77 
145 ?1426293 7 240.50 0.60 0.028 0.40 0.77 
220 ?1426370 7 244.25 0.60 0.052 0.25 0.87 
221 ?1426371 7 244.25 0.60 0.052 0.25 0.87 
232 PI426382 7 224.63 0.60 0,028 0.40 0.77 
235 ?1426385 7 227.00 0.60 0.028 0.40 0.77 
241 PI426391 7 227.00 0.60 0.028 0.40 0.77 
243 Pl426394 7 224.63 0.60 0.028 0.40 0.77 
247 PI426398 7 238.25 0.60 0.040 0.32 0.82 
250 PI426401 7 240.50 0.60 O.o28 0.40 0.77 
265 PI432383 7 251.00 0.60 0.040 0.32 0.82 
268 PI432386 7 238.50 0.60 0.028 0.40 0.77 
272 Pl432390 7 216.75 0.60 0.040 0.32 0.82 
280 Pl458929 7 240.50 0.60 0.028 0.40 0.77 
306 ?1478325 7 227.00 0.60 0.028 0.40 0.77 
348 PI633089 7 240.50 0.60 0.028 0.40 0.77 
350 PI633091 7 227.00 0.60 0.028 0.40 0.77 
356 PI633097 7 238.50 0.60 0.028 0.40 0.77 
369 ?1633110 8 246.50 0.60 0.040 0.32 0.82 
398 ?1649123 7 222.13 0.60 0.052 0.25 0.87 
19 PI! 75068 7 232.25 0.62 0.021 0.47 0.75 
41 PI l 79857 8 232.25 0.62 0.021 0.47 0.75 
44 Pll 79862 7 241.38 0.62 0.044 0.31 0.86 
84 Pl250139 8 229.13 0.62 0.056 0.24 0.89 
98 Pl288727 7 242.75 0.62 0.021 0.47 0.75 
109 PI34021 I 7 242.75 0.62 0.021 0.47 0.75 
168 Pl426317 7 255.25 0.62 0.021 0.47 0.75 
189 ?1426338 7 274.00 0.62 0.036 0.37 0.83 
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A.6. Continued 
Confidence Interval 
Treatment effect i95%l 
Median Treatment 
Accession Disease Mean relative Standard Lower Upper 
number Name Ratinlii Rank effect error Limit Limit 
255 ?1426406 7 274.00 0.62 0.036 037 0.83 
258 PI432367 7 242.75 0.62 0.021 0.47 0.75 
267 PI432385 7 244.75 0.62 0.021 0.47 0.75 
313 Pl478332 7 274.00 0.62 0.036 0.37 0.83 
383 Pl649108 7 232.25 0.62 0.021 0.47 0.75 
52 Pll 80422 7 262.25 0.63 0.044 0.31 0.86 
94 P1280637 8 264.50 0.63 0.044 0.31 0.86 
32 PII 79644 7 258.25 0.66 0.027 0.45 0.82 
43 PII 79859 7 258.25 0.66 0.027 0.45 0.82 
45 P1180264 8 245.00 0.66 0.027 0.45 0.82 
50 P1180420 8 258.25 0.66 0.027 0.45 0.82 
58 PI181040 7 258.25 0.66 0.027 0.45 0.82 
69 Pl208734 7 256.50 0.66 0.027 0.45 0.82 
80 PI 250131 6 244.38 0.66 0.027 0.45 0.82 
81 Pl 250133 7 268.75 0.66 0.027 0.45 0.82 
92 P1271453 8 259.88 0.66 0.052 0.28 0.91 
106 Pl340207 7 257.50 0.66 0.027 0.45 0.82 
119 PI 340221 6 245.00 0.66 0.027 0.45 0.82 
148 Pl426296 7 253.63 0.66 0.049 030 0.90 
167 Pl426316 7 264.00 0.66 0.0~2 0.28 0.91 
196 PI426345 7 244.38 0.66 0.027 0.45 0.82 
208 Pl426357 7 271.00 0.66 0.027 0.45 0.82 
216 PI426365 7 271.00 0.66 0.027 0.45 0.82 
300 PI459007 8 245.00 0.66 0.027 0.45 0.82 
321 Pl531267 7 244.38 0.66 0.027 0.45 0.82 
325 Pl531271 7 244.38 0.66 0.027 0.45 0.82 
380 PI649105 7 240.13 0.66 0.049 0.30 0.90 
404 Pl207465 6 271.00 0.66 0.027 0.45 0.82 
226 Pl426376 8 263.38 0.68 0.033 0.43 0.86 
353 PJ633094 8 281.25 0.68 0.033 0.43 0.86 
362 Pl633 I03 7 281.25 0.68 0.033 0.43 0.86 
4 Ames21749 8 278.88 0.69 0.043 0.36 0.90 
7 Pll20923 7 284.50 0.69 0.032 0.44 0.86 
18 PII 74801 8 257.13 0.69 0.032 0.44 0.86 
48 PII 80269 8 257.13 0.69 0.032 0.44 0.86 
77 PI217516 7 257.13 0.69 0.032 0.44 0.86 
87 Pl254361 7 275.00 0.69 0.018 0.55 0 80 
93 ?1271455 8 284.25 0.69 0.043 036 0.90 
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A.6. Continued 
Confidence Interval 
Treatment effect (95%} 
Median Treatment 
Accession Disease Mean relative Standard Lower Upper 
number Name Rating Rank effect error Limit Limit 
135 Pl390137 5 257.13 0.69 0.032 0.44 0.86 
193 Pl426342 7 257.13 0.69 0.032 0.44 0.86 
199 Pl426348 7 257.13 0.69 0.032 0.44 0.86 
203 Pl426352 7 303.00 0.69 0.055 0.27 0.93 
233 P1426383 8 257.13 0.69 0.032 0.44 0.86 
262 Pl432380 7 257.13 0.69 0.032 0.44 0.86 
275 PI449437 7 280.25 0.69 0.043 0.36 0.90 
298 PI459005 7 257.13 0.69 0.032 0.44 0.86 
305 PI470241 8 257.13 0.69 0.032 0.44 0.86 
307 PI478326 8 257.13 0.69 0.032 0.44 0.86 
361 PI633102 7 284.50 0.69 0.032 044 0.86 
371 PI633112 7 257.13 0.69 0.032 0.44 0.86 
375 P1633I 16 7 257.13 0.69 0.032 0.44 0.86 
15 Pl173872 7 272.00 0.70 0.054 0.28 0.93 
28 Pll 79635 8 276.75 0.70 0.054 0.28 0.93 
2 Amesl5645 8 293.13 0.72 0.036 0.43 0.89 
46 Pl 180266 7 264.13 0.72 0.036 0.43 0.89 
73 P1212082 7 274.88 0.72 0.023 0.54 0.85 
83 P1250137 8 285.13 0.72 0.046 0.35 0.92 
123 PI347616 7 265.75 0.72 0.037 0.42 0.90 
127 Pl358591 5 265.75 0.72 0.037 0.42 0.90 
128 PI370744 7 265.75 0.72 0.037 0.42 0.90 
I 76 Pl426325 8 268.38 0.72 0.037 0.42 0.90 
178 Pl426327 8 268.38 0.72 0.037 0.42 0.90 
206 Pl426355 8 274.63 0.72 0.023 0.54 0.85 
278 Pl458927 7 276.25 0.72 0.023 0.54 0.85 
360 Pl633101 8 290.75 0.72 0.023 0.54 0.85 
363 PI633104 7 288.50 0.72 0.023 0.54 0.85 
74 PI212594 7 292.38 0.73 0.045 0.36 0.93 
124 Pl347617 8 275.38 0.74 0.040 0.41 0.92 
63 PJl83112 7 305.63 0.75 0,047 0.34 0.95 
82 PI250134 7 293.00 0.75 0.003 0.73 0.77 
276 Pl449438 7 293.00 0.75 0.003 0.73 0.77 
9 Pi169076 7 304.25 0.76 0.026 0.54 0.89 
26 PI 179191 7 301.13 0.76 0.026 0.54 0.89 
36 Pl 179653 8 287.63 0.76 0.026 0.54 0.89 
68 Pl I 95553 7 290.38 0.76 0.026 0.54 0.89 
95 PI286417 8 304.25 0.76 0.026 0.54 0.89 
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A.6. Continued 
Confidence Interval 
Treatment effect {95%) 
Median Treatment 
Accession Disease Mean relative Standard Lower Upper 
number Name Rating Rank effect error Limit Limit 
403 Pl 175608 6 302.50 0.76 0.026 0.54 0.89 
34 Pll 79649 8 312.13 0.78 0.050 0.32 0.96 
38 Pll 79850 8 308.75 0.78 0.010 0.71 0.85 
49 Pll 80417 8 306.50 0.78 0.010 0.71 0.85 
88 Pl257240 8 307.38 0.78 0.029 0.52 0.92 
89 Pl269432 8 306.50 0.78 0.010 0.71 0.85 
153 P1426301 8 296.00 0.78 0.030 0.51 0.92 
245 Pl426396 8 308.75 0.78 0.010 0.71 0.85 
13 Pl! 73857 7 314.63 0.79 0.028 0.54 0.92 
27 PII 79192 7 301.13 0.79 0.028 0.54 0.92 
406 P1649162 7 314.63 0.79 0.028 0.54 0.92 
191 Pl426340 8 307.50 0.8[ 0.033 0.49 0.95 
200 Pl426349 8 310.13 0.81 0.030 0.52 0.94 
354 Pl633095 8 324.88 0.81 0.033 0.49 0.95 
47 PI180267 7 319.25 0.82 0.011 0.73 0.89 
91 PI271442 7 320.88 0.82 0.011 0.73 0.89 
249 P1426400 8 317.88 0.82 0.011 0.73 0.89 
405 PI 426281 6 325.75 0.82 0.031 0.52 0.95 
39 Pll 79854 7 327.25 0.84 0.016 0.70 0.92 
71 Pl 209781 7 321.00 0.84 0.03;1 0.48 0.97 
355 Pl633096 7 332.50 0.84 0.016 0.70 0.92 
370 Pl6331 l l 7 329.38 0.84 0.016 0.70 0.92 
33 Pll 79647 7 335.00 0.85 0.010 0.77 0.91 
244 PI426395 8 347.13 0.89 0.002 0.88 0.90 
253 Pl426404 8 347.13 0.89 0.002 0.88 0.90 
289 Pl458996 8 363.25 0.89 0.002 0.88 0.90 
150 PI426298 8 348.50 0.90 0.016 0.73 0.97 
217 Pl426366 8 355.63 0.91 0.006 0.86 0.95 
266 Pl432384 8 355.63 0.9[ 0.006 0.86 0.95 
407 Dk 3042 8 358.38 0.91 0.007 0.85 0.95 
192 Pl426341 8 385.75 0.94 ( O.Ql5 ) 0.72 0.99 
Standard errors (se) are given in brackets after the estimates, which were determined based on 
output of the SAS macro. In general, if the SAS macro is not available, se can be roughly 
approximated by se I N, in which se is the standard error of the mean rank for the ithaccession 
(treatment) as determined in the MIXED procedure of SAS with the LSMEANS option (SAS 
Institute, Cary, NC). 
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A.7. Median, mean rank and estimated relative treatment effects for the severity of foliar 
symptoms on 54 commercial canola cultivars based on their reaction to inoculation 
with three Leptosphaeria maculans isolates of PG 3. 
Confidence 
Treatment effect Interval {95%l 
Median Treatment 
Accession Disease Mean relative Standard Lower Upper 
number Name Rating Rank effect error Limit Limit 
37 Croplan Hyclass 906P 6 23.00 
0.32 
0.036 0.13 0.59 
29 Canterra SWK5352RR 7 24.63 
0.33 
0.020 0.21 0.48 
Monsanto DKL52-4 I Plus 7 24.63 
0.33 
0.020 0.21 0.48 75 
5 Agriprogress 30503-86 7 25.88 
0.35 
0.043 0.13 0.66 
7 Agri progress 30217 -C7 6 28.13 
0.36 
0.031 0.18 0.58 
28 Cargill V 2010 7 27.88 
0.36 
0.031 0.18 0.58 
21 Brett Young 44 l 4RR 8 29.25 0.38 0.048 0.13 0.72 
25 Cargill V2018 7 30.00 
0.40 
0.023 0.26 0.56 
38 Croplan Hyclass 906 7 30.63 
0.40 
0.023 0.26 0.56 
41 Croplan Hyclass 41 O 7 30.50 
0.40 
0.023 0.26 0.56 
31 Canterra 1818 7 31.38 0.43 0.031 0.24 0.64 
74 Monsanto G75449 7 31.38 
0.43 
0.046 0.17 0.73 
13 Agriprogress 3061 l-C7 7 36.25 0.46 0.036 0.24 0.70 
II Agriprogress 30412-86 7 36.50 0.47 0.020 034 0.60 
33 Canterra 30507-86 7 35.63 0.47 0.020 0.34 0.60 
56 Mycogen Seeds 02X0023 7 35.00 0.47 0.020 0.34 0.60 
3 Agriprogress 30416-86 7 41.00 0.54 0.004 0.51 0.57 
4 Agriprogress 30423-C7 7 41.00 0.54 0.004 0.51 0.57 
18 Bayer lnvigor 8440 7 41.00 0.54 0.004 0.51 0.57 
39 Croplan Hyclass 712 7 41.00 0.54 0.004 0.51 0.57 
55 Mycogen Seeds DN05 I 874 7 41.00 0.54 0.004 0.51 0.57 
58 Mycogen Seeds Nexera 845 CJ 7 41.00 0.54 0.004 0.51 0.57 
71 Monsanto G72003 7 41.00 0.54 0.004 0.51 0.57 
79 Proseed 2066 7 41.00 0.54 0.004 0.51 0.57 
81 Pioneer 45H28 7 41.00 0.54 0.004 0.51 0.57 
26 Cargill VI037 7 42.38 0.57 0.038 0.31 0.79 
15 Agriprogress 302 I 4-C7 8 46.00 0.60 0.018 0.48 0.72 
64 Mycogen Seeds ONO 51505 7 46.13 0.60 0.018 0.48 0.72 
73 Monsanto 072021 7 46.13 0.60 0.018 0.48 0.72 
78 Proseed 30 Caliber 7 46.13 0.60 0.018 0.48 0.72 
27 Cargill Vl035 7 47.75 0.63 0.027 0.44 0.79 
36 Croplan Hyclass 924 7 47.75 0.63 0.027 0.44 0.79 
51 Mycogen Seeds G2X0043 8 51.13 0.67 0.020 0.51 0.79 
57 Mycogen Seeds Nexera 830 CL 8 50.25 0.67 0.020 0.51 0.79 
63 Mycogen Seeds DNOS 1493 7 49.75 0.67 0.020 0.51 0.79 
123 
A. 7. Continued 
Confidence 
Treatment effect Interval {95%) 
Median Treatment 
Accession Disease Mean relative Standard Lower Upper 
number Name Rating Rank effect error Limit Limit 
66 Monsanto Z4409 8 53.00 0.70 0.027 0.49 0.84 
67 Monsanto G7501 I 8 52.38 0.70 0.027 0.49 0.84 
69 Monsanto G67012 7 52.88 0.70 0.027 0.49 0.84 
42 Dekalb IS7145 7 55.50 0.73 0.031 0.48 0.89 
54 Mycogen Seeds G2X0044 8 55.38 0.73 O.Ql8 0.59 0.83 
12 Agriprogress 30408-C7 8 56.63 0.76 0.022 0.58 0.88 
59 Mycogen Seeds DN051607 8 57.88 0.76 0.022 0.58 0.88 
68 Monsanto G72061 7 57.38 0.76 0.022 0.58 0.88 
48 lntegra Seed IX08712 IR 8 60.38 0.79 0.025 0.57 0.91 
32 Canterra 30120-86 8 62.38 0.82 0.009 0.75 0.88 
43 Dekalb 52-41 8 65.00 0.86 0.010 0.77 0.91 
53 Mycogen Seeds G2X0024 8 67.13 0.87 0.014 0.74 0.94 
47 lntegraSeed IX08-7321 R 8 66.88 0.89 0.009 0.81 0.93 
62 Mycogen Seeds DN051535 8 67.50 0.89 0.009 0.81 0.93 
45 Dekalb DKL72-55 8 70.38 0.91 0.012 0.78 0.96 
83 Dk3242 I 8 69.38 0.92 0.002 0.90 0.93 
44 Dekalb IS3057 8 71.63 0.94 0.005 0.89 0.96 
52 Mycogen Seeds G2X0022 8 71.63 0.94 0.005 0.89 0.96 
72 Monsanto G64034 8 71.63 0.94 ( 0.005 ) 0.89 0.96 
Standard errors (se) are given in brackets after the estimates, which were determined based on 
output of the SAS macro. In general, if the SAS macro is not available, se can be roughly 
approximated by se I N, in which se is the standard error of the mean rank for the ithaccession 
(treatment) as determined in the MIXED procedure of SAS with the LSMEANS option (SAS 
Institute, Cary, NC). 
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A.8. Median, mean rank and estimated relative treatment effects for the severity of foliar 
symptoms on 54 commercial canola cultivars based on their reaction to inoculation 
with one Leptosphaeria maculans isolate of PG 4. 
Confidence Interval 
Treatment effect {95%~ 
Treatment 
Median relative 
Accession Disease Mean effect Standard Lower Upper 
number Name Rating Rank error Limit Limit 
33 Canterra 30507-86 7 
31.63 0.40 
0.021 0.27 0.55 
74 Monsanto 075449 7 
30.38 0.40 
0.021 0.27 0.55 
79 Proseed 2066 8 
31.00 0.40 
0.021 0.27 0.55 
81 Pioneer 45H28 8 
30.63 0.40 
0.021 0.27 0.55 
17 Bayer lnvigor 5440 8 
30.50 0.41 
0.037 0.19 0.67 
3 Agriprogress 30416-86 8 
36.13 0.47 
0.018 0.35 0.59 
5 Agriprogress 30503-86 8 
34.88 0.47 
0.018 0.35 0.59 
7 Agriprogress 302 I 7-C7 7 
35.88 0.47 
0.018 0.35 0.59 
Agriprogress 30412-86 
35.25 0.47 
0.70 11 7 0.036 0.25 
Bayer lnvigor 8440 8 
35.63 
18 
0.47 
0.036 0.25 0.70 
26 Cargill VI037 7 
34.88 0.47 
0.036 0.25 0.70 
Croplan Hyclass 906 8 
35.25 
38 
0.47 
0.018 0.35 0.59 
Interstate I 005 8 
35.25 
46 
0.47 
0.018 0.35 0.59 
76 Proseed 50 Caliber 7 
36.25 0.47 
0.036 0.25 0.70 
Agriprogress 30423-C7 8 
41.13 
4 
0.54 
0.030 0.33 0.73 
27 Cargill V1035 7 
40.38 0.54 
0.030 0.33 0.73 
Agriprogress 30214-C7 8 45.38 0.60 15 0.019 0.46 0.72 
Mycogen Seeds DN05 I 874 8 
45.38 0.60 
55 0.019 0.46 0.72 
58 Mycogen Seeds Nexera 845 Cl 8 
46.25 0.60 
0.019 0.46 0.72 
Mycogen Seeds DNO 51505 8 
45.38 0.60 
64 0.019 0.46 0.72 
Monsanto Z4409 8 
45.38 0.60 
66 0.019 0.46 0.72 
Monsanto 072021 8 
46.25 
73 
0.60 
0.019 0.46 0.72 
Monsanto G7206 I 8 
48.00 0.64 
68 0.030 0.42 0.81 
Mycogen Seeds G2X0043 8 51.25 0.67 51 0.022 0.50 0.80 
Mycogen Seeds DN05 I 607 8 49.88 59 0.67 0.022 0.50 0.80 
69 Monsanto G67012 8 49.88 0.67 0.022 0.50 0.80 
28 Cargill V 2010 8 53.38 0.71 0.042 0.37 0.91 
42 Dekalb IS7145 8 55.75 0.74 0.019 0.59 0.84 
43 Dekalb 52-41 8 55.75 0.74 0.019 0.59 0.84 
54 Mycogen Seeds G2X0044 8 55.75 0.74 0.019 0.59 0.84 
56 Mycogen Seeds G2X0023 8 54.88 0.74 0.019 0.59 0.84 
57 Mycogen Seeds Nexera 830 CL 8 54.88 0.74 0.019 0.59 0.84 
78 Proseed 30 Caliber 8 55.75 0.74 0.019 0.59 0.84 
48 lntegra Seed IX08712 IR 9 59.38 0.77 0.025 0.56 0.90 
12 Agriprogress 30408-C7 8 60.75 0.80 0.003 0.78 0.82 
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A.8. Continued 
Confidence Interval 
Treatment effect !95%! 
Treatment 
Median relative 
Accession Disease Mean effect Standard Lower Upper 
number Name Rating Rank error Limit Limit 
32 Canterra 30120-86 8 60.75 0.80 0.003 0.78 0.82 
36 Croplan Hyclass 924 8 60.75 0.80 0.003 0.78 0.82 
39 Croplan Hyclass 712 8 60.75 0.80 0.003 0.78 0.82 
63 Mycogen Seeds DN051493 8 60.75 0.80 0.003 0.78 0.82 
67 Monsanto 075011 8 60.75 0.80 0.003 0.78 0.82 
83 Dk3242 8 60.75 0.80 0.003 0.78 0.82 
47 lntegraSeed IX08-7321 R 8 63.88 0.84 0.011 0.75 0.90 
53 Mycogen Seeds G2X0024 8 63.88 0.84 0.011 0.75 0.90 
62 Mycogen Seeds DNOS 1535 8 63.88 0.84 0.011 0.75 0.90 
45 Dekalb DKL72-55 9 68.63 0.89 0.014 0.75 0.95 
44 Dekalb IS3057 9 70.63 0.93 0.012 0.79 0.98 
52 Mycogen Seeds G2X0022 9 71.38 0.93 0.012 ) 0.79 0.98 
72 Monsanto 064034 9 74.63 0.98 ( 0.002 ) 0.96 0.99 
Standard errors (se) are given in brackets after the estimates, which were determined based on 
output of the SAS macro. In general, if the SAS macro is not available, se can be roughly 
approximated by se / N, in which se is the standard error of the mean rank for the ith accession 
(treatment) as determined in the MIXED procedure of SAS with the LSMEANS option (SAS 
Institute, Cary, NC). 
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